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Triple-negative breast cancer (TNBC) is a clinically aggressive disease that is associated with 
bleak outcomes due to its metastatic propensity, frequent failure to respond to chemotherapy, and 
lack of alternative treatment options. Despite decades of major translational research efforts, there 
has been very little success thus far in the development of effective targeted therapies for this 
disease. It is imperative to develop novel therapeutic strategies to improve patient outcomes, as 
well as minimize the toxicity associated with standard-of-care chemotherapeutics. Given that 
metastatic disease accounts for the vast majority of TNBC-related deaths, a better understanding 
of therapeutic responses within common sites of metastasis is crucial for developing effective 
treatment strategies. Given the molecular heterogeneity of TNBC, the clinical success of new 
therapies additionally depends on the identification of reliable drug targets within each TNBC 
subtype for more effective patient stratification. The studies presented herein sought to address 
these matters, using clinically relevant patient-derived xenograft (PDX) models to characterize 
chemotherapeutic efficacy in distinct metastatic sites, to identify promising targeted therapeutic 
candidates and combination strategies, and to assess the translational potential of these 
therapeutic strategies, with a focus on both the basal-like and luminal androgen receptor (LAR) 
subtypes of TNBC. We hypothesized that therapeutic efficacy in the primary tumor setting would 
be maintained in the metastatic setting, and that PDXs of distinct TNBC subtypes would respond 
to particular targeted therapies based on the distinct molecular pathways that drive their 
progression. We therefore expected that therapies targeting the epidermal growth factor receptor 
(EGFR) and the androgen receptor (AR) would have efficacy in basal-like TNBC and LAR TNBC, 
respectively, and would be ideal for incorporation into novel combination regimens for these 
specific disease subtypes. Using a combination of in vitro and in vivo drug response studies, we 
identified a drug combination, co-targeting EGFR and survivin, that was synergistic across multiple 
PDX models of basal-like TNBC, despite some of these models responding differently to standard 
chemotherapies, thus revealing potential pathways that may serve as reliable drug targets in this 
subset of patients. Furthermore, we identified several potential drug targets and therapeutic 
candidates for combination with AR-targeted therapies in LAR TNBC. In addition to identifying 
novel therapeutic strategies that have potential to provide clinical benefit for these subsets of TNBC 
patients, these studies highlight the utility of PDX models for in vitro and in vivo drug development 
studies, and demonstrate that the molecular and drug response profiles of primary tumors are 
maintained in the metastatic setting, indicating that studies employing PDX mammary tumor 
models can be applicable in advanced disease. Collectively, the data generated in these studies 
have the potential not only to directly provide clinical benefit for TNBC patients, but also to inspire 
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CHAPTER 1: Introduction 
1.1 Introduction to breast cancer 
1.1.1 Breast cancer history and statistics 
The first documented cases of breast cancer date back to ancient times, when cancer 
was deemed an incurable illness [1, 2]. Throughout ancient Egyptian and Greek history, 
breast cancer and other cancers were treated surgically, with palliative intent, as cancer 
was poorly understood apart from its invasive nature [2, 3]. Although early centuries saw 
gradual improvements in diagnostic and surgical techniques, it was not until the 18th and 
19th centuries that scientists and physicians began working towards advancing our 
understanding of breast cancer with the intent to develop curative treatments, the first of 
which was the radical mastectomy [2, 4]. During the 20th century, major cancer research 
efforts resulted in a vast expansion in our comprehension of breast cancer biology and 
pathogenesis, leading to the discovery of the roles of the estrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in 
breast cancer [5] and the development of ER- and HER2-targeted therapeutics [6–8], along 
with the development of chemotherapy [9, 10]. Tailoring of therapeutic regimens to 
accommodate the individual patient, along with advancements in molecular biology and 
genomic analysis techniques, resulted in the concept of personalized medicine. This has 
more recently been facilitated by the identification of the intrinsic molecular subtypes of 
breast cancer [11–14], which are now known to have significant therapeutic and prognostic 
implications [15–18]. The development of improved treatment strategies and patient 
stratification protocols, along with the implementation of routine diagnostic screening, has 
led to a steady decline in breast cancer mortality over the past several decades [19]. 
Although the field of breast cancer has come a long way, the disease remains a 
significant medical problem in the U.S. and the rest of the world in the 21st century [20]. 
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Breast cancer is currently the second most common cancer and the second leading cause 
of cancer-related mortality in women in the U.S., and it is estimated that 1 in 8 women will 
develop breast cancer over the course of life [19]. Each year, over 268,000 Americans are 
diagnosed with invasive breast cancer, and over 41,000 die as a result of disease burden 
[19]. It is therefore imperative to continue our research efforts to further advance our 
understanding and improve the treatment and outcomes of this disease. 
1.1.2 Breast cancer subtype classification and clinical implications 
Significant advancements in the field of breast cancer research over the past several 
decades can largely be attributed to the identification and characterization of the distinct 
molecular subtypes of breast cancer [11–14], which govern treatment and predict 
prognosis [15–18]. In the clinic, breast cancer is most commonly subtyped based on ER, 
PR, and HER2 status, and this is one of the primary determining factors for pharmacologic 
treatment decisions as well as prognosis [21–23]. ER-positive breast cancer is typically 
well-differentiated, less proliferative, and less likely to bear oncogenic mutations compared 
to ER-negative disease [24–26]. Patients with ER-positive tumors are treated with ER-
targeted therapeutics, including selective estrogen receptor modulators (SERMs) such as 
tamoxifen or selective estrogen receptor degraders (SERDs) such as fulvestrant. These 
are administered with or without adjuvant or neoadjuvant chemotherapy, depending on 
other tumor characteristics such as tumor stage. Given its association with lower tumor 
grade and the availability of targeted therapies, ER-positive disease is associated with 
relatively favorable outcomes, particularly when PR is co-expressed with ER [27–29]. 
HER2-positive breast cancer is associated with less favorable outcomes compared to ER-
positive disease [30–32], however prognosis is substantially improved when patients are 
treated with HER2-targeted therapeutics, including the anti-HER2 monoclonal antibody 
trastuzumab, along with chemotherapy. Hormone receptor and/or HER2 positive disease 
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collectively account for approximately 85% of breast cancers, largely contributing to the 
current overall breast cancer 5-year survival rate of nearly 90% [19, 33]. 
Triple-negative breast cancer (TNBC), which accounts for the remaining 15% of breast 
cancers, is negative for ER, PR, and HER2 [22, 23], and no reliable therapeutic targets 
have yet been identified despite decades of translational research [34]. Therefore, 
treatment for this subtype is currently limited to adjuvant or neoadjuvant chemotherapy. 
TNBC is associated with the worst prognosis of all histologic subtypes [35], as these tumors 
are typically high grade with a greater propensity to metastasize to visceral organs [36–
38]. TNBC tumors are also more likely to be associated with oncogenic mutations [39, 40], 
and approximately 20% of TNBCs are associated with BRCA1 mutations [41]. Despite 
aggressive chemotherapeutic regimens consisting of highly toxic anthracyclines, taxanes, 
and/or alkylating agents, TNBC often fails to respond or acquires resistance to 
chemotherapy, leading to refractory and recurrent disease, and contributing largely to the 
poor prognosis associated with this subtype [38].  
Breast cancer is classified not only histologically based on ER/PR/HER2 status, but 
also molecularly based on gene expression profiling. Differential expression of a 50-gene 
signature divides breast tumors into five distinct intrinsic subtypes (luminal A, luminal B, 
HER2-enriched, basal-like, and claudin-low) as well as a normal-like subtype, in which 
expression of the gene signature resembles that of the normal breast tissue [11–14]. 
PAM50 analysis (now known as Prosigna), the genomic test performed to assess these 
expression profiles in tumors, has been demonstrated as valuable in predicting therapeutic 
response and prognosis [42, 43]. Although receptor status alone cannot accurately predict 
intrinsic subtype, there is considerable overlap between the histologic and intrinsic 
subtypes of breast cancer. Over 70% of ER-positive tumors are classified as luminal A or 
B, over 60% of HER2-positive tumors are HER2-enriched, and nearly 80% of TNBC tumors 
are basal-like [42, 44]. Likewise, luminal tumors are associated with less aggressive 
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disease and favorable outcomes, while basal-like tumors are associated with highly 
aggressive disease and poor outcomes [15, 18].  
Luminal A and B tumors are characterized by high expression of luminal epithelial 
markers including keratins 8 and 18 [11], and are usually ER-positive. Luminal A tumors 
are associated with more favorable outcomes relative to luminal B tumors, as luminal B 
tumors are characterized by a higher proliferation index and metastatic propensity, 
particularly to bone [18]. HER2-enriched tumors are characterized by overexpression of 
the ERBB2 amplicon [11], and are typically HER2-positive. HER2-enriched disease has a 
propensity to metastasize to the liver [18] and is associated with poorer outcomes than 
luminal disease. Basal-like tumors are characterized by high expression of basal epithelial 
markers including keratins 5, 6, and 17 [11], and are typically triple-negative [44]. These 
tumors have a high proliferation index, are poorly differentiated, and aggressively 
metastasize to the brain and lung [18]. Basal-like disease is consequently associated with 
very poor outcomes compared to other intrinsic subtypes. Claudin-low tumors are 
characterized by high expression of mesenchymal and extracellular matrix (ECM) genes 
as well as immune-related genes [12, 45], and are also usually triple-negative, highly 
metastatic, and associated with a poor prognosis [18]. Given the clinically important 
distinctions between these intrinsic subtypes that cannot be discerned solely by 
ER/PR/HER2 status, stratification of patients by tumor gene expression profiling is a crucial 
step towards improving targeted treatment strategies. 
1.1.3 Breast cancer metastasis 
Metastasis, one of the hallmarks of cancer [46], is the process by which cancer cells 
travel away from the primary tumor site and colonize distant organs. This involves a 
cascade of cancer cell detachment, migration, and local tissue invasion, intravasation of 
tumor cells into blood vessels or lymphatics, circulation of tumor cells, and extravasation 
followed by colonization and growth of tumor cells in distant tissues [47]. There are several 
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mechanisms by which cancer cells may develop the potential to metastasize [47], the most 
common being the clonal acquisition of mutations by subpopulations of tumor cells 
throughout tumor progression [48, 49]. Genomic alterations have also been shown to 
promote metastasis of cancer cells to specific organs [50–53], providing a molecular basis 
for the “seed and soil” hypothesis originally described in 1889 [54]. 
Breast cancer preferentially metastasizes to the brain, liver, lung, and bone, and distinct 
breast cancer subtypes have differential organ tropism [18, 50–53, 55],  as described 
above. There are currently over 150,000 women living with metastatic breast cancer in the 
U.S. [19], and metastatic disease accounts for over 90% of cancer-related deaths, including 
those due to breast cancer [56–59]. Overall survival rates for patients with metastatic breast 
cancer have improved over the past three decades [60–62], largely due to therapeutic 
advancements in ER-positive/luminal and HER2-positive disease, which make up the 
majority of breast cancers. However, metastatic breast cancer remains a clinical challenge, 
particularly for triple-negative/basal-like disease, as this subtype is both the most clinically 
aggressive and the most difficult to treat.  
Patients with TNBC are more likely to have distant recurrences compared to those with 
other subtypes [36]. TNBC tumors preferentially metastasize to visceral organs [36, 38], 
and basal-like tumors (80% of TNBCs) in particular have a high propensity to spread to the 
brain and lung [18]. TNBC patients have the highest risk of developing brain metastases, 
and metastatic disease in the brain is particularly aggressive when it results from TNBC 
[63–66]. The bleak prognosis and very limited therapeutic strategies for metastatic disease 
in the central nervous system (CNS) emphasize the critical need for novel TNBC treatments 
that not only are more effective than current therapies but also cross the blood-brain barrier. 
Although this may further complicate drug development efforts, it is imperative to develop 




1.2 Triple-negative breast cancer 
1.2.1 Triple-negative breast cancer: a challenge in cancer therapeutics 
As aforementioned, TNBC (which is most commonly basal-like) has the worst prognosis 
of all the breast cancer subtypes [35, 36]. This is due not only to the highly malignant 
features of triple-negative tumor cells, but also to the current lack of reliable molecular 
markers that can be targeted with pharmacological agents. Whereas ER-positive and 
HER2-positive disease can be treated with drugs specifically targeting those receptors, no 
equivalent proteins have yet been identified in TNBC. Thus, despite major translational 
research efforts, pharmacologic treatment for patients with TNBC is largely limited to 
chemotherapy. Patients with early-stage or locally advanced TNBC are currently treated 
with adjuvant or neoadjuvant, respectively, regimens including anthracyclines, taxanes, 
and/or alkylating agents, along with surgery and radiation. Although TNBC patients have 
better initial responses to neoadjuvant chemotherapy compared to non-TNBC subtypes, 
they have significantly shorter progression-free survival and a greater risk of metastasis 
[36, 38]. Patients with metastatic disease, after confirming the maintenance of TNBC status 
via a repeat biopsy, receive combination or single-agent chemotherapy, depending on the 
extent of disease progression. This is sometimes known as a therapeutic rechallenge, as 
patients with recurrent or metastatic disease may be treated with the same 
chemotherapeutics they were given previously, given the limited treatment options for 
triple-negative disease.  
Because chemotherapeutics nonspecifically target rapidly-dividing cells, these drugs 
are highly toxic to normal tissue in addition to cancer cells, and consequently lead to 
adverse effects involving multiple organ systems. Furthermore, TNBC tumors are often 
intrinsically refractory or acquire resistance to these drugs [38, 67, 68], leaving patients 
who develop advanced or recurrent disease with multidrug-resistant tumors and very few 
alternative treatment options. In addition to the toxicity and limited/inconsistent 
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effectiveness of chemotherapy, it has been shown that several chemotherapeutics 
currently approved for breast cancer can promote early steps in the metastatic cascade, 
despite their anti-proliferative effects on primary tumors [69]. For all these reasons, it is 
imperative to develop new therapeutic strategies that are both more effective and less toxic 
for patients with TNBC. The success of this endeavor will likely depend on the identification 
of reliable targets and more effective patient stratification. 
1.2.2 Triple-negative breast cancer subtypes and clinical implications 
The clinical challenge of treating TNBC can be attributed not only to the lack of reliable 
drug targets, but also to the molecular heterogeneity of this breast cancer subtype. Given 
the clinical importance of stratifying patients based on molecular tumor characteristics, the 
identification of distinct TNBC subtypes [70] was a major advancement in the field of 
translational breast cancer research. TNBC tumors have been classified into six subtypes 
based on gene expression profiling: basal-like 1 (BL1), basal-like 2 (BL2), 
immunomodulatory (IM), mesenchymal-like (M), mesenchymal stem-like (MSL), and 
luminal androgen receptor (LAR) [70]. BL1 tumors are characterized by expression of 
genes involved in the cell cycle, proliferation, and DNA repair, whereas BL2 tumors express 
genes involved in growth factor pathways and glucose metabolism; IM tumors are 
characterized by expression of immune cell markers and genes indicative of medullary 
breast cancer; M and MSL tumors highly express genes involved in cell motility, 
differentiation, growth factor signaling, and epithelial-to-mesenchymal transition (EMT), 
however MSL tumors are less proliferative; and LAR tumors are characterized by androgen 
receptor (AR) signaling and have a luminal gene expression profile [70]. These subtypes 
have more recently been refined into four types (BL1, BL2, M, and LAR), as the IM and 
MSL types were found to have resulted from infiltrating immune and stromal cells, 
respectively [71]. BL1 and BL2 tumors make up the majority of TNBCs (60%) and have the 
worst prognosis; 25% of TNBCs are M subtype and 15% are LAR subtype [70, 71]. AR is 
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a particularly important marker, and AR-negative TNBCs (the majority of which are basal-
like) have been coined quadruple-negative breast cancer (QNBC), which is associated with 
therapeutic resistance and very poor outcomes [72–74].  
The distinct gene signatures and characteristics of each of these TNBC subtypes 
explain why certain populations of TNBC patients respond to particular therapies while 
others do not; importantly, these distinctions are crucial to predict which patients will 
respond to specific therapeutics and to identify pathways that may be effective targets 
within each subset of TNBC patients. For instance, BL1 and BL2 tumors respond better 
than other subtypes to taxanes given their high expression of cell cycle and proliferation 
markers, whereas LAR tumors respond to AR inhibitors given they are driven by AR 
signaling [70, 71, 75]. There are likely additional pathways driving tumor progression within 
each TNBC subtype that remain to be identified and may serve as effective drug targets.  
1.2.3 The search for successful targeted therapies for triple-negative breast cancer 
Currently, there are only three targeted treatments approved for select subsets of TNBC 
patients [76]. Nearly 60% of TNBC tumors are positive for programmed cell death ligand 1 
(PDL-1) [77], and patients with PDL-1 positive advanced TNBC are candidates for 
treatment with PDL-1 inhibitors such as atezolizumab, recently approved by the U.S. Food 
and Drug Administration (FDA) for use in conjunction with standard chemotherapy in this 
subset of patients [78]. The poly ADP-ribose polymerase (PARP) inhibitors talazoparib and 
olaparib have recently been FDA-approved for patients with BRCA1-mutated advanced 
TNBC [79, 80]. However, these drugs offer no benefit for patients with PDL-1-negative and 
BRCA1-wildtype disease. Thus, the search for effective targeted therapies in TNBC 
continues.  
Many other targeted therapies have shown promise in preclinical studies, but thus far 
none of these agents have demonstrated enough success in clinical trials to be approved 
for TNBC [34, 81, 82]. These include drugs and/or antibodies that target epidermal growth 
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factor receptor (EGFR) [83–88], AR [89, 90], vascular endothelial growth factor (VEGF) 
(angiogenesis) [91–94], trophoblast cell-surface antigen 2 (TROP-2) [95], phosphoinositide 
3-kinase (PI3K) and mammalian target of rapamycin (mTOR) [96, 97], beta-adrenergic 
receptor [98–101], heat shock protein 90 (HSP90) and histone deacetylases (HDACs) [102, 
103], and programmed cell death protein-1 (PD-1) [77]. Many of these proteins are 
overexpressed or mutated in TNBC or specific TNBC subtypes, and/or have been shown 
to play important roles in TNBC progression, making them appealing drug targets. 
However, given the results of clinical studies combining such drugs with standard-of-care 
chemotherapies, it is likely that synergistic combinations with other targeted agents are 
needed to achieve clinical benefit.  
1.3 Patient-derived xenograft models 
1.3.1 Utility and relevance of patient-derived xenograft models in cancer research 
Preclinical studies of cancer biology, and the development and testing of new therapies, 
rely heavily upon the use of in vivo models that accurately recapitulate the characteristics 
and progression of tumors in humans. Patient-derived xenograft (PDX) models, in which 
tumor cells derived from human surgical specimens are transplanted into immunodeficient 
mice, have emerged as preclinical models to study the molecular biology and in vivo 
treatment responses of cancers of various organs [104–114], including the breast [115]. 
PDXs have been shown to more faithfully maintain the characteristics, behavior, and drug 
response profiles of human primary tumors and metastases compared to xenograft models 
utilizing immortalized human cancer cell lines [116–123]. Consequently, preclinical drug 
development studies using PDX models are more likely to be predictive of clinical success 
compared to other types of models [124], which is why PDX models were utilized for the 





1.3.2 Patient-derived xenograft models of primary and metastatic breast cancer 
As described above, breast cancer is a heterogenous disease, which poses significant 
therapeutic challenges. Most drugs that show promise in preclinical studies end up failing 
in clinical trials due to lack of efficacy. This highlights the importance of utilizing preclinical 
models that faithfully represent the spectrum of breast cancer seen in humans. Indeed, 
PDX models have been established for all breast cancer subtypes, providing clinically 
relevant models that represent the heterogeneity of this disease. Some of the first breast 
cancer PDXs were not initially successful due to instability of tumor engraftments in mice 
[125–134], however this has improved considerably with the development of better 
immunodeficient mouse strains [118, 119, 135]. Importantly, breast cancer PDX models 
have been shown to retain the heterogeneity, histology, molecular profiles, hormone-
dependency, drug responses, growth patterns, metastatic behavior, and disease outcomes 
of human breast cancer, even after multiple passages in mice [116–120, 136–138]. PDX 
models are therefore considered to be superior to immortalized cell line models regarding 
their clinical relevance and translational potential in breast cancer [139, 140]. 
PDX models of metastatic breast cancer are particularly valuable for studying advanced 
disease. Whereas cell line xenografts do not accurately emulate the metastatic patterns of 
human disease, orthotopic PDX tumors have been shown to spontaneously metastasize 
to the same distant sites in the mouse as in the patient from which the PDX models were 
originally derived [116]. It should be noted that, while spontaneous metastasis models are 
suitable for studying metastatic disease in the lymph nodes and lungs, experimental 
metastasis models, in which tumor cells are injected directly into the circulation or organ, 
are relatively more robust for generating brain and liver metastases in mice [52, 141–143]. 
Although such experimental models do not mimic the entire metastatic cascade, they 
provide an efficient and reliable means of studying drug response in the setting of 
established metastatic disease. This is especially important for TNBC, as this subtype 
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tends to metastasize early in the disease course, and, consequently, patients often present 
with TNBC that has already disseminated to distant sites. It is therefore important that drug 
development efforts focus on identifying therapeutic strategies that are effective in treating 
established metastases in vital organs. Given that PDX tumors retain many of the 
properties of their human counterparts, the use of these models for experimental 
metastasis studies is justified.  
1.3.3 Use of patient-derived xenograft models for preclinical drug screening studies 
In addition to utilizing PDX models for in vivo studies, PDX cells obtained from digested 
tumor tissue can be cultured in suspension [135] and used for in vitro drug screening 
assays. The non-adherent conditions in which the PDX cells are suspended prevent these 
cells from undergoing genetic and epigenetic changes associated with adaptation to growth 
on plastic [144–146]. Studies have shown that, whereas established cell lines do not 
faithfully maintain the transcriptional profiles of corresponding clinical samples [147], short-
term in vitro cultures of breast cancer PDXs maintain the molecular characteristics and 
heterogeneity of their in vivo counterparts and are therefore suitable models for studying 
tumor biology and drug response, both in vivo and ex vivo/in vitro [107, 110, 112, 121–123, 
148, 149].  
1.4 Overview of dissertation 
1.4.1 Overall goals of this research 
The research presented herein collectively sought to: 1) characterize breast cancer PDX 
suspension culture, mammary tumor, and metastasis models, 2) characterize 
chemotherapeutic responses in these models, 3) identify targeted/non-chemotherapeutic 
drug candidates for TNBC, and 4) identify and test synergistic combination therapies in 
vitro and in vivo. The overall goal of this research was to use clinically relevant PDX models 




1.4.2 Part One 
The first part of this work employs two basal-like TNBC PDX models to optimize in vitro 
suspension cultures for use in drug screening assays, and to characterize responses to 
currently approved chemotherapeutics in vitro and in vivo in both the primary and 
metastatic setting, with a particular focus on relative efficacy in distinct metastatic sites. 
1.4.3 Part Two 
The next part of this work focuses on identifying currently FDA-approved or late-stage 
investigational therapeutic compounds with efficacy in basal-like TNBC through screening 
of a wide range of drugs in multiple PDX models, and further investigating drugs of interest 
to identify novel synergistic drug combinations with promise in treating this subset of 
patients. 
1.4.4 Part Three 
The final part of this work focuses on characterizing responses of AR-positive breast cancer 
PDX and cell line models to AR-targeted drugs, and identifying genes of interest and 














CHAPTER 2: Characterizing the efficacy of cancer therapeutics in patient-derived 
xenograft models of metastatic breast cancer [149] 
 
Reprinted/adapted by permission from Springer Nature Customer Service Centre GmbH: Springer, Breast 
Cancer Research and Treatment; [149] Characterizing the efficacy of cancer therapeutics in patient-
derived xenograft models of metastatic breast cancer; Turner TH, Alzubi MA, Sohal SS, Olex AL, 
Dozmorov MG, and Harrell JC; © Springer Science+Business Media, LLC (2018) 
 
 
2.1 Background and rationale 
Each year, over 40,000 patients die due to invasive breast cancer [19]. TNBC is associated 
with a particularly poor prognosis relative to other breast cancer subtypes due to the frequent 
failure of chemotherapy and lack of alternative treatment strategies, as well as its metastatic 
propensity [36, 37]. Prior to surgical resection, TNBC tumors often metastasize to vital organs, 
including the brain, liver, and lungs [18, 65, 150], and it is unclear why some metastases 
respond to chemotherapeutic treatment whereas others do not. A better understanding of 
relative therapeutic efficacy in distinct metastatic sites is an important step towards improving 
therapeutic strategies for TNBC, given that metastatic disease accounts for virtually all TNBC-
related deaths. 
2.2 Experimental approach 
This study sought to evaluate the efficacy of cancer therapeutics in primary and metastatic 
breast cancer using two PDX models, WHIM2 and WHIM30, obtained from separate patients 
with basal-like TNBC [117, 120]. We initially tested the effects of twelve different cancer 
therapeutics, currently FDA-approved for various types of cancer, on the viability of WHIM2 
and WHIM30 cells cultured in vitro. Selected drugs were then tested in the mammary tumor 
and metastatic setting to evaluate their efficacy in vivo and compare responses between the 
two PDXs, between primary tumors and metastases, and between distinct metastatic sites 




2.3 Materials and methods 
2.3.1 PDX mouse models and preparation of tumor cell suspensions 
Two basal-like, TNBC PDX lines, WHIM2 and WHIM30, were obtained from the Institute of 
Clinical and Translational Sciences, Washington University, St. Louis. Cells were 
resuspended 1:1 in Matrigel (Corning) and injected into the fourth mammary fat pads of 
non-obese diabetic severe combined immunodeficient gamma (NSG) mice. Mammary 
tumors were digested with a solution of Dulbecco’s Modified Eagle Medium/Nutrient 
Mixture F12 (DMEM/F12), 5% fetal bovine serum (FBS), 300 U/ml collagenase (Sigma) 
and 100 U/ml hyaluronidase (Sigma). Digested tissue was resuspended in NH4Cl, and 
trypsinized to generate single cells, which were transduced with lentivirus (BLIV101PA-1; 
Systems Biosciences) encoding green fluorescent protein (GFP) and luciferase. Tumor 
growth was monitored by luciferase expression using the IVIS Spectrum In Vivo Imaging 
System (Xenogen IVIS-200) and Living Image software (PerkinElmer). Prior to imaging, 
mice were injected subcutaneously with 150 mg/kg D-luciferin (Gold Biotechnology).  
2.3.2 Optimization of culture conditions and in vitro drug studies 
WHIM2 and WHIM30 cells were plated in M87 or human breast epithelial cell (HBEC) 
media [135], in triplicate (25,000 cells/100μl per well) in 96-well plates coated with poly-2-
hydroxyethyl-methylacrylate (poly-HEMA) [151] to provide a low-attachment surface, and 
incubated at 37C, 5% CO2 for 3 or 7 days. It should be noted that these suspension 
cultures were distinct from organoid or spheroid models, as the cells were not suspended 
in an ECM-like matrix or subjected to centrifugation to encourage spheroid formation once 
plated; instead, the cells were simply plated in medium and allowed to freely interact with 
each other three-dimensionally. Cells were imaged and analyzed using a Zeiss 
AxioObserver A1 Inverted Microscope and Zeiss AxioCam 503 mono, and ZEN2 software. 
To assess cell viability over time, D-luciferin (15 mg/ml, 10μl/well) was added and plates 
were IVIS imaged on days 0, 3 and 7. Twelve pharmaceutical-grade cancer therapeutics 
15 
 
(Table 2.1) were obtained from VCU Dalton Oncology Clinic. Cells were treated for 72h 
with three concentrations of each drug (Table 2.2), determined from prior in vitro studies. 
Cell viability was measured by luciferase activity and CellTiter-Glo assay (Promega). 
 
Table 2.1: Twelve clinically approved cancer therapeutics tested in WHIM2 and WHIM30 PDXs in vitro. 
Adapted by permission from Springer Nature: [149] © Springer Science+Business Media, LLC (2018) 
Drug Mechanism of action Current clinical use 
Carboplatin Alkylating agent Testicular, bladder, ovary, lung carcinomas 
 
Dacarbazine Alkylating agent Melanoma, Hodgkin’s lymphoma, sarcomas, pancreatic 
adenocarcinoma 
 
Cyclophosphamide Alkylating agent Hematologic malignancies, brain cancer, various solid tumors 
 
Gemcitabine Pyrimidine analog Pancreatic, breast, bladder, non-small cell lung carcinomas 
 
Cytarabine Pyrimidine analog Leukemias and lymphomas 
 
Doxorubicin Anthracycline, intercalates DNA Various carcinomas, hematologic malignancies 
 
Cetuximab EGFR inhibitor Colorectal cancer, non-small cell lung carcinoma, head and 
neck cancers 
 
Rituximab Anti-CD20 monoclonal antibody Hematologic malignancies, autoimmune disorders 
 
Bevacizumab VEGF inhibitor Colorectal, lung, renal cancers 
 
Bortezomib Proteasome inhibitor Multiple myeloma 
 
5-Fluorouracil Antimetabolite, thymidylate synthase 
inhibitor 
Various gastric and head and neck cancers 
 
 
Irinotecan Topoisomerase I inhibitor Colon cancer 
 
Table 2.2: Concentrations and dosing of drugs for in vitro and in vivo studies in WHIM2 and WHIM30. 
Adapted by permission from Springer Nature: [149] © Springer Science+Business Media, LLC (2018) 




Carboplatin 1 µM, 10µM, 100µM 
 
90, 160 mg/kg 270, 480 mg/m2 300-360 mg/m2 
Dacarbazine 1mM, 5mM, 10mM 
 
60, 100 mg/kg 180, 300 mg/m2 150-375 mg/m2 
Cyclophosphamide 1mM, 10mM, 20mM 
 
75, 150 mg/kg 225, 450 mg/m2 600 mg/m2 
Gemcitabine 100nM, 1µM, 10µM 
 
   
Cytarabine 100nM, 1µM, 10µM 
 
   
Doxorubicin 10nM, 100nM, 1µM 
 
   
Cetuximab 500nM, 1µM, 5µM 
 
   
Rituximab 100nM, 1µM, 10µM 
 
   
Bevacizumab 1µM, 10µM, 50µM 
 
   
Bortezomib 100nM, 500nM, 1µM 
 
0.3, 0.75 mg/kg 0.9, 2.25 mg/m2 1.3 mg/m2 
5-Fluorouracil 1µM, 10µM, 100µM 
 
   
Irinotecan 100nM, 1µM, 10µM    
aBolded dosages for in vivo studies indicate the optimal dose determined by initial in vivo experiments. 
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2.3.3 RNA preparation and sequencing 
Mammary tumor and brain tissues were homogenized in lysis buffer using an electric tissue 
homogenizer. Cells were plated at 1.5x106 cells/well in poly-HEMA-coated 6-well plates 
and collected 7 days later. RNA was isolated from tissue/cell lysates using the RNeasy Mini 
Kit (Qiagen). Samples were sequenced on the Illumina Hi-Seq 2500 according to Illumina’s 
sequencing-by-synthesis protocol. KAPA Stranded mRNA-Seq Kit was used for library 
preparation. 125bp paired-end reads were generated, yielding on average 17M reads per 
sample. These data have been deposited in the NCBI Gene Expression Omnibus (GEO) 
(GSE110626). RNA-sequencing data were processed and analyzed by Amy Olex, as 
described in Turner et al. 2018 [149]. Gene expression data are represented as log2 
(TPM+1) (transcripts per million) values.  
2.3.4 Analysis of BRCA1 variants in WHIM2 and WHIM30 tumors 
The Integrated Genome Browser [152] version 9.0.0 was used to search for BRCA1 
mutations in WHIM2 and WHIM30 tumor samples. The coding region of the BRCA1 gene 
(human chromosome 17: 43,044,194-43,125,583) in WHIM2 and WHIM30 sequences was 
aligned to the corresponding region in the human reference genome (GRCh38) [153]. 
WHIM2 and WHIM30 BRCA1 sequences were then scanned for mutations, using a 
threshold of 10 or more reads distinct from the reference genome to indicate a mutation at 
a particular position in the sequence. The specific mutations observed were searched for 
using the University of California Santa Cruz (UCSC) Genome Browser [154] and 
compared with established ClinVar [155] variants. Additional analysis of BRCA1 variants 
in the PDXs was performed by Amy Olex, as described in Turner et al. 2018 [149]. 
2.3.5 In vivo mammary tumor studies 
WHIM2 and WHIM30 cells in HF buffer were resuspended 1:1 in Matrigel and injected 
(500,000 cells) into the fourth mammary fat pads of NSG mice. Mice were anesthetized 
prior to and during injection using 4% isoflurane, 1 L/min oxygen flow. For initial studies, 
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drug treatment was initiated when tumors reached 20mm2 by caliper measurement. To 
determine optimal dosing, mice were treated via intraperitoneal (IP) injection with low- or 
high-dose bortezomib, dacarbazine, carboplatin, or cyclophosphamide (Table 2.2), 
determined based on human-to-mouse dose conversions 
(https://www.fda.gov/downloads/drugs/guidances/ucm078932.pdf) [156] and previous in 
vivo studies. Mice were divided into 5 groups: vehicle (normal saline), bortezomib, 
dacarbazine, carboplatin, and cyclophosphamide (2 low-dose, 3 high-dose per treatment 
group). Carboplatin and cyclophosphamide were administered 1x/week; bortezomib 
2x/week; dacarbazine 3x/week. Mice were IVIS imaged weekly to monitor tumor growth; 
luciferase activity of the tumor area was quantified as total flux (photons/second, p/s). Mice 
were euthanized when tumors reached burden and/or mice displayed signs of drug toxicity, 
such as weight loss, trembling or hunching behavior, and/or difficulty with ambulation. A 
single dose of each drug (Table 2.2) was chosen for subsequent studies based on efficacy 
versus toxicity. Subsequent single-dose studies were performed in multiple cohorts of mice: 
WHIM30 bilateral tumors with treatment initiation at 20mm2 (5 mice per group), WHIM2 
bilateral tumors with treatment initiation at 20mm2 (5 mice per group), WHIM30 unilateral 
tumors with treatment initiation at 50mm2 (5 mice per group), and WHIM2 unilateral tumors 
with treatment initiation one week after tumor cell injection (4 mice per group). An additional 
study was conducted in which mice bearing bilateral WHIM30 tumors were treated with 
cyclophosphamide (5 low-dose, 4 high-dose) with treatment initiation at 100mm2. For all 
studies, tumor growth was monitored as described above. For select studies, tumors were 
excised, photographed, and harvested for histological analysis. 
2.3.6 In vivo metastasis studies 
PDX cells were injected into the left ventricle of the heart in NSG mice (WHIM2: 15 mice 
total, 1 cohort; WHIM30: 62 mice total, 5 cohorts). For intracardiac injection, mice were 
anesthetized using 4% isoflurane, 1 L/min oxygen flow, and maintained on 2.5% isoflurane, 
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1 L/min oxygen flow throughout the procedure. Prior to injection, the skin overlying the 
chest was sterilized with betadine followed by ethanol. Subsequently, 500,000 cells in 
100μl HF buffer were mixed with D-luciferin and injected into the left ventricle using a 1cc 
syringe. Following injection, each mouse was immediately IVIS imaged to verify proper 
seeding of tumor cells in the brain. Drug treatments were initiated 10 days post-injection. 
Each experimental cohort of mice was randomized into 3 groups and treated weekly with 
IP vehicle (normal saline), carboplatin, or cyclophosphamide, at a single dose per drug 
(Table 2.2). Collectively, this consisted of 5 mice per treatment group for WHIM2; and 18 
vehicle, 22 carboplatin, 22 cyclophosphamide for WHIM30. Mice were imaged weekly to 
monitor metastases; brain luciferase activity was quantified as total flux (p/s). Mice were 
euthanized when the vehicle group displayed signs of drug toxicity and/or became 
moribund; brains, livers, and lungs were excised and imaged ex vivo for each treatment 
group. These tissues were also harvested for histology. 
2.3.7 Histology 
Hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) were performed 
on WHIM2 and WHIM30 mammary tumors, brain, liver, and lung tissues. All tissues were 
fixed in 10% formalin, paraffin-embedded, and sectioned using a Kedee KD-2258 rotary 
microtome, at 10µm per section. H&E staining was performed according to standard 
procedures. IHC was performed by standard procedures, using the following primary 
antibodies: rabbit anti-pan-cytokeratin (1:100; ThermoFisher #PA1-27114), rabbit anti-
vimentin (1:800; Cell Signaling Technology #5741,), rabbit anti-Ki67 (1:100; Cell Signaling 
Technology #9027), rabbit anti-HIST1H3B3 (phosphohistone-H3) (1:500; One World Lab 
#42033), and rabbit anti-cleaved caspase-3 (1:200; Cell Signaling Technology #9661). 
Heat-induced antigen retrieval was conducted using a pressure cooker, in pH 9 Tris-EDTA. 
Detection was performed using the rabbit Dako EnVision system (Agilent K406511-2). 
Stained tissue sections were observed and photographed using a Zeiss AxioLab Upright 
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Microscope and Zeiss AxioCam ICc 5 camera. Image analysis was performed using the 
ZEN2 software, blue edition. 
2.3.8 Statistics 
For in vitro studies testing the twelve cancer therapeutics, unpaired two-tailed t-tests were 
performed between control and drug treatment conditions to determine statistical 
significance. For in vitro studies testing suspension cultures in two different media, and for 
all in vivo studies, differences between treatment groups were analyzed at each timepoint 
using a randomized block design ANOVA, with experimental cohort as a blocking factor. 
Treatment-time interactions were included in the model. Post-hoc Tukey’s Honest 
Significant Difference tests were performed to detect pairwise differences. All analyses 
were performed in R computing environment v.3.4.0, with the assistance of Dr. Mikhail 
Dozmorov.  
2.4 Results 
2.4.1 PDX cells can be maintained in suspension culture for up to 7 days 
Luciferase-expressing WHIM2 and WHIM30 mammary tumors were used for these studies 
(Fig. 2.1a). When cultured in suspension, the tumor cells clustered together over time (Fig. 
2.1b). Luciferase activity (total photon flux emitted per second after addition of luciferin 
substrate) was used to assess cell viability. Over time, in two different media formulations 
(M87 and HBEC) [135], WHIM2 cells showed an increase (p<5.0x10-5) followed by a 
decline (p<5.0x10-4) in viability, with no significant change in viability over 7 days (p>0.6) 
(Fig. 2.1c); WHIM30 cell viability initially decreased (p<6.0x10-5) and then remained 
relatively constant (p>0.7), with an overall decrease in viability over 7 days (p<6.0x10-6) 
(Fig. 2.1d). These effects were irrespective of the culture media for both WHIM2 (p>0.3) 
and WHIM30 (p=0.9). Data shown in Fig. 2.1c,d are from one representative experiment 
per PDX line, however statistical analyses incorporated two independent experiments per 
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line; absolute flux values varied between experiments, however they showed similar trends 
in cell viability over time for both PDXs (Fig. 2.2). 
2.4.2 PDX gene expression is maintained in suspension culture and in the metastatic setting 
Pearson correlation analyses, performed on RNA-sequencing data from tumor tissue and 
cell suspensions, revealed strong correlations between parental mammary tumors and 
suspension cultures over time, for both WHIM2 and WHIM30 (Fig. 2.3). WHIM2 and 
WHIM30 brain metastases also correlated strongly with mammary tumors and cell 
suspensions (Fig. 2.3).  
   
Figure 2.1: WHIM2 and WHIM30 PDX cells can be maintained in suspension culture for up to 7 days. (a) 
IVIS images depicting luciferase-positive mammary gland tumors in mice, 2 and 4 weeks post-injection of 
WHIM2 or WHIM30 PDX cells. (b) Microscopic images (20X) of WHIM2 and WHIM30 cells in suspension 
culture on days 0, 3, and 7 after plating. (c,d) Viability of WHIM2 (c) and WHIM30 (d) cells in suspension 
culture in two different media (M87 or HBEC) over time, as measured by luciferase activity in total photon 
flux per second (p/s), showing one representative experiment per PDX line. Graphs are shown in log10 
scale. Error bars represent standard deviation of triplicate values for each condition. Reprinted by permission 





Figure 2.2: WHIM2 and WHIM30 cell viability in suspension culture over time. Viability of WHIM2 (a) and 
WHIM30 (b) cells cultured in suspension in two different media (M87, HBEC) immediately after plating (day 
0), and after 3 and 7 days in culture. These graphs represent one of two independent experiments per PDX 
line, the others of which are shown in Fig. 2.1. Graphs are shown in log10 scale. Error bars represent 
standard deviation of triplicate values for each condition. Reprinted by permission from Springer Nature: 






Figure 2.3: Gene expression is maintained when WHIM2 and WHIM30 mammary tumor cells are cultured 
in suspension over time. RNA-sequencing was performed on WHIM2 and WHIM30 mammary tumors and 
cells cultured in suspension immediately after processing (SCSd0) and after 7 days in culture (SCSd7); 3 
tumors and matched day 0 and day 7 suspension culture samples were sequenced and analyzed for each 
PDX line. The correlation plot was generated by calculating all-by-all Pearson’s correlation coefficient matrix 
using the filtered log2 TPM expression profiles of each sample, which was then clustered using Hierarchal 
clustering, average linkage, and Euclidean distance as the dissimilarity measure. The color bar indicates 
correlation between indicated sample expression profiles, which were all above 0.79 positive correlation. 












2.4.3 Drug efficacy varies across basal-like PDX lines in vitro 
To determine the optimal measure of cell viability for in vitro drug screening, WHIM30 
cultures were treated with four cancer therapeutics: carboplatin, gemcitabine, cytarabine, 
and bortezomib. Both luciferase and ATP generation (CellTiter-Glo) assays yielded similar 
percent decreases in cell viability in response to each drug, however CellTiter-Glo 
produced more inter-experiment variability (Fig. 2.4a), likely due to contaminating mouse 
stromal cells. We next tested twelve cancer therapeutics on WHIM2 and WHIM30 
suspension cultures. Some of these drugs (carboplatin, gemcitabine, 5-fluorouracil, 
doxorubicin, cyclophosphamide) were chosen based on their clinical use or prior testing in 
breast cancer and their blood-brain barrier permeabilities, whereas some drugs indicated 
for other types of cancer (e.g. rituximab for hematological malignancies) were expected to 
be ineffective in our breast cancer models and were therefore used as controls. Cytotoxicity 
varied greatly across the drugs and the PDX lines (Fig. 2.4b-d). The PDXs responded 
differently to several drugs; for example, carboplatin was cytotoxic to WHIM30 but not 
WHIM2 cells (Fig. 2.4c,d). Bortezomib, dacarbazine, and cyclophosphamide were 





Figure 2.4: Cancer therapeutics are differentially cytotoxic to WHIM2 and WHIM30 cells in vitro. (a) 
Comparison of luciferase activity versus ATP production (CellTiter-Glo) to measure cell viability in response 
to carboplatin (100µM), gemcitabine (10µM), cytarabine (10µM), and bortezomib (100nM). Data represent 
two independent experiments in which WHIM30 cells were plated in triplicate for each condition; error bars 
represent standard deviation. (b) IVIS images of WHIM2 and WHIM30 cells in suspension culture treated 
for 72h with increasing concentrations (see Table 2.2) of twelve cancer therapeutics. Cells were plated in 
triplicate, with one column of wells skipped between sets of triplicates for each condition. (c,d) Effect of 
cancer therapeutics on the viability of WHIM2 (c) and WHIM30 (d) cells in suspension culture, as measured 
by luciferase activity (total flux). Concentrations used were as follows: carboplatin 100μM, dacarbazine 1mM, 
cyclophosphamide 20mM, gemcitabine 10μM, cytarabine 10μM, doxorubicin 1μM, cetuximab 5μM, rituximab 
10μM, bevacizumab 50μM, bortezomib 100nM, 5-fluorouracil 100μM, and irinotecan 10μM. Data shown 
represent three independent experiments for WHIM2 and four independent experiments for WHIM30; error 
bars represent standard deviation. Significance of treatment effects of each drug compared to control was 
determined by unpaired two-tailed t-tests: *p<0.05, **p<0.01, ***p<0.001. Reprinted by permission from 







2.4.4 BRCA1 status differs between two basal-like PDX lines 
Given the differential efficacy of carboplatin between the PDXs in vitro, and the association 
of BRCA1 mutations with sensitivity to platinum agents [157, 158], we became interested 
in the BRCA1 status of WHIM2 and WHIM30 tumors. Dr. Shunqiang Li (Washington 
University, St. Louis) confirmed that WHIM30 carries BRCA1 mutations whereas WHIM2 
does not. We verified this using our tumor RNA-sequencing data. Variant analyses 
revealed a total of 7 BRCA1 mutations in WHIM30 that were absent in WHIM2: 3 
synonymous mutations (rs16940, Leu-to-Leu; rs1799949, Ser-to-Ser; rs1060915, Ser-to-
Ser), 3 missense mutations (rs1799966, Ser-to-Gly; rs16942, Lys-to-Arg; rs16941, Glu-to-
Gly), and 1 mutation in the 3’-UTR (rs8176318) (Table 2.3; Fig. 2.5). According to our 
database searches, these specific mutations have been associated with familial breast and 
ovarian cancer. 
Table 2.3: Results of BRCA1 variant analyses in WHIM2 and WHIM30 mammary tumors. Adapted by 
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aIDs for mutations present in WHIM30 samples but not WHIM2 samples are bolded and italicized. 
bREF refers to the normal base in the human reference genome sequence. 
cALT refers to the altered base for each specific mutation.  





Figure 2.5: BRCA1 status differs between WHIM2 and WHIM30 tumors. Using the Integrated Genome 
Browser, the BRCA1 gene (human chromosome 17: 43,044,194-43,125,583) in WHIM2 and WHIM30 
sequences was aligned to a human reference genome and scanned for mutations, defined as 10 or more 
reads distinct from the reference genome. Point mutations were observed at positions 43,093,219 (rs16940) 
(a) and 43,093,448 (rs1799949) (b) in WHIM30, but not in WHIM2, tumor sequences. The labels T1, T2, 
and T3 represent the 3 tumor samples analyzed for each PDX line. Reprinted by permission from Springer 





2.4.5 Cancer therapeutics are differentially efficacious in treating PDX mammary tumors in vivo 
Based on in vitro studies, bortezomib, dacarbazine, carboplatin, and cyclophosphamide 
were administered to mice bearing PDX mammary tumors. The drugs were ineffective in 
shrinking WHIM2 tumors when treatment was initiated at 20mm2 (Fig. 2.6a) or just one 
week post-inoculation, when tumors were beginning to become palpable (Fig. 2.6b); for 
both studies, p>0.2 with each drug compared to vehicle at week 2. Treatment-week 
interactions, indicating treatment effects on tumor growth rate, were significant for 
cyclophosphamide (p<0.005) in both WHIM2 studies and for dacarbazine (p<0.03) and 
carboplatin (p<0.003) in the latter study, but insignificant otherwise (p>0.2). Carboplatin 
and cyclophosphamide were significantly effective, at both doses, in shrinking WHIM30 
mammary tumors when treatment was initiated at 20mm2 (Fig. 2.6c,d); with each drug 
compared to vehicle at week 3, carboplatin: p<0.001, cyclophosphamide: p<0.003. 
WHIM30 tumors treated with carboplatin or cyclophosphamide were eradicated by the 
study endpoint; however, bortezomib and dacarbazine were ineffective in vivo (Fig. 2.6d). 
Treatment-week interactions were significant for bortezomib (p<2.0x10-6), dacarbazine 
(p=0.0498), carboplatin (p<3.0x10-13), and cyclophosphamide (p<3.0x10-16). Bortezomib, 
though initially effective, was toxic at its most effective dose, with mice displaying signs of 
neurotoxicity. When WHIM30 tumors were treated starting at 50mm2, carboplatin and 
cyclophosphamide had similar efficacy compared with studies on smaller tumors, whereas 
bortezomib and dacarbazine were still ineffective (Fig. 2.6e); treatment-week interactions 
were insignificant (p>0.4). Cyclophosphamide was equally effective in treating WHIM30 
tumors when initiated at 100mm2 (Fig. 2.6f), with insignificant treatment-week interactions 
(p=0.06). Mice treated with high-dose cyclophosphamide were tumor-free by the endpoint 




             
Figure 2.6: Cancer therapeutics are differentially efficacious in treating WHIM2 and WHIM30 mammary 
tumors in vivo. Mice were treated IP with vehicle (normal saline), bortezomib, dacarbazine, carboplatin, or 
cyclophosphamide (high and low dosages indicated in Table 2.2). (a,c) IVIS images depicting WHIM2 (a) 
and WHIM30 (c) mammary tumors prior to treatment (Week 0), when tumors were approximately 20mm2, 
and after 1 and 2 weeks of treatment; images show two representative mice from each treatment group 
(bortezomib 0.3 mg/kg, dacarbazine 60 mg/kg, carboplatin 90 mg/kg, cyclophosphamide 75 mg/kg). (b,d) 
Effects of the four drugs on WHIM2 (b) and WHIM30 (d) tumor growth over time as measured by luciferase 
activity of the tumor region (bilateral tumors were considered one region of interest); values at each timepoint 
were averaged for all mice in each treatment group. Significance of treatment effects of each drug compared 
to vehicle was determined by Post-hoc Tukey’s Honest Significant Difference tests: *p<0.05, **p<0.01, 
***p<0.001. (e) Gross images of WHIM2 and WHIM30 mammary tumors after 4 weeks of treatment with the 
four drugs, when treatment was initiated at 50mm2. (f) Effect of low and high dose cyclophosphamide (Table 
2.2) on the growth of near-burden WHIM30 mammary tumors over time, as measured by luciferase activity 
of the tumor region. Reprinted by permission from Springer Nature: [149] © Springer Science+Business 
Media, LLC (2018) 
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2.4.6 Cancer therapeutics are differentially efficacious in treating PDX metastases in vivo 
Given their efficacy in treating mammary tumors, carboplatin and cyclophosphamide were 
tested in treating metastases generated by intracardiac injection of PDX cells. Using this 
model, the frequency of metastasis to specific organs was as follows: for WHIM2, 100% of 
mice develop metastases in the brain, 50% in the liver, 33% in the lung, 83% in the ovary, 
and 25% in the adrenal glands; for WHIM30, 100% of mice develop metastases in the 
brain, 100% in the liver, 78% in the lung, and 66% in the femur. Neither drug reduced 
WHIM2 metastasis burden in general (Fig. 2.7a), or specifically in the brain (p>0.5) (Fig. 
2.7b); treatment-week interactions were insignificant (p>0.06). Both drugs were effective in 
reducing WHIM30 brain metastases (Fig. 2.7c,d); with each drug compared to vehicle at 
week 5, p<2.0x10-4 for carboplatin and p<3.0x10-4 for cyclophosphamide, both with 
significant treatment-week interactions (p<4.0x10-10). Whole-body IVIS images (Fig. 2.7c) 
depicted differential efficacy of the drugs in treating WHIM30 metastases, therefore 
endpoint necropsies were performed on all mice to image the brain, liver, and lungs ex 
vivo. In some cohorts of mice, carboplatin and cyclophosphamide were equally effective in 
eliminating lung metastases, whereas carboplatin appeared to be superior to 
cyclophosphamide in treating liver metastases; both showed similar activity towards brain 
metastases (Fig. 2.7e). However, other cohorts showed considerably different efficacy 
profiles, with similar efficacy of the drugs in the three sites, or lacking efficacy (Fig. 2.8). 
Collectively, despite this variability, quantification of ex vivo luciferase activity in the three 
organs demonstrated that carboplatin and cyclophosphamide were each efficacious in 
reducing WHIM30 metastatic burden in the brain, liver, and lung (Fig. 2.7f); p-values for 
carboplatin and cyclophosphamide, respectively, compared to vehicle, were 0.04 and 0.04 
in the brain, 1.78x10-7 and 2.42x10-5 in the liver, and 3.09x10-8 and 4.48x10-8 in the lung. 
Carboplatin and cyclophosphamide had similar efficacy profiles, when compared to each 
other, in all three organs (Fig. 2.7f). Treatment efficacy in the liver was particularly striking 
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in some cohorts, in which we observed protruding tumor growths off the liver in vehicle-
treated mice, whereas the livers of drug-treated mice did not have grossly visible 
metastases (Fig. 2.7g). As aforementioned, some cohorts of mice did not show a complete 
treatment response (Fig. 2.8), which explains the smaller, albeit significant, treatment 







                  
Figure 2.7: Cancer therapeutics are differentially efficacious in treating WHIM2 and WHIM30 metastases in 
vivo. For metastasis studies, mice were injected with tumor cells in the left ventricle of the heart. Drug 
treatment was initiated 10 days following inoculation, allowing for proper seeding of metastases. Mice were 
treated IP weekly with vehicle (normal saline), carboplatin 90 mg/kg, or cyclophosphamide 75 mg/kg. (a,c) 
IVIS images depicting WHIM2 (a) and WHIM30 (c) metastases prior to treatment (Week 0), and after 2 and 
4 weeks of treatment; images show two representative mice from each treatment group. (b,d) Effects of the 
four drugs on the growth of WHIM2 (b) and WHIM30 (d) brain metastases over time as measured by 
luciferase activity in the brain region of the live mouse; values were averaged for all mice in each treatment 
group. (e) IVIS images of mice bearing WHIM30 metastases in vivo prior to euthanasia, and of brain, liver, 
and lung ex vivo, after 5 weeks of treatment with vehicle, carboplatin, or cyclophosphamide. Images are 
from one representative mouse per treatment group. (f) Effects of carboplatin and cyclophosphamide 
compared to vehicle on WHIM30 brain, liver, and lung metastases, as measured by luciferase activity of 
each organ ex vivo. Significance of treatment effects of each drug compared to vehicle was determined by 
Post-hoc Tukey’s Honest Significant Difference tests: *p<0.05, **p<0.01, ***p<0.001. (g) Gross images of 
livers from WHIM30 mice after treatment with vehicle, carboplatin, or cyclophosphamide. Reprinted by 




Figure 2.8: IVIS images of ex vivo brain, liver, and lungs from all mice used in WHIM30 metastasis studies 
evaluating the response to carboplatin and cyclophosphamide as compared to vehicle. Cohorts represent 
groups of mice used in each individual experiment. In each experiment, mice were intracardiac injected with 
WHIM30 tumor cells and treatment with vehicle or drug was initiated 10 days later, and continued until the 
vehicle group reached metastatic burden. At this endpoint, all mice were necropsied and brains, livers, and 
lungs were removed for IVIS imaging and analysis. Reprinted by permission from Springer Nature: [149] © 








2.4.7 Carboplatin and cyclophosphamide reduce the number and size of metastatic lesions 
H&E staining of WHIM30 metastases revealed differences in number and size of metastatic 
lesions between vehicle and both treatment groups, with larger lesions in the vehicle group; 
no tumor cells or metastatic lesions were observed in livers from carboplatin-treated mice 
(Fig. 2.9a). No metastases were observed in lungs from carboplatin- or cyclophosphamide-
treated mice (data not shown). Per whole-organ section, vehicle-treated mice had an 
average of 7.5 metastatic lesions in the brain (n=2) and 15.5 in the liver (n=2). Carboplatin-
treated mice had an average of 3.33 metastatic lesions in the brain (n=3) and 0 in the liver 
(n=3). Cyclophosphamide-treated mice had an average of 3.67 metastatic lesions in the 
brain (n=3) and 1 in the liver (n=3).  
2.4.8 PDX mammary tumors and metastases have distinct patterns of cytokeratin and vimentin 
expression 
To examine the effects of chemotherapeutic treatment on markers of malignant cellular 
processes at the tissue level, as well as differences in these markers between the two 
PDXs, WHIM2 and WHIM30 mammary tumors and metastases were analyzed by IHC for 
expression of pan-cytokeratin and vimentin as respective markers of epithelial and 
mesenchymal cell states, Ki67 and phosphohistone-H3 as markers of proliferation, and 
cleaved caspase-3 as a marker of apoptotic activity. All tissues were positive for Ki67 and 
phosphohistone-H3, and clusters of cleaved caspase-3-positive tumor cells were observed 
in many of the tissues; however, no differences were observed between treatment groups 
(data not shown). Patterns of cytokeratin and vimentin expression were distinct in WHIM2 
versus WHIM30 tissues. WHIM30 mammary tumors contained cells expressing either pan-
cytokeratin or vimentin (Fig. 2.9b). Regardless of treatment, WHIM30 brain metastases 
were cytokeratin-positive/vimentin-negative, surrounded by vimentin-positive stromal cells 
(Fig. 2.9b); 35/36 brain lesions were cytokeratin-positive, 36/36 were vimentin-negative. 
Liver metastases were either cytokeratin-positive/vimentin-negative or cytokeratin-
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negative/vimentin-positive (Fig. 2.9b); 26/35 liver lesions were cytokeratin-positive, 14/35 
were vimentin-positive. In contrast, WHIM2 tumors and metastases were all cytokeratin-
positive/vimentin-positive (Fig. 2.9c).  
 
 
Figure 2.9: WHIM30 metastases show a histological response to chemotherapeutics and have distinct 
patterns of cytokeratin and vimentin expression, in contrast to WHIM2 metastases. (a) H&E staining of 
WHIM30 brain and liver metastases after treatment with vehicle, carboplatin, or cyclophosphamide. All H&E 
images are 20X. (b) IHC analysis of cytokeratin and vimentin expression in WHIM30 mammary tumor, brain 
and liver metastasis tissue. Mammary tumor and brain images are 40X, liver images are 5X. (c) IHC analysis 
of cytokeratin and vimentin expression in WHIM2 mammary tumor, brain and liver metastasis tissue. 
Mammary tumor and liver images are 40X, brain images are 20X. Adapted by permission from Springer 




2.5 Discussion and conclusions 
Our goal was to determine if cancer therapeutics are equally effective in treating TNBC 
mammary tumors and metastases in the brain, liver, and lung, using two PDX models of basal-
like TNBC. We first screened drugs on PDX cells in suspension culture to identify those that 
may be effective in vivo. Cells in suspension culture clustered together over time, forming 
emboli-like aggregates, which recapitulate physiological tumor cell morphology, gene 
expression, signaling, microenvironment, and drug responses better than two-dimensional 
monolayers [159–161]. Other studies have demonstrated that PDX cultures maintain the 
characteristics and drug response profiles of their in vivo counterparts [148]; we found that 
mammary tumor and brain metastasis gene expression profiles were broadly maintained in 
suspension cultures over time. Of the twelve cancer therapeutics tested in vitro, some drugs 
were cytotoxic to both PDX lines, some were not cytotoxic to either line, and others were 
differentially effective between the two lines. Carboplatin was cytotoxic to WHIM30 cells but 
not to WHIM2 cells, likely attributable, at least in part, to BRCA1 status; BRCA1 mutations, 
present in WHIM30 but absent in WHIM2, are indeed associated with sensitivity to platinum-
based agents [157, 158].  
Surprisingly, efficacy profiles were not consistently comparable between in vivo and in vitro 
studies. WHIM30 mammary tumors could be eliminated by carboplatin or cyclophosphamide; 
the latter was equally effective when treatment was delayed until tumors were near-burden, 
recapitulating the clinical scenario in which a patient presents with an established, potentially 
high-grade tumor prior to receiving therapy. Bortezomib, despite its toxicity, slowed the growth 
of WHIM30 tumors. However, in contrast to in vitro results, all four drugs were ineffective in 
treating WHIM2 mammary tumors. Dacarbazine has a short physiological half-life [162] and 
may have greater efficacy if dosing parameters were altered. Of note, both the WHIM2 and 
WHIM30 PDXs were treatment naïve in origin—the original tumor samples were obtained from 
the patients prior to initiation of chemotherapy [117]. Therefore, prior exposure to 
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chemotherapeutics cannot explain the differential drug sensitivities observed in these models. 
However, the lack of treatment response in the WHIM2 model parallels clinical data indicating 
that the WHIM2 patient was treated with neoadjuvant doxorubicin, cyclophosphamide, and 
paclitaxel, which did not achieve a pathologic complete response; the patient developed 
metastatic disease in the brain less than one year following chemotherapy, whereas the 
WHIM30 patient was not reported to develop any post-treatment recurrences [117, 138].  
Basal-like tumors tend to metastasize to the brain, liver, and lungs [18]. Brain metastasis 
is a particularly significant cause of morbidity and mortality due to its severe neurological 
effects and the lack of effective treatment strategies [163, 164]. We therefore chose to generate 
metastases in mice via intracardiac injection, which has been used previously to study brain 
metastasis [53, 142, 143, 165, 166] and is a more efficient method of seeding tumor cells in 
the brain, liver, and lungs compared to spontaneous metastasis models. Although this model 
only mimics the later stages of metastasis, not initial intravasation, in our experience, mice 
bearing PDX mammary tumors only sporadically develop spontaneous brain metastases after 
primary tumor resection. We hypothesized that carboplatin and cyclophosphamide would have 
similar efficacy profiles in the metastatic setting as compared to the primary setting, especially 
given their abilities to cross the blood-brain barrier [167–169] and the similarities in overall gene 
expression profiles that we observed between primary tumors and metastases. Indeed, both 
drugs were effective in treating WHIM30 metastases in the brain, liver, and lung, suggesting 
that these metastatic tumor cells, despite growing in foreign microenvironments, retained 
properties of primary tumor cells that conferred sensitivity to certain drugs.  
To examine the effects of carboplatin and cyclophosphamide on mammary tumors and 
metastases at the cellular level, we evaluated the expression of markers of proliferation (Ki67, 
phosphohistone-H3) and apoptosis (cleaved caspase-3), as well as cytokeratin and vimentin. 
All tissues were positive for proliferation markers, with scattered tumor cells expressing cleaved 
caspase-3, without notable differences between treatment groups. Thus, the drugs did not 
37 
 
affect proliferation or apoptosis in remaining cells within the primary or metastatic setting. 
However, histologically, metastases in the brain and liver were smaller, and fewer or 
nonexistent, in drug-treated mice compared to vehicle-treated mice. Thus, the drugs were 
effective in reducing both the number and size of metastatic lesions, confirming the reduction 
in ex vivo luciferase activity, reflecting metastatic burden, in these organs in response to these 
treatments.  
Cytokeratin and vimentin—markers of epithelial cells and mesenchymal cells, 
respectively—are often used to reflect EMT, throughout which tumor cells downregulate 
cytokeratin and upregulate vimentin, transitioning from an adhesive phenotype to a migratory, 
invasive phenotype. Vimentin expression, particularly a high vimentin/keratin ratio, has been 
associated with basal-like tumors and is a poor prognostic indicator [170–172]. Neither 
carboplatin nor cyclophosphamide influenced cytokeratin or vimentin expression in any tissue, 
suggesting that neither drug induced or deterred EMT. However, we observed remarkably 
distinct patterns of cytokeratin and vimentin expression in WHIM2 and WHIM30 mammary 
tumors and metastases in the brain and liver, regardless of treatment, illuminating the possible 
existence of distinct tumor cell subpopulations within each PDX line. WHIM2 tumors and 
metastases were positive for both cytokeratin and vimentin, whose co-expression has been 
associated with more invasive tumor behavior [173]. In contrast, WHIM30 metastatic lesions 
were either cytokeratin-positive/vimentin-negative or cytokeratin-negative/vimentin-positive. 
Brain metastases were all cytokeratin-positive/vimentin-negative, with a ring of vimentin-
positive stromal cells surrounding each lesion. Reactive astrocytes are known to localize to 
sites of brain injury or tumor/metastasis growth and upregulate vimentin and other filament 
proteins [174–176]. Of note, these rings of vimentin-positive stromal cells were absent in 
WHIM2 brain metastases, which may indicate an impaired response of glial cells to these tumor 
cells, potentially affecting tumor behavior and treatment response [177–179]. High vimentin 
expression has been associated with drug resistance in breast cancer [180, 181] and other 
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cancer types [182–184]. Tumor cell subpopulations with distinct intermediate filament 
expression patterns may have differential sensitivities to therapeutics, in addition to their 
tendencies to form metastases in certain tissue types. Recent studies have demonstrated that 
different subpopulations of cells within primary tumors can co-migrate, seed, and invade distant 
tissues, resulting in heterogeneous metastatic lesions [185–188]. Based on our findings in the 
two models tested, we believe that distinct subpopulations of primary tumor cells may 
preferentially seed and thrive in different organs, and it appears that the brain may be more 
selective than the liver in terms of providing a microenvironment suitable for the colonization 
of particular subpopulations. Alternatively, certain subpopulations of tumor cells may have an 
enhanced ability to penetrate the blood-brain barrier. 
These studies highlight the importance of conducting in vivo studies of cancer therapeutics 
in different metastatic sites, as drug response can be impacted by physiological factors such 
as drug transport, metabolism, and microenvironment. Although in vitro screening assays are 
widely accepted in preclinical research, in vivo studies are superior when evaluating drug 
responses for advanced disease [189]. We have demonstrated that treatment responses can 
vary considerably between basal-like TNBC tumors derived from two different patients. This 
recapitulates the clinical challenges faced in cancer treatment, as patients with the same 
histologic or molecular subtype often respond differently to the same therapies. It is imperative 
to discover better ways to predict subsets of patients who will respond to particular therapies, 
just as we can now predict that the majority of patients with ER- and PR-positive tumors will 
respond to tamoxifen.  
2.6 Future directions 
Future studies will focus on investigating the mechanisms underlying the differential responses 
of WHIM2 and WHIM30 to chemotherapeutics, as well as employ additional PDX models to 
study chemotherapeutic resistance. These studies will assess differential gene expression in 
PDX cells with intrinsic sensitivity, intrinsic resistance, and acquired resistance to 
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chemotherapies such as carboplatin, to identify genes and pathways that may play a role in 
differential responses to these drugs.  Future studies will also focus on characterizing 
subpopulations of tumor cells with distinct cytokeratin and vimentin expression patterns and 
exploring their potential roles in metastatic propensity/tropism and treatment efficacy using 
additional TNBC PDX models. This will involve single-cell RNA sequencing of tumors to 
determine differential gene expression profiles within each distinct tumor cell subpopulation. 
Insights gained from this study will help design future in vivo studies evaluating the efficacy of 





















CHAPTER 3: Identification of synergistic drug combinations using breast cancer patient-
derived xenografts [190] 
 
Reprinted/adapted from Springer Nature: Nature Research, Scientific Reports; [190] Identification of 
synergistic drug combinations using breast cancer patient-derived xenografts; Turner TH, Alzubi MA, and 
Harrell JC; © the Authors (2020) https://creativecommons.org/licenses/by/4.0/legalcode 
 
3.1 Background and rationale 
It is estimated that each year over 268,000 American women will be diagnosed with invasive 
breast cancer, and over 41,000 will have fatal outcomes from the disease [19, 33]. Survival 
rates have considerably improved over the past several decades due to the identification and 
characterization of distinct histologic and molecular subtypes of breast cancer [11–14], which 
predict patient outcomes and have led to the development of targeted therapeutics, allowing 
treatment regimens to be tailored based on specific tumor characteristics [15–18]. ER/PR-
positive (predominantly luminal) tumors or HER2-positive (HER2-enriched) tumors, which 
collectively make up the majority of breast cancer cases, are treated with ER- or HER2-
targeted drugs, respectively, largely contributing to the current overall breast cancer 5-year 
survival rate of nearly 90% [19, 33]. However, for the approximately 15% of breast cancers that 
are histologically triple-negative, few clinically successful targeted therapies have yet been 
developed, despite major translational research efforts [34]. Patients with TNBC, a relatively 
aggressive and highly metastatic subtype, are therefore limited to treatment with 
chemotherapy, which is highly toxic and often ineffective in treating advanced disease, leading 
to relatively poor outcomes compared to patients with other subtypes of breast cancer [36, 37, 
191]. Development of successful therapeutic strategies for TNBC is a challenge due not only 
to the current lack of reliable drug targets, but also to the heterogeneity of the disease; TNBC 
can be classified based on gene expression profiles into four distinct subtypes, each of which 
is dominated by distinct molecular pathways, contributing to differential responses to 
chemotherapy and investigational targeted therapies [70, 71]. Nearly 60% of TNBCs are basal-
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like [70, 71], which is characterized by a high propensity to metastasize to vital organs and is 
associated with a particularly poor prognosis [15, 17, 18]. In the realm of translational breast 
cancer research, there is a critical need to identify reliable molecular targets in each subtype 
of TNBC, particularly basal-like, to enable the development of tailored therapeutic regimens 
with superior efficacy and less toxicity than current standard-of-care chemotherapeutic 
cocktails. Given the lack of clinical success with targeted therapies as single agents or 
combined with chemotherapies in TNBC, it is likely that novel combination strategies are 
needed to successfully treat this disease. 
3.2 Experimental approach 
To identify novel therapeutic candidates, we performed in vitro screening of 1,363 drugs in ten 
breast cancer PDX models. Using this approach, we generated a dataset that can be used to 
quickly assess and compare responses of breast cancer PDXs of varying subtypes to many 
different drugs, most of which are approved by the FDA for various cancer or non-cancer 
indications. From these data, we identified 176 drugs that were consistently effective across 
four basal-like TNBC PDXs, encompassing a wide variety of molecular targets and 
mechanisms of action. Several of these drugs have shown promising efficacy in TNBC and 
other solid tumors, however it is likely that incorporation into combination regimens is needed 
to maximize their efficacy and thus their likelihood of clinical success. Through a series of in 
vitro drug response assays, we selected four drugs to test in various two-drug combinations: 
carfilzomib (proteasome inhibitor), afatinib (EGFR inhibitor), and YM155 (inhibitor of 
baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5; survivin) expression), along with 
carboplatin, a chemotherapeutic that is part of the current standard-of-care for TNBC and that 
we have previously tested in several PDXs [149]. Given the overexpression of EGFR in basal-
like TNBC, and the involvement of its downstream pathways in multiple protumorigenic 
processes, we hypothesized that EGFR inhibition would be efficacious and have synergistic 
effects with several drugs due to the potential crosstalk of many drug target pathways with 
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EGFR signaling. Of the six drug combinations tested, we found that the combination of afatinib 
and YM155 was synergistically cytotoxic across four basal-like TNBC PDXs, and this drug 
combination significantly reduced PDX mammary tumor growth in vivo, without observable 
toxicity. We then analyzed the expression of the targets of these drugs (EGFR and BIRC5) 
across breast cancer PDXs, cell lines, and patients, and explored the effects of EGFR and 
BIRC5 co-expression on metastasis-free survival (MFS), to determine whether co-targeting of 
these genes may be a promising strategy for effective treatment of advanced basal-like TNBC. 
Through Western blotting for EGFR, we also gained preliminary insight into a potential 
mechanism of synergism between afatinib and YM155 in the context of this disease. 
3.3 Materials and methods 
3.3.1 Breast cancer PDX models and preparation of tumor cell suspensions 
Breast cancer PDX models of varying subtypes were used in these studies: triple-negative, 
basal-like (HCI01, HCI16, UCD52, WHIM2, WHIM30); triple-negative, LAR type (HCI09); 
ER-positive, luminal (HCI03, HCI11, HCI13); and HER2-enriched (HCI08). HCI01, HCI03, 
HCI08, HCI09, HCI11, HCI13, and HCI16 were obtained from the Huntsman Cancer 
Institute, University of Utah; WHIM2 and WHIM30 were obtained from Washington 
University, St. Louis; UCD52 was obtained from the University of Colorado. All studies 
involving mice were approved by the VCU Institutional Animal Care and Use Committee 
(IACUC) (Protocol# AD10001247; approved June 29, 2018), and all experiments were 
performed in accordance with IACUC guidelines and regulations. Tumor fragments were 
grown in the fourth mammary fat pads of female NSG mice. Established tumors were 
removed from mice, finely chopped, and digested for 1h at 37°C in DMEM/F12 containing 
5% FBS, 300 U/ml collagenase (Sigma), and 100 U/ml hyaluronidase (Sigma). Digested 
tumor tissue was then resuspended in ammonium chloride and trypsinized to generate 
single cell suspensions. Tumor cells were transduced with a lentivirus (BLIV101PA-1, 
Systems Biosciences) encoding GFP and luciferase, and GFP-luciferase expressing tumor 
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cells were suspended 1:1 in Matrigel (Corning) and injected into the fourth mammary fat 
pads of NSG mice (500,000 cells per injection). Mammary tumors were removed for 
experimental use once they reached approximately 100mm2 by caliper measurement. 
Tumors were processed into single cell suspensions as described above.  
3.3.2 Breast cancer cell lines 
Three basal-like TNBC cell lines, MDA468, HCC1143, and HCC1937, were employed to 
validate the results of PDX studies. MDA468 cells were provided by Dr. Youngman Oh 
(VCU Department of Pathology); HCC1143 and HCC1937 cells were obtained from the 
American Type Culture Collection (ATCC) and used within 10 passages of the original 
stocks. Cell lines were cultured in Roswell Park Memorial Institute 1640 (RPMI-1640) 
GlutaMAX medium (ThermoFisher Scientific) supplemented with 10% FBS and 
penicillin/streptomycin. 
3.3.3 Cell viability assays 
For PDX cell viability assays, PDX cell suspension cultures were plated in 96-well plates 
at 25,000 cells per well in M87 medium [135] and treated with drugs for 72h, followed by 
imaging and measurement of luciferase activity (total photon flux per second) two minutes 
after the addition of D-luciferin (15 mg/ml; Gold Biotechnology) to each well (1/10 of total 
volume per well), using the IVIS Spectrum In Vivo Imaging System (Xenogen IVIS-200) 
and Living Image software (PerkinElmer), as described in our previous work [149]. For cell 
line viability assays, MDA468, HCC1143, or HCC1937 cells were plated in 96-well plates 
at 5,000 cells per well in complete RPMI-1640 GlutaMAX medium, cultured overnight to 
allow for adherence, and subsequently treated with drugs for 72h. Viability of cell lines was 






3.3.4 In vitro drug screening studies 
PDX tumor cells (HCI01, HCI16, UCD52, WHIM2, WHIM30, HCI08, HCI09, HCI03, HCI11, 
HCI13) were treated with 1,363 drugs (ApexBio DiscoveryProbe FDA-approved Drug 
Library), at 10µM per drug, and cell viability was measured after 72h as described above. 
Drug response was assessed and compared between drugs and PDXs by calculating the 
percent of vehicle (0.1% dimethylsulfoxide (DMSO)) viability for each drug-treated well. 
Replicates were then averaged for each PDX and analyzed based on breast cancer 
subtype, with a focus on identifying promising targeted therapeutic candidates for basal-
like TNBC using four PDXs of this subtype (HCI01, UCD52, WHIM2, WHIM30). To select 
drug candidates for further studies, drug response data for each of these four PDXs were 
ranked in order of increasing efficacy (decreasing % of vehicle viability), and the 200 most 
effective drugs were chosen for each individual PDX line. We then used a Venn diagram 
(https://bioinfogp.cnb.csic.es/tools/venny/) to determine the extent of overlap in the most 
effective drugs across the four PDXs. Based on this analysis, we selected 176 drugs for 
further testing in basal-like TNBC models, consisting of: 1) 71 drugs that overlapped across 
all four PDXs, 2) 53 drugs that overlapped in three of the PDXs, 3) 48 drugs that overlapped 
in two of the PDXs, 4) two drugs that were exclusive to one of the PDXs (erlotinib and 
carboplatin), and 5) two drugs that were not included on these lists but were of interest from 
a mechanistic standpoint, to compare with other drugs with similar mechanisms of action 
(birinapant and bortezomib). All subsequent drug studies were performed using the same 
drug stock solutions purchased from ApexBio.  
3.3.5 Single-dose drug combination studies 
All drug combination studies were carried out in vitro using the same cell viability assay 
methods described above. For initial combination studies, the 176 selected drugs were 
tested on PDX cells (HCI01, UCD52, WHIM2, WHIM30) at 1µM alone and in combination 
with the proteasome inhibitor carfilzomib (10nM for HCI01, UCD52, and WHIM30; 100nM 
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for WHIM2) or the EGFR inhibitor afatinib (10nM for HCI01, UCD52, and WHIM2; 1µM for 
WHIM30). To assess for additive/supra-additive/sub-additive trends (defined here based 
on whether the efficacy of a combination was equal to/greater than/less than the sum of 
the efficacies of each drug alone), percent cell viability values were used to calculate the 
difference in percent inhibition between each drug as a single agent and in combination: 
(percent inhibition of combination) – [(percent inhibition of drug 1 alone) + (percent 
inhibition of drug 2 alone)]. Using this approach, if the calculated value for a combination is 
greater than zero, the combination has supra-additive trends; if it is zero, it has additive 
trends; if it is less than zero, it has sub-additive trends. The data generated in these studies 
were used to help select drugs of interest for more expansive combination testing, 
described below. 
3.3.6 Multiple-dose drug combination studies 
Based on initial screening and single-dose drug combination data, as well as drug target 
gene expression data, 13 drugs were selected for dose response analysis: three 
proteasome inhibitors (carfilzomib, bortezomib, ixazomib), five drugs that target apoptosis 
pathways (YM155, navitoclax, ABT-199, embelin, birinapant), an EGFR inhibitor (afatinib), 
a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor (abemaciclib), a selective serotonin 
reuptake inhibitor (SSRI) (fluoxetine), synthetic vitamin D3 (calcitriol), and an 
antiarrhythmic agent (dronedarone). These drugs included the two drugs tested in 
combination with the 176 drugs in the single-dose combination screen (carfilzomib and 
afatinib), one of the most effective of the 176 drugs in the prior screening studies (YM155), 
drugs with similar mechanisms of action (two additional proteasome inhibitors and four 
additional drugs that target apoptosis pathways), and drugs with mechanisms that are not 
typically targeted in cancer therapy (calcitriol, dronedarone, and fluoxetine). Basal-like 
TNBC PDX cells (HCI01, UCD52, WHIM2, WHIM30) were treated with increasing 
concentrations of each of the 13 drugs (ranging from 0.1-10µM) for 72h, followed by cell 
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viability measurement. Based on potency and efficacy across the four PDXs, three of these 
drugs (carfilzomib, YM155, and afatinib) were selected for subsequent combination testing, 
along with carboplatin, a chemotherapeutic agent that is part of the standard-of-care 
regimen for TNBC and that we have previously tested in several PDXs [149]. 
Pharmaceutical-grade carboplatin was obtained from the VCU Dalton Oncology Clinic. 
PDX cells (HCI01, UCD52, WHIM30) were treated for 72h in vitro with 7 doses of each 
drug alone, and with all possible two-drug combinations: carboplatin+carfilzomib, 
carboplatin+afatinib, carboplatin+YM155, carfilzomib+afatinib, carfilzomib+YM155, 
afatinib+YM155. Afatinib+YM155 was additionally tested in the WHIM2 PDX model, as well 
as three breast cancer cell lines (MDA468, HCC1143, HCC1937). Two independent 
experiments, each in triplicate, were performed for each PDX/cell line. Fraction inhibition 
(Fa) values were calculated using percent viability values for each drug and drug 
combination. Triplicate Fa values were averaged, and data were analyzed for drug 
combination effects using the CompuSyn software, which employs the Chou-Talalay 
method [192–194]. Combination index (CI) and dose reduction index (DRI) values, 
generated by CompuSyn software simulation, were averaged for each PDX/cell line and 
used to generate Fa-CI and Fa-DRI plots for each constant-ratio drug combination. 
3.3.7 Data clustering 
Data were hierarchically clustered using Cluster 3.0, and heatmaps were generated using 
Java Treeview. This was performed for drug response data (percent cell viability in 
response to the 176 drugs selected from initial screening, and difference in percent 
inhibition of the 176 drugs alone and in combination with carfilzomib or afatinib), as well as 
gene expression data (log2 (TPM+1) values) to assess drug target expression across the 
PDXs. The latter data were obtained from previous RNA-sequencing of PDXs [141], and 
are publicly available in the NCBI Gene Expression Omnibus (GEO Accession: 
GSE118942). Data were clustered by both drugs/genes and PDX line. 
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3.3.8 In vivo PDX drug treatment studies 
HCI01 cell suspensions were prepared from mammary tumors as described above and 
injected into the fourth mammary fat pads of NSG mice. After 12 days of tumor growth, 
monitored by weekly caliper measurements, mice were divided into four treatment groups: 
untreated (n=3), afatinib (n=3), YM155 (n=3), and afatinib+YM155 (n=3). Afatinib 
(AChemBlock) was dissolved in 1% methylcellulose + 0.1% Tween-80 and administered at 
25 mg/kg via daily oral gavage for 7 days. YM155 (Adooq Bioscience) was dissolved in 
saline and administered at 5 mg/kg as a 7-day continuous subcutaneous infusion via Alzet 
pump (Alzet 1007D). Alzet pumps were implanted subcutaneously on the back, posterior 
to the scapulae. During and following the treatment period, tumor growth was monitored 
via biweekly caliper measurements. Mice were weighed and observed regularly throughout 
the study for signs of illness or distress related to tumor growth and/or drug toxicity. All 
mice were euthanized by CO2 asphyxiation followed by cervical dislocation once tumors of 
untreated mice reached near protocol-defined tumor size limits. Tumors were then 
immediately removed, weighed ex vivo, and photographed. Alzet pumps were also 
removed and examined to confirm that all their contents were administered to the mice. 
3.3.9 Western blot studies 
HCI01 PDX cell suspensions were prepared from mammary tumors as described above, 
plated in 100mm dishes at 5 million cells per dish in M87 medium, and treated for 24h with 
vehicle (DMSO) or YM155 (1 or 10 nM). For protein extraction, treated HCI01 cell 
suspensions were pelleted and resuspended in Pierce RIPA buffer (ThermoFisher 
Scientific, 89900) + protease inhibitor (ThermoFisher Scientific, A32963) for cell lysis, and 
centrifuged at max speed at 4°C for 15 min to collect protein lysates. Protein concentrations 
were determined using Pierce BCA Protein Assay Kit (ThermoFisher Scientific, 23225). 
Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred to Immobilon-FL membranes (Millipore), which were then 
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blocked in Odyssey Blocking Buffer in Tris-buffered saline (TBS) (Li-Cor) for 1h at room 
temperature. Primary and secondary antibodies were diluted in Odyssey Blocking Buffer in 
TBS (Li-Cor) + 0.1% Tween-20. Membranes were incubated for 1h at room temperature 
with rabbit anti-β-actin (1:1000; Cell Signaling Technology #4970) and overnight at 4°C 
with rabbit anti-EGFR (1:1000; Cell Signaling Technology #4267). For detection, 
membranes were incubated with IRDye 680RD donkey anti-rabbit secondary antibody 
(1:10,000; Li-Cor 926-68073) for 1h at room temperature. All washes were performed using 
TBS-T (TBS + 0.1% Tween-20). Membranes were imaged using the Odyssey Fc Imaging 
System (Li-Cor). Densitometry analysis was performed using ImageJ software; EGFR was 
normalized to actin.  
3.3.10 Analysis of EGFR and BIRC5 gene expression in PDXs, cell lines, and patients 
Expression levels of EGFR and BIRC5 were assessed using a PDX RNA-sequencing 
dataset [141], as well as RNA-sequencing data from two publicly available breast cancer 
cell line gene expression databases: the Harvard Medical School (HMS) Library of 
Integrated Network-based Cellular Signatures (LINCS) Breast Cancer Profiling Project 
(http://lincs.hms.harvard.edu/db/datasets/20348/) and the Broad Institute Cancer Cell Line 
Encyclopedia (CCLE) (https://portals.broadinstitute.org/ccle). Gene expression data from 
LINCS are represented as RPKM (reads per kilobase of transcript, per million mapped 
reads) values, and those from CCLE are represented as log2 RPKM values. Expression of 
the two genes was also assessed using a breast cancer patient dataset consisting of 
microarray gene expression data and clinical data [53, 195] from 855 patients; this dataset 
was generated by combining four breast cancer microarray datasets (GSE2034, 
GSE12276, GSE2603, and NKI295) [18]. PDXs, cell lines (from each database separately), 
and the 855-patient data were each grouped based on breast cancer intrinsic subtype, and 
EGFR and BIRC5 expression values were averaged for each subtype.  
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3.3.11 Assessment of the effects of EGFR and BIRC5 expression on patient clinical parameters 
and outcomes 
The 855-patient dataset was used to assess the relationships between EGFR/BIRC5 
expression and clinical parameters/outcomes. Pearson correlations were performed to 
determine correlations between EGFR/BIRC5 expression and clinical characteristics 
(breast cancer intrinsic subtype, ER/PR/HER2 status, patient age, lymph node status, 
differentiation and proliferation scores, MFS time, as well as relapse-free survival in the 
brain, liver, and lung). The 140 patients with basal-like tumors were ranked and divided 
based on EGFR and BIRC5 expression separately: EGFRhigh (top 50%) or EGFRlow (bottom 
50%) and BIRC5high (top 50%) or BIRC5low (bottom 50%). These patients were 
subsequently divided into four groups based on the designated expression levels (high or 
low) for each gene: EGFRhighBIRC5high (N=32), EGFRhighBIRC5low (N=38), 
EGFRlowBIRC5high (N=38), EGFRlowBIRC5low (N=32). Kaplan-Meier analysis was performed 
to determine the differences across these four groups in terms of MFS time, liver relapse-
free survival, and lung relapse-free survival. 
3.3.12 Statistical analyses 
Statistical analyses were performed using unpaired two-tailed student’s t-tests to determine 
the significance of differences in cell viability between control and drug-treated conditions 
in vitro, the significance of differences in drug target gene expression between PDXs, as 
well as the significance between all treatment conditions in vivo; p<0.05 was considered 
statistically significant. For the single-dose drug combination studies, we performed 
unpaired two-tailed t-tests to determine the significance of differences between mean 
differences in percent inhibition across PDXs, and we calculated 95% confidence intervals 
of the mean differences in percent inhibition and of the proportion of PDXs showing supra-
additive or sub-additive trends based on our analysis method. Where appropriate, data are 
presented as means ± standard deviations. Tukey’s multiple comparisons tests were 
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performed to analyze differences in EGFR and BIRC5 expression between breast cancer 
subtypes using the 855-patient dataset. Relationships between EGFR and BIRC5 
expression and clinical characteristics in the 855-patient dataset were analyzed by Pearson 
correlation. The effects of EGFR and BIRC5 expression on MFS in patients with basal-like 
breast cancer were statistically analyzed using log-rank tests. All statistical tests were 
performed using GraphPad Prism 8.  
3.4 Results 
3.4.1 Drug screening of breast cancer PDXs reveals potential targeted therapeutic candidates 
for TNBC 
Given the lack of successful targeted therapies currently available for the treatment of 
TNBC, and the superior clinical relevance of using PDX cultures as opposed to cell lines 
for assessing drug response in cancer [189], we first sought to identify effective targeted 
agents through drug screening of breast cancer PDXs: basal-like TNBC (HCI01, HCI16, 
UCD52, WHIM2, WHIM30), LAR subtype TNBC (HCI09), luminal ER-positive (HCI03, 
HCI11, HCI13), and HER2-enriched (HCI08). We characterized response profiles, in terms 
of percent cell viability, of these PDXs of varying breast cancer subtypes to 1,363 drugs, 
most of which are FDA-approved for various cancer/non-cancer indications (Appendix A). 
This dataset is most appropriately useful for assessing drugs that are cytotoxic to tumor 
cells (less than 100% viability in response), as several drugs or classes of drugs, most 
notably HDAC inhibitors, appeared to increase tumor cell viability, due to activation of the 
cytomegalovirus (CMV) promoter responsible for luciferase expression in the PDX models; 
HDACs are known to inactivate viral promoters [196], and HDAC inhibitors have been 
shown to enhance CMV promoter activity [197–199]. It is possible that other drugs may 
affect CMV promoter activity as well. Using this drug screening dataset, we identified 176 
drugs that were most cytotoxic across four of the basal-like PDXs (HCI01, UCD52, WHIM2, 
WHIM30) (Fig. 3.1a), encompassing an interestingly wide range of molecular targets, 
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mechanisms of action, and indications (Appendix A, bolded drugs). The variety of proteins 
and pathways targeted by these drugs include the cell cycle, proteasome, ion channels, 
apoptosis pathways, calcium/vitamin D receptor (VDR) signaling, EGFR and mitogen-
activated protein kinase (MAPK) signaling, and serotonin signaling, as well as several non-
human, microbial pathogen targets, indicating these drugs for treatment of a range of 
diseases, including cancer, cardiac arrhythmias, calcium imbalance, depression, and 
bacterial/viral/parasitic infections. Although several drugs of similar classes or with similar 
mechanisms of action (e.g. doxorubicin and epirucibin, fluoxetine and duloxetine, 
benidipine and amlodipine) clustered together in terms of PDX drug response profiles, most 
drugs of similar classes or mechanisms were part of distinct clusters. Analysis of previous 
RNA-sequencing data [141] revealed that about half of the genes encoding human targets 
of the 176 drugs are highly expressed across TNBC PDXs (Fig. 3.1b). Among the highly 
expressed genes in TNBC PDXs were CDK4, proteasome subunit beta 5 (PSMB5), EGFR, 
BIRC5 (survivin), and VDR, which encode the targets of abemaciclib (LY2835219), 
carfilzomib/bortezomib/ixazomib, afatinib, YM155, and calcitriol, respectively. Conversely, 
many of the drug target genes were differentially expressed to some extent between the 
TNBC PDXs (Appendix B), which may provide insight into their differential responses to 
certain drugs. For example, many of these genes were differentially expressed between 
WHIM2 and WHIM30, which we previously showed were differentially responsive to 
chemotherapeutics [149]. Most notably, ABCG2 and PTGS2 (prostaglandin endoperoxide 
synthase 2), which respectively encode a multidrug efflux transporter and a pro-
inflammatory enzyme that has been associated with breast cancer brain and lung 




Figure 3.1: Selection of targeted drug candidates in TNBC PDXs based on a 1,363-drug screen. (a) 
Heatmap showing relative response to 176 drugs across PDXs of varying subtypes, selected based on 
efficacy in basal-like TNBC PDXs (HCI01, UCD52, WHIM2, WHIM30) on initial screening of 1,363 drugs at 
10µM. Hierarchical clustered cell viability data (average percent of vehicle) are represented in the heatmap 
for comparison of drug response across PDXs (n=2 per PDX). The 1,363-drug screening data are provided 
in Appendix A, with the 176 selected drugs bolded. (b) Heatmap showing relative expression of target genes 
of the 176 selected drugs across TNBC PDXs. Clustered log2 (TPM+1) values from PDX RNA-sequencing 
data (averaged for each PDX) are represented in the heatmap for analysis of target gene expression levels 





3.4.2 Carfilzomib and afatinib have supra-additive trends when combined with other select 
targeted agents 
Although proteasome and EGFR inhibitors have demonstrated preclinical efficacy in TNBC, 
it is likely that synergistic combinations with other targeted agents are necessary to achieve 
efficacy that is sufficient for clinical success [200–206]. We therefore tested carfilzomib and 
afatinib in combination with each of the 176 selected drugs, at a 10-fold lower dose (1µM) 
relative to prior screening assays, in four basal-like PDXs (HCI01, UCD52, WHIM2, 
WHIM30) (Appendices C,D). Drug combination effects were assessed by calculating the 
difference in percent inhibition (efficacy) between each combination and each drug alone, 
with positive values indicating supra-additivity (efficacy of combination > sum of efficacies 
of each drug alone), zero indicating additivity (efficacy of combination = sum of efficacies 
of each drug alone), and negative values indicating sub-additivity (efficacy of combination 
< sum of efficacies of each drug alone). There was considerable heterogeneity in drug 
combination effects between the PDXs (Fig. 3.2), which is reflective of the heterogeneity 
in drug response seen in patients with the same tumor subtypes in the clinic. Given our 
goal of identifying treatments that have the potential to provide maximal clinical benefit for 
TNBC patients, we chose to focus on drugs that were effective across multiple PDX models 
of basal-like TNBC. Several drugs were found to have additive or supra-additive trends in 
at least two of the four basal-like PDXs when combined with carfilzomib (including 
benidipine, bexarotene, carvedilol, isoconazole, embelin, dronedarone, and abemaciclib) 
(Fig. 3.2a) or afatinib (including benidipine, bexarotene, carvedilol, isoconazole, fluoxetine, 
amiodarone, candesartan, and dovitinib) (Fig. 3.2b), providing several drugs/drug classes 
of interest for further studies. When mean differences in percent inhibition were analyzed 
across all four PDXs (relative to a difference in percent inhibition of zero), only isoconazole 
and meclizine were significantly supra-additive when combined with carfilzomib and only 
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bexarotene was significantly supra-additive when combined with afatinib; all other drugs 






        
Figure 3.2: Efficacy of 176 selected drugs combined with carfilzomib or afatinib in basal-like TNBC PDXs. 
PDX cells (HCI01, UCD52, WHIM2, WHIM30) were treated with 176 drugs at 1µM +/- carfilzomib or afatinib. 
Difference in percent inhibition of cell viability between each drug combination and each drug alone was 
calculated to assess for additive, supra-additive, or sub-additive trends: (percent inhibition of combination) 
– [(percent inhibition of drug 1 alone) + (percent inhibition of drug 2 alone)]. Heatmaps depict clustered 
differences in average percent inhibition between each of the 176 drugs combined with carfilzomib (a) or 
afatinib (b) compared with either drug alone; n=2 for HCI01, UCD52, WHIM2; n=3 for WHIM30. Differences 
in percent inhibition of 0 indicate additive trends (white), >0 indicate supra-additive trends (blue), and <0 
indicate sub-additive trends (red). The 176 selected drugs +/- carfilzomib/afatinib combination data, along 
with confidence intervals and p-values, are provided in Appendices C-F. Reprinted from [190] 
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3.4.3 Carfilzomib, afatinib, and YM155 are cytotoxic to TNBC PDX cells 
Given that the prior combination studies consisted of a single dose of each drug, this posed 
a significant limitation in that it was not possible to assess additive or supra-additive trends 
in combination with drugs that were highly cytotoxic as single agents at 1µM, such as 
YM155 (Appendices C,D). Therefore, several drugs/classes of drugs were selected for 
dose response testing to assess both potency and efficacy across the four basal-like PDX 
lines: carfilzomib, bortezomib, and ixazomib (proteasome inhibitors) (Fig. 3.3a); YM155 
(survivin inhibitor), navitoclax and ABT-199 (B-cell lymphoma 2 (BCL2) inhibitors), embelin 
(X-linked inhibitor of apoptosis (XIAP) inhibitor), and birinapant (inhibitor of apoptosis (IAP) 
inhibitor/second mitochondria-derived activator of caspases (SMAC) mimetic), all of which 
promote apoptosis (Fig. 3.3b); afatinib (EGFR inhibitor), abemaciclib (CDK4/6 inhibitor), 
fluoxetine (SSRI), calcitriol (synthetic vitamin D3), and dronedarone (ion channel blocker) 
(Fig. 3.3c). All p-values are listed in Table 3.1. Proteasome inhibitors were significantly 
effective across the PDXs in the micromolar range; it should be noted that certain doses of 
ixazomib and/or bortezomib appeared to cause an increase in cell viability in HCI01 and 
WHIM2 at lower doses, followed by a decrease in viability with higher doses, which we 
believe to be due to proteasome inhibitor activity at CMV promoters causing an increase in 
expression of luciferase, as seen with HDAC inhibitors in the 1,363-drug screen. The 
survivin inhibitor YM155 was the most potent drug tested and was significantly effective 
across all four PDXs in the nanomolar range. Carfilzomib, YM155, and afatinib were 
selected for subsequent multiple-dose combination studies, given their efficacy across 





Figure 3.3: Dose responses of basal-like TNBC PDXs to selected classes of targeted therapeutics. Graphs 
depict cell viability (percent of vehicle) in response to increasing concentrations of the indicated drugs for 
each of four basal-like PDX lines (HCI01, UCD52, WHIM30, WHIM2): (a) proteasome inhibitors (carfilzomib, 
bortezomib, ixazomib); (b) drugs targeting apoptosis pathways (YM155, navitoclax, ABT-199, embelin, 
birinapant); and (c) EGFR inhibitor (afatinib), CDK4/6 inhibitor (abemaciclib), SSRI (fluoxetine), synthetic 
vitamin D3 (calcitriol), antiarrhythmic (dronedarone). Experiments were performed in triplicate. Error bars 











Table 3.1: P-values for in vitro dose response experiments shown in Figure 3.3. t-tests were performed to 
compare each drug treatment condition with vehicle controls for each PDX line. Significant values (p<0.05) 
are bolded and italicized. Adapted from [190] 
HCI01 N a 0.01µM 0.1µM 1µM 10µM 
Bortezomib 2 0.063381 0.005474 0.000043 0.000092 
Carfilzomib 3 0.04963 0.007833 0.005388 <0.000001 
Ixazomib 2 0.110962 0.06093 0.001144 0.001801 
ABT-199 3 0.007255 0.001172 0.00003 0.000083 
Birinapant 3 0.000288 0.00015 0.000021 0.000003 
Embelin 3 0.007419 0.000892 0.000018 0.001437 
Navitoclax 4 0.001159 0.001534 0.000527 0.002758 
YM155 4 0.000238 0.000005 <0.000001 <0.000001 
Abemaciclib 2 0.014298 0.03196 0.000116 0.000001 
Afatinib 2 0.221783 0.044243 0.036208 N/A 
Calcitriol 2 0.000008 0.000193 0.002056 0.003609 
Dronedarone 2 0.000991 0.002264 0.000811 0.057112 
Fluoxetine 2 0.000008 0.104927 0.041811 0.20296 
UCD52 N a 0.01µM 0.1µM 1µM 10µM 
Bortezomib 3 0.026413 0.000039 <0.000001 <0.000001 
Carfilzomib 4 0.091647 0.032814 <0.000001 <0.000001 
Ixazomib 3 0.004423 0.014659 0.000068 <0.000001 
ABT-199 3 0.183095 0.652814 0.268487 0.000003 
Birinapant 3 0.319556 0.024892 0.006759 0.001068 
Embelin 3 0.156021 0.937212 0.868763 0.962227 
Navitoclax 4 0.830949 0.996264 0.029684 0.005872 
YM155 4 0.000112 <0.000001 <0.000001 <0.000001 
Abemaciclib 4 0.29377 0.41761 0.030087 <0.000001 
Afatinib 4 0.062199 0.009366 0.000071 <0.000001 
Calcitriol 3 0.050349 0.000418 0.000007 0.000643 
Dronedarone 3 0.317764 0.200828 0.004828 0.000084 
Fluoxetine 3 0.16584 0.160174 0.073714 0.062933 
WHIM30 N a 0.01µM 0.1µM 1µM 10µM 
Bortezomib 3 0.815718 0.000042 0.000006 <0.000001 
Carfilzomib 4 0.746654 0.000106 <0.000001 0.000004 
Ixazomib 3 0.000619 0.361073 0.000107 <0.000001 
ABT-199 2 0.301903 0.333421 0.534922 0.014036 
Birinapant 2 0.00193 0.004334 0.009629 0.011227 
Embelin 2 0.087373 0.168851 0.031747 0.114093 
Navitoclax 2 0.03891 0.420622 0.490906 0.175765 
YM155 2 0.003486 0.000422 0.001594 0.000244 
Abemaciclib 2 0.686389 0.769689 0.97588 0.858871 
Afatinib 2 0.208958 0.158912 0.378832 0.001984 
Table continues on next page 
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Table 3.1, continued 
Calcitriol 1 N/A N/A N/A N/A 
Dronedarone 1 N/A N/A N/A N/A 
Fluoxetine 1 N/A N/A N/A N/A 
WHIM2 N a 0.01µM 0.1µM 1µM 10µM 
Bortezomib 3 0.068183 0.059901 0.058861 0.000033 
Carfilzomib 4 0.310044 0.333459 0.000359 0.000278 
Ixazomib 3 0.000784 0.05822 0.15067 0.06533 
ABT-199 2 0.355539 0.089689 0.028295 0.669916 
Birinapant 2 0.482637 0.000351 0.002711 0.006058 
Embelin 2 0.572152 0.347313 0.115227 0.040586 
Navitoclax 3 0.231318 0.024578 0.617452 0.002852 
YM155 3 0.000252 0.000069 0.001651 0.000426 
Abemaciclib 4 0.153799 0.459897 0.422449 <0.000001 
Afatinib 4 0.167517 0.003227 0.000542 0.000036 
Calcitriol 2 0.529639 0.009585 0.002376 0.037265 
Dronedarone 2 0.534513 0.280651 0.977216 0.070761 
Fluoxetine 2 0.175073 0.214316 0.663944 0.702763 
     a N indicates number of independent experiments for each drug tested. 
 
 
3.4.4 Afatinib and YM155 are synergistically cytotoxic across TNBC PDXs 
We next sought to identify synergistic combinations among drugs we have established as 
consistently effective with highly expressed drug targets in basal-like TNBC PDXs 
(carfilzomib, YM155, and afatinib), as well as carboplatin, a standard-of-care 
chemotherapeutic agent. HCI01, UCD52, and WHIM30 cells were treated with seven doses 
of each of these four drugs (WHIM2 cells with afatinib and YM155 only), and all possible 
two-drug combinations. Percent viability values were converted into fraction inhibition 
values (Fa). Drug doses were tailored for each PDX (Table 3.2) based on prior dose 
response data to achieve a consistent dose response for each drug across the PDXs, and, 
as established previously, the four drugs were significantly cytotoxic to these PDX cells, 
and YM155 was the most potent of the four drugs tested in the PDXs (Fig. 3.4); all p-values 





Table 3.2: Drug doses used for in vitro dose response experiments shown in Figure 3.4. Adapted from [190] 
Carboplatin (µM) Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 Dose 7 
HCI01 0.4 2 10 50 250 500 1000 
UCD52 0.04 0.2 1 5 25 125 625 
WHIM30 0.16 0.8 4 20 100 200 400 
Carfilzomib (µM) Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 Dose 7 
HCI01 0.004 0.02 0.1 0.5 2.5 12.5 62.5 
UCD52 0.0016 0.008 0.04 0.2 1 5 25 
WHIM30 0.0008 0.004 0.02 0.1 0.5 2.5 12.5 
Afatinib (µM) Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 Dose 7 
HCI01 0.004 0.02 0.1 0.5 2.5 12.5 62.5 
UCD52 0.0004 0.002 0.01 0.05 0.25 1.25 6.25 
WHIM30 0.04 0.2 1 5 10 20 40 
WHIM2 0.0004 0.002 0.01 0.05 0.25 1.25 6.25 
YM155 (µM) Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 Dose 7 
HCI01 0.00008 0.0004 0.002 0.01 0.05 0.25 1.25 
UCD52 0.00004 0.0002 0.001 0.005 0.025 0.125 0.625 
WHIM30 0.00004 0.0002 0.001 0.005 0.025 0.125 0.625 
WHIM2 0.00008 0.0004 0.002 0.01 0.05 0.25 1.25 
               
                       
Figure 3.4: Dose responses of basal-like TNBC PDXs to four promising drug candidates. Graphs depict cell 
viability (percent of vehicle) in response to increasing concentrations of carboplatin (a), carfilzomib (b), 
afatinib (c), or YM155 (d) for each PDX line (HCI01, UCD52, WHIM30, WHIM2). Each experiment was 
performed in triplicate. Error bars represent standard deviation between independent experiments (n=2 for 
each PDX); drug doses are listed in Table 3.2, and p-values are listed in Table 3.3. Reprinted from [190] 
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Table 3.3: P-values for in vitro dose response experiments shown in Figure 3.4. t-tests were performed to 
compare each drug treatment condition with vehicle controls for each PDX line. Significant values (p<0.05) 
are bolded and italicized. Adapted from [190] 
Carboplatin Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 Dose 7 
HCI01 0.011969 0.188374 0.000454 0.003011 0.000032 0.000084 0.000222 
UCD52 0.073298 0.018515 0.108632 0.024821 0.000717 0.000519 0.000599 
WHIM30 0.046447 0.000012 0.090614 0.008275 0.000309 <0.000001 0.063431 
Carfilzomib Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 Dose 7 
HCI01 0.425251 0.007535 0.013284 0.001064 0.000463 0.000027 0.000004 
UCD52 0.000417 0.291974 0.023256 0.017735 0.000731 0.000625 0.000382 
WHIM30 0.00319 0.131364 0.000132 0.0323 0.000143 0.000083 <0.000001 
Afatinib Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 Dose 7 
HCI01 0.076782 0.210436 0.001735 0.007566 0.000711 0.000058 0.000073 
UCD52 0.210197 0.007077 0.009177 0.002972 0.019954 0.000267 0.000522 
WHIM30 0.00052 0.028389 0.013618 0.000322 0.000013 0.000003 0.000002 
WHIM2 0.187042 0.99756 0.257375 0.012296 0.001094 0.115623 0.000009 
YM155 Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 Dose 7 
HCI01 0.000167 0.154071 0.011395 0.016656 0.00195 0.000156 0.000009 
UCD52 0.217038 0.099011 0.009378 0.047491 0.005413 0.001095 0.000506 
WHIM30 0.18806 0.088101 0.08598 0.000325 0.000149 0.000179 0.000579 
WHIM2 0.994948 0.00007 0.032879 0.572891 0.001695 0.000122 0.000029 
 
 
To identify synergistic drug combinations, data were analyzed using CompuSyn [192–194] 
to determine CI and DRI values for each drug combination tested at a constant dose ratio. 
CI values indicate the effect of combining multiple drugs (synergistic, additive, or 
antagonistic); DRI values represent the fold decrease in the dose of a drug needed when 
in a combination to achieve the same efficacy (Fa) as the drug alone. Using this approach, 
drug combinations with CI values <1 are synergistic, and DRI values >1 are favorable given 
the concern for toxicity when combining multiple drugs. When assessing drug combinations 
for cancer treatment, these criteria are most important if met at high effect (Fa) levels, when 
the drug combinations are killing most of the tumor cells, as this is the goal of cancer 
therapy. We therefore considered any drug combination with CI<1 and DRI>1 (for both 
drugs in the combination) at Fa>0.75 to be a promising combination. Based on CI values: 
carboplatin was synergistic with carfilzomib, afatinib, and YM155 in UCD52 and WHIM30; 
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carfilzomib was synergistic with afatinib in WHIM30 and with YM155 in UCD52; and afatinib 
was synergistic with YM155 in HCI01, UCD52, WHIM30, and WHIM2 (Fig. 3.5). DRI values 
were favorable for carboplatin when combined with carfilzomib, afatinib, or YM155 in 
UCD52 and WHIM30; for carfilzomib when combined with carboplatin, afatinib, or YM155 
in HCI01, UCD52, and WHIM30; for afatinib when combined with carboplatin, carfilzomib, 
or YM155 in HCI01, UCD52, and WHIM30, and with YM155 in WHIM2; and for YM155 
when combined with carboplatin, carfilzomib, or afatinib in HCI01, UCD52, and WHIM30, 
and with afatinib in WHIM2 (Fig. 3.6). Collectively, these data indicate that the combination 
of afatinib and YM155 is synergistic, with favorable dose reductions, across all four basal-
like PDX lines tested. Afatinib and YM155 were also found to be effective as single agents 
(Fig. 3.7a,b) and synergistic (Fig. 3.7c) with favorable dose reductions (Fig. 3.7d,e) in 
three basal-like TNBC cell lines (MDA468, HCC1143, HCC1937), further confirming the 
efficacy and synergism of afatinib and YM155 in basal-like TNBC. All p-values for data 
shown in Fig. 3.7a,b are listed in Table 3.4. 
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Figure 3.5: Drug combination analysis reveals synergism between afatinib and YM155 across four basal-
like TNBC PDXs. PDX cells were treated with four drugs (carboplatin, carfilzomib, afatinib, and YM155), 
seven doses each, alone and in all possible two-drug combinations. Combination index (CI) values were 
generated using CompuSyn software, and Fa-CI plots were generated using constant dose ratio combination 
data for each of the six drug combinations in each of the PDXs. CI<1 indicates synergism; CI=1 indicates 
additivity; CI>1 indicates antagonism. The regions highlighted in yellow are synergistic (CI<1) at optimal 
effect levels (Fa>0.75). Dose ratios (Drug1:Drug2) for each drug combination and PDX are indicated in the 




                    
Figure 3.6: Drug combination analysis reveals favorable dose reduction of several drugs when combined 
with other agents in basal-like TNBC PDXs. PDX cells were treated with four drugs (carboplatin, carfilzomib, 
afatinib, and YM155), seven doses each, alone and in all possible two-drug combinations. Dose reduction 
index (DRI) values were generated using CompuSyn software, and Fa-DRI plots were generated using 
constant dose ratio combination data for each of the six drug combinations in each of the PDXs. DRI 
indicates the fold decrease in drug dose needed to achieve a given effect when in combination with another 
drug vs. as a single agent. DRI>1 indicates favorable dose reduction; DRI<1 indicates unfavorable dose 
reduction. Dose ratios (Drug1:Drug2) for each drug combination and PDX are indicated in the legend of each 




Figure 3.7: Afatinib and YM155 are synergistically cytotoxic to three basal-like TNBC cell lines. MDA468, 
HCC1143, and HCC1937 cells were treated in triplicate for 72h in vitro with seven doses of afatinib or 
YM155, as well as all possible dose combinations of the two drugs. Graphs depict cell viability (percent of 
vehicle) of each of the three cell lines in response to afatinib (a) or YM155 (b). Two independent experiments 
were performed for each cell line; error bars represent standard deviation; p-values are listed in Table 3.4. 
Data were analyzed using CompuSyn software, and constant dose ratio combination data were used to 
generate a Fa-CI plot (c) and Fa-DRI plots for both afatinib (d) and YM155 (e). Dose ratios (Drug1:Drug2) 
for each cell line are indicated in the graph legends. CI<1 indicates synergism; CI=1 indicates additivity; 
CI>1 indicates antagonism. The region highlighted in yellow is synergistic (CI<1) at optimal effect levels 
(Fa>0.75). DRI indicates the fold decrease in drug dose needed to achieve a given effect when in 
combination with another drug vs. as a single agent. DRI>1 indicates favorable dose reduction; DRI<1 
indicates unfavorable dose reduction. Reprinted from [190] 
 
Table 3.4: P-values for in vitro dose response experiments shown in Figure 3.7a,b. t-tests were performed 
to compare each drug treatment condition with vehicle controls for each cell line. Significant values (p<0.05) 
are bolded and italicized. Adapted from [190] 
Afatinib 0.0032μM 0.016μM 0.08μM 0.4μM 2μM 10μM 50μM 
MDA468 0.005145 0.00005 0.000268 0.000776 0.000685 0.005603 0.000036 
HCC1143 0.003195 0.107024 0.048012 0.004614 0.018885 0.016815 0.000443 
HCC1937 0.028664 0.007818 0.015839 0.000845 0.014367 0.003326 0.001422 
YM155 0.000064μM 0.00032μM 0.0016μM 0.008μM 0.04μM 0.2μM 1μM 
MDA468 0.046448 0.041252 0.005506 0.000008 <0.000001 <0.000001 <0.000001 
HCC1143 0.002632 0.008782 0.026343 0.012459 0.000029 0.000006 <0.000001 







3.4.5 Afatinib and YM155 reduce PDX mammary tumor growth in vivo 
To validate the efficacy of afatinib and YM155 in vivo, mice bearing HCI01 PDX mammary 
tumors were either untreated or treated with afatinib alone, YM155 alone, or 
afatinib+YM155. Both afatinib and YM155 as single agents, as well as afatinib and YM155 
combined, significantly reduced mammary tumor growth over time compared to the control 
group (Fig. 3.8a). YM155 was significantly more effective as a single agent in reducing 
tumor growth compared to afatinib as a single agent, and the combination of 
afatinib+YM155 was significantly more effective than afatinib alone; there was no 
significant difference in tumor growth between YM155 alone and afatinib+YM155 treated 
groups (Fig. 3.8a). All p-values are listed in Table 3.5. Importantly, mice did not display 
any signs of drug toxicity throughout or following the treatment period, and no considerable 
changes in mouse weight were observed in treated mice compared to control mice (Fig. 
3.8b). Once tumors in control mice reached near protocol-defined burden, all mice were 
euthanized, and mammary tumors were removed. Mammary tumor weights were not 
significantly different between afatinib-treated and untreated mice, however tumor weights 
were significantly reduced in mice treated with YM155 as a single agent and combined with 
afatinib compared to control mice (Fig. 3.8c). All p-values are listed in Table 3.5. Grossly, 
afatinib-treated tumors appeared slightly smaller, and YM155- and afatinib+YM155- treated 




Figure 3.8: Afatinib and YM155 reduce PDX mammary tumor growth in vivo. HCI01 PDX cells were injected 
into the mammary fat pads of NSG mice. After 12 days of tumor growth, mice were divided into four groups 
(n=3 mice per group): untreated, afatinib (25 mg/kg, daily oral gavage for 7 days), YM155 (5 mg/kg, 7-day 
continuous subcutaneous infusion via Alzet pump), and afatinib + YM155 (same doses and routes of 
administration as monotherapy groups). (a) Tumor area (length x width) over time for each treatment group, 
monitored via caliper measurements. The treatment period is indicated by red dotted lines. Error bars 
represent standard deviation. Significance is shown only for endpoint measurements (*p<0.05, **p<0.01); p-
values for all timepoints are listed in Table 3.5. (b) Mouse weights over time for each treatment group. The 
treatment period is indicated by red dotted lines. (c) Tumor weights for each treatment group, obtained after 
tumor removal at the study endpoint; ***p<0.001; p-values are listed in Table 3.5. (d) Photographs of 












Table 3.5: P-values for in vivo drug treatment experiments shown in Figure 3.8a,c. t-tests were performed 
to compare all treatment conditions at each timepoint for tumor growth and at the study endpoint for tumor 
weights. Significant values (p<0.05) are bolded and italicized. Adapted from [190] 
Treatment group comparison 
Tumor growth Tumor weights 
Day 14 Day 17 Day 21 Day 24 Day 28 Endpoint 
Untreated vs. Afatinib >0.999999 0.101192 0.06405 0.089521 0.015093 0.212763 
Untreated vs. YM155 >0.999999 0.106166 0.003654 0.001496 0.001343 0.000315 
Untreated vs. Afatinib+YM155 >0.999999 0.017797 0.002192 0.000991 0.001174 0.000157 
Afatinib vs. YM155 >0.999999 0.724659 0.125798 0.098082 0.01975 0.067574 
Afatinib vs. Afatinib+YM155 >0.999999 0.237796 0.054921 0.054978 0.012391 0.054311 
YM155 vs. Afatinib+YM155 >0.999999 0.565533 0.101192 0.228229 0.403088 0.441823 
 
 
3.4.6 YM155 reduces EGFR expression in basal-like TNBC PDX cells 
To preliminarily explore potential crosstalk between the pathways targeted by afatinib and 
YM155, we performed Western blots to assess the effects of YM155 treatment on EGFR 
expression in the HCI01 PDX line. Interestingly, we found that YM155 treatment (at 10 nM) 
resulted in reduced EGFR protein expression in HCI01 cells compared to vehicle controls 
(Fig. 3.9a,b), indicating that YM155 has activity against the molecular target of afatinib in 
these basal-like TNBC cells. 
                                                 
Figure 3.9: YM155 reduces EGFR expression in basal-like TNBC PDX cells. (a) Western blot showing 
EGFR expression in HCI01 cells treated with vehicle (DMSO) or YM155 (1 or 10 nM); actin was used as a 
loading control (100µg per sample). Images are cropped blots showing proteins from different parts of the 
same gel. (b) Densitometry graph showing EGFR normalized to actin for each treatment condition. Samples 
were run on the same gel, and loading controls were run on the same blot. Reprinted from [190] 
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3.4.7 EGFR and BIRC5 are highly expressed in basal-like PDXs, cell lines, and patient tumors 
EGFR and BIRC5 (survivin) mRNA expression levels were assessed based on breast 
cancer intrinsic subtype using our PDX RNA-sequencing data, as well as RNA-sequencing 
data from two different breast cancer cell line gene expression databases: the HMS LINCS 
Breast Cancer Profiling Project (http://lincs.hms.harvard.edu/db/datasets/20348/) and the 
Broad Institute CCLE (https://portals.broadinstitute.org/ccle). These analyses found that 
EGFR is most highly expressed in the basal-like subtype compared to the other subtypes 
in PDXs and cell lines (Fig. 3.10a), while BIRC5 expression is consistently high across all 
of the intrinsic subtypes in PDXs and cell lines (Fig. 3.10b). Analyses using an 855-patient 
breast cancer gene expression dataset [18, 53, 195] identified that both EGFR and BIRC5 
have significantly higher expression levels in basal-like patient tumors compared to those 






Figure 3.10: EGFR and BIRC5 are highly expressed in basal-like PDXs, cell lines, and patient tumors. RNA-
sequencing data from breast cancer PDXs (log2 TPM+1) and cell lines (LINCS and CCLE databases, RPKM 
and log2 RPKM, respectively) were used to assess expression levels of EGFR (a) and BIRC5 (b) according 
to intrinsic subtype: basal-like (Basal), claudin-low (Claudin), luminal A (LumA), luminal B (LumB), HER2-
enriched (Her2). Gene expression data from 855 breast cancer patients were used to assess expression 
levels of EGFR (c) and BIRC5 (d) in patients according to intrinsic subtype: basal-like (Basal), claudin-low 
(Claudin), luminal A (LumA), luminal B (LumB), HER2-enriched (Her2), normal-like (Normal). Tukey’s 
multiple comparisons tests were used to analyze differences in expression levels of each gene between 
each subtype; tables in right panels depict p-values. PDX, cell line, and patient datasets were each grouped 
by breast cancer intrinsic subtype, and expression values for each gene were averaged; graphs depict the 
average (marker) and range (bars) of expression of EGFR or BIRC5 in each breast cancer subtype. 
Reprinted from [190] 
 
 
Pearson correlation analysis was performed to assess the relationships between EGFR 
and BIRC5 expression and clinical characteristics of breast cancer patients using the 855-
patient dataset. This revealed positive correlations of both EGFR and BIRC5 expression 
with basal-like triple-negative tumors, and negative correlations of both EGFR and BIRC5 
expression with luminal ER/PR-positive tumors and differentiation score (Fig. 3.11). In 
addition, BIRC5 expression showed a strong positive correlation with proliferation score 




Figure 3.11: EGFR and BIRC5 expression correlate with clinical characteristics of patient tumors. Using an 
855-patient dataset consisting of gene expression data as well as clinical information, Pearson correlations 
were performed to assess the relationships of EGFR and BIRC5 expression with clinical parameters. Intrinsic 
subtype: basal-like (Basal), claudin-low (Claudin), luminal A (LumA), luminal B (LumB), HER2-enriched 
(Her2), normal-like (Normal). Receptor status: estrogen receptor (ER), progesterone receptor (PR), human 
epidermal growth factor receptor 2 (HER2), triple-negative breast cancer (TNBC). Other parameters: patient 
age, lymph node (LN) status, differentiation (D) score, proliferation (Prolif) score. Clinical outcomes: 
metastasis-free survival (MFS), relapse-free survival (any relapse, brain, liver, lung, bone). Heatmap depicts 
Pearson correlation values for each comparison of parameters: negative correlation (red), no correlation 













3.4.8 EGFR and BIRC5 expression are negatively associated with patient outcomes 
The 855-patient dataset was used to determine the effect of EGFR and BIRC5 expression 
levels on clinical outcomes for patients with basal-like tumors (N=140) in terms of MFS 
time, as well as relapse-free survival pertaining to liver and lung metastases. Basal-like 
patients were divided into four groups based on EGFR/BIRC5 expression levels: 
EGFRhighBIRC5high, EGFRhighBIRC5low, EGFRlowBIRC5high, EGFRlowBIRC5low. Kaplan-Meier 
analyses revealed that patients with EGFRhighBIRC5high tumors had significantly reduced 
liver relapse-free survival relative to those with EGFRlowBIRC5high tumors (Fig. 3.12a) as 
well as significantly reduced lung relapse-free survival compared to those with 
EGFRhighBIRC5low, EGFRlowBIRC5high, and EGFRlowBIRC5low tumors (Fig. 3.12b). Patients 
with EGFRhighBIRC5high tumors also had significantly shorter MFS times compared to those 
with EGFRhighBIRC5low, EGFRlowBIRC5high, and EGFRlowBIRC5low tumors (Fig. 3.12c). All 
p-values are listed in Table 3.6. Collectively, these results indicate that high tumor 
expression levels of both EGFR and BIRC5 are associated with more rapid development 
of liver and lung metastases in patients compared to tumors with low expression of one or 
both of these genes. 
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Figure 3.12: EGFR and BIRC5 expression are negatively associated with metastasis-free survival in 
patients with basal-like tumors. Using an 855-patient breast cancer dataset, patients with basal-like tumors 
(N=140) were divided into four groups based on expression levels of EGFR and BIRC5: EGFRhighBIRC5high, 
EGFRhighBIRC5low, EGFRlowBIRC5high, EGFRlowBIRC5low. Kaplan-Meier curves were generated to assess the 
effect of high versus low expression of the two genes on (a) liver relapse-free survival, (b) lung relapse-free 
survival, and (c) metastasis-free survival (MFS) time. Log-rank tests were performed to determine statistical 








Table 3.6: P-values for Kaplan-Meier survival curves shown in Figure 3.12. Log-rank tests were performed 
between all basal-like patient groups (based on EGFR/BIRC5 expression levels) for relapse-free survival 
(liver and lung) and metastasis-free survival (MFS) time. Significant values (p<0.05) are bolded and 
italicized. Adapted from [190] 
Liver relapse P-value 
EGFRhigh/BIRC5high vs EGFRhigh/BIRC5low 0.0764 
EGFRhigh/BIRC5high vs EGFRlow/BIRC5high 0.0153 
EGFRhigh/BIRC5high vs EGFRlow/BIRC5low 0.0787 
EGFRhigh/BIRC5low vs EGFRlow/BIRC5high 0.627 
EGFRhigh/BIRC5low vs EGFRlow/BIRC5low 0.9262 
EGFRlow/BIRC5high vs EGFRlow/BIRC5low 0.8038 
Lung relapse P-value 
EGFRhigh/BIRC5high vs EGFRhigh/BIRC5low 0.0284 
EGFRhigh/BIRC5high vs EGFRlow/BIRC5high 0.0204 
EGFRhigh/BIRC5high vs EGFRlow/BIRC5low 0.0337 
EGFRhigh/BIRC5low vs EGFRlow/BIRC5high 0.9187 
EGFRhigh/BIRC5low vs EGFRlow/BIRC5low 0.9291 
EGFRlow/BIRC5high vs EGFRlow/BIRC5low 0.8673 
MFS time P-value 
EGFRhigh/BIRC5high vs EGFRhigh/BIRC5low 0.022 
EGFRhigh/BIRC5high vs EGFRlow/BIRC5high 0.0178 
EGFRhigh/BIRC5high vs EGFRlow/BIRC5low 0.009 
EGFRhigh/BIRC5low vs EGFRlow/BIRC5high 0.8503 
EGFRhigh/BIRC5low vs EGFRlow/BIRC5low 0.42 




3.5 Discussion and conclusions 
Despite decades of translational research, no reliable targeted therapeutics have yet been 
FDA-approved for the treatment of TNBC. Although several classes of targeted drugs have 
shown promise in preclinical studies, most of these drugs have failed in clinical trials, and it is 
likely that effective synergistic combination regimens are needed to successfully combat this 
disease [34]. One factor that certainly can contribute to the discrepancy in results between 
preclinical studies and clinical trials is the use of immortalized cell line models for preclinical 
drug response testing. Cell lines have been shown to undergo considerable changes while in 
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culture that can affect drug response, whereas three-dimensional PDX cultures have been 
shown to more faithfully maintain tumor cell morphology, gene expression, and drug response 
profiles [159–161]. Indeed, we have previously found that two of the breast cancer PDXs 
employed in the present studies maintain the gene expression profiles of their in vivo 
counterparts after seven days in cell culture [149]. Therefore, preclinical drug screening studies 
using PDXs are more likely than those using cell lines to be indicative of in vivo efficacy, and 
in vivo PDX drug studies are more likely to predict clinical potential [189]. Thus, the studies 
presented herein employ breast cancer PDX models, in addition to cell lines, to assess drug 
response. 
Through screening of 1,363 drugs in ten PDXs of varying breast cancer subtypes, we have 
generated a drug response dataset that can be used to assess and compare drug response 
profiles of patient-derived breast cancer cells to many specific drugs or classes of drugs, 
currently approved for a wide range of clinical indications. From this dataset, we identified 176 
drugs that were most effective in four basal-like TNBC PDXs, and through a series of 
subsequent drug screening assays, we selected four drugs of interest for combination testing 
and Chou-Talalay analysis: carfilzomib (proteasome inhibitor), afatinib (EGFR inhibitor), 
YM155 (survivin inhibitor), and carboplatin (standard-of-care chemotherapeutic). In addition to 
their efficacy in screening experiments, the former three drugs were of interest given the high 
level of expression of the genes encoding their targets. Of the six two-drug combinations, only 
afatinib and YM155 were found to be synergistic in the four basal-like PDXs tested, as well as 
in three cell lines. Notably, this combination was also favorable given the reduced dose of each 
drug required to achieve a given level of efficacy when combined with one another, suggesting 
that this drug combination could potentially minimize toxicity associated with combining 
multiple drugs. Indeed, our in vivo study employing the HCI01 PDX model demonstrated not 
only that both drugs, as single agents and in combination, were efficacious in reducing 
76 
 
mammary tumor growth, but also that both drugs were very well-tolerated, with no observable 
signs of toxicity.  
It should be noted that, although the in vivo study showed a greater reduction in HCI01 
tumor growth when afatinib was combined with YM155 compared to afatinib treatment alone, 
there was no significant difference in tumor growth between mice treated with the combination 
versus YM155 alone—both YM155-containing treatment groups showed a marked reduction 
in tumor growth, regardless of the presence or absence of afatinib. This indicates that the 
efficacy of the drug combination was dominated by the effects of YM155, therefore synergism 
was not discernible. Future studies incorporating lower doses of YM155 would be needed to 
detect synergism in vivo. Furthermore, prolonged drug administration may have caused tumor 
shrinkage rather than slowed growth, however this type of study design would be difficult to 
implement using these PDX models given the rapid growth rates of untreated tumors.  
Nevertheless, the efficacy of both afatinib and YM155 in vivo, and their minimal toxicity profiles, 
further suggest that these drugs are promising candidates for TNBC treatment.  
YM155 is an investigational inhibitor of survivin expression that has shown promise in 
preclinical models of TNBC [207, 208], drug-resistant ER-positive breast cancer [209, 210], 
and other solid tumor types [211–216]. BIRC5, the gene encoding survivin, is upregulated in 
many human cancers [217], and in the breast cancer PDXs and cell lines employed in our 
study, and has been shown to have low levels of expression in normal tissue types [218, 219], 
which makes survivin an appealing drug target. The preclinical success of YM155 has led to 
its testing in several clinical trials, one of which was focused on combining YM155 with 
docetaxel in HER2-negative breast cancer (including TNBC), however this trial did not find 
significant benefit of the combination relative to docetaxel as a single agent [220]. The failure 
of preclinical drug studies to translate into clinical success is not uncommon. Thus, although 
YM155 was highly effective as a single agent in reducing mammary tumor growth in the in vivo 
study presented herein, its clinical track record to date suggests that its preclinical 
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monotherapeutic efficacy would be unlikely to translate into success in clinical trials, whether 
or not it is combined with standard-of-care chemotherapeutics. It is likely that identification of 
synergistic combinations incorporating YM155 would maximize its efficacy and potential for 
clinical benefit.  
Our present findings indicate that, in several basal-like TNBC PDX models, YM155 is 
synergistic with afatinib, an EGFR inhibitor currently approved for the treatment of non-small 
cell lung cancer. EGFR is expressed in a large percentage of TNBCs [71, 221], including TNBC 
PDX models and the cell lines used in this study, and it has been explored as a potential 
therapeutic target in this disease [34, 222, 223]. However, EGFR inhibitors and anti-EGFR 
antibodies have thus far been unsuccessful in TNBC clinical trials [83–88], suggesting that, like 
for YM155, more effective combinations must be identified to maximize its efficacy. Based on 
our collective findings, we propose that YM155 and afatinib could potentially enhance each 
other’s efficacy in TNBC. Interestingly, YM155 has been shown to reduce EGFR expression 
and tumor cell proliferation and survival in pancreatic cancer [224] as well as EGFR-positive 
non-small cell lung cancer, in which YM155 was found to be synergistic with afatinib [225] and 
other EGFR inhibitors [226], to reverse resistance to the EGFR inhibitor erlotinib in EGFR-
mutant lung cancer [227], and to inhibit EGFR autophosphorylation which promotes lung 
cancer stemness [228]. The EGFR inhibitor lapatinib was also found to enhance the efficacy 
of YM155 in neuroblastoma by inhibiting drug efflux through the ABCB1 transporter [229].  
Mechanisms of synergism between YM155 and EGFR inhibitors such as afatinib have not 
yet been extensively explored in breast cancer. We have demonstrated herein that YM155 
reduces EGFR expression in a PDX model of basal-like TNBC, consistent with the 
aforementioned studies in pancreatic and lung cancer. Based on this finding, and on the 
aforementioned studies in other cancer types, we can postulate that YM155, in addition to 
promoting tumor cell apoptosis by inhibiting survivin, downregulates EGFR expression in 
breast cancer cells that highly express both BIRC5 and EGFR. When YM155 and afatinib are 
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combined, this may potentiate the inhibition of EGFR-mediated pathways, leading to enhanced 
inhibition of tumor cell proliferation and survival. In turn, afatinib may enhance the efficacy of 
YM155 in breast cancer cells by inhibiting YM155 efflux; indeed, afatinib has been shown to 
inhibit the ABCB1 drug efflux transporter in ovarian cancer [230] and the ABCG2 drug efflux 
transporter in other cancer types [231]. Notably, ABCG2 is known to be expressed and 
contribute to drug resistance in breast cancer cells, hence it is also known as breast cancer 
resistance protein (BCRP) [232]. Further investigation of the mechanisms underlying the 
synergism between afatinib and YM155 in basal-like TNBC is warranted to explore these and 
alternative possibilities.  
Our studies collectively provide compelling evidence that the combination of afatinib and 
YM155 holds promise for potential clinical benefit in the treatment of basal-like TNBC. This is 
further supported by our analyses of the 855-patient gene expression and clinical dataset. Both 
EGFR and BIRC5 were found to have the highest expression levels in basal-like tumors 
compared to other subtypes. In addition, both genes were positively correlated with basal-like 
triple-negative tumor status, and negatively correlated with luminal ER/PR-positive tumor 
status and differentiation score. BIRC5 was also positively correlated with proliferation score, 
as this is one of the 11 proliferation markers that is included in the PAM50 gene list, which is 
used clinically for breast cancer subtyping and predicting patient prognosis [42]. Taken 
together with the aforementioned studies demonstrating the prevalence and functions of these 
genes in cancer, these findings suggest that both EGFR and BIRC5 may be important drug 
targets in basal-like TNBC. Our analyses of the 855-patient dataset further revealed that high 
co-expression of EGFR and BIRC5 was associated with significantly reduced MFS time and 
relapse-free survival specifically in the liver and lung. This suggests that co-targeting of EGFR 
and BIRC5 may have significant clinical impacts for patients with advanced basal-like TNBC, 
who currently face considerable limitations in treatment options and bleak outcomes relative to 
patients with tumors of other, currently targetable, subtypes. Based on our collective findings, 
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the combination of afatinib and YM155, and combinations incorporating other EGFR and 
survivin inhibitors, warrant further investigation as novel therapeutic regimens for the treatment 
of basal-like TNBC.  
In conclusion, the studies reported herein provide a valuable 1,363-drug response dataset, 
employing clinically relevant PDX models, that has the potential to inspire and inform many 
future studies focusing on therapeutic development in breast cancer. Using this dataset to 
inform more focused follow-up screening studies, with an emphasis on basal-like TNBC, we 
have uncovered a promising drug combination that, to our knowledge, has not yet been 
established or explored in the context of this disease. Based on our collective findings and on 
previous research in other cancers, we believe that, upon further preclinical investigation, the 
combination of afatinib and YM155, and perhaps other EGFR and survivin inhibitors, could 
potentially be incorporated into novel therapeutic regimens for eventual clinical testing in 
humans. Furthermore, additional therapeutic strategies that may be explored based on our 
drug screening dataset, such as the repurposing of non-cancer therapeutics for breast cancer 
treatment, have the potential to make major translational impacts on treatment decisions, 
clinical outcomes, and quality of life for patients with advanced breast cancer. 
3.6 Future directions 
Future studies will focus on investigating the mechanisms of synergism between afatinib and 
YM155 in the context of basal-like TNBC, and potentially in other subtypes of breast cancer, 
beginning with known mechanisms of synergism in other cancer types (the reduction of EGFR 
protein levels by YM155 and the inhibition of drug efflux by afatinib). This would be particularly 
interesting to study in the WHIM2 PDX model, which has the highest expression of ABCG2 
compared to the other basal-like TNBC PDXs. To identify other potentially important genes 
that are up- or down-regulated in response to the drugs, mechanistic studies will also involve 
global gene expression profiling of cells and/or tumor samples with and without treatment. In 
addition, it would be of interest to explore potential mechanisms of resistance to afatinib and 
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YM155 and strategies for sensitizing tumor cells to these drugs, as resistance to targeted 
therapeutics is a common occurrence in advanced disease. Furthermore, given the efficacy, 
potency, and tumor cell specificity of YM155, high-throughput in vitro combination studies will 
be performed to identify other drugs this survivin inhibitor may synergize with. In order to pursue 
the goal of translating the combination of afatinib and YM155 into the clinic, further in vivo 
studies with dose escalations will be performed to validate the efficacy, detect synergism, and 
assess the toxicity profile of this drug combination in multiple PDX models, with a particular 
focus on detecting in vivo synergism using lower doses of YM155. Lastly, afatinib and YM155 
will be tested in the metastatic setting using PDX metastasis models to evaluate their efficacy 
in treating brain, liver, and lung metastases. This is especially important given that advanced 
or recurrent TNBC is often resistant to current standard-of-care therapies, and also that brain 
metastases in particular pose a unique challenge in cancer drug development. Afatinib is 
known to cross the blood-brain barrier [233, 234] and has demonstrated efficacy in the context 
of brain metastasis in lung cancer [235, 236], although it was not efficacious in treating HER2-
positive breast cancer brain metastases [237]. Although YM155 does not effectively penetrate 
the blood-brain barrier [238], it is a therapeutic candidate in glioblastoma multiforme (GBM) 
based on its efficacy in in vitro and in vivo studies using intratumoral delivery of the drug [239–
241]. However, the activity of YM155 against metastatic disease in the CNS is unknown. Given 
the propensity of basal-like TNBC to metastasize to the brain, and the challenges in 
pharmacologic management of brain metastases, it is especially important to investigate the 
potential efficacy of afatinib and YM155 in this specific context. In testing the efficacy of afatinib 
and YM155 in treating metastases, particularly those in the brain, it would be important to 
compare this treatment regimen to the current standard of care, including chemotherapy and 
radiation. The latter is especially important in breaking down the blood-brain barrier to enhance 
drug penetration into the brain. This type of study, designed like a clinical trial, would help 
determine whether the combination of afatinib and YM155 has superior efficacy to the standard 
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of care. Given the minimal toxicity profiles of afatinib and YM155, efficacy that is equivalent to 



























CHAPTER 4: Targeting the androgen receptor in triple-negative breast cancer 
4.1 Background and rationale 
As aforementioned, TNBC is a highly aggressive subtype of breast cancer with a propensity 
to metastasize to vital organs. Treatment for TNBC is limited to chemotherapy, which is toxic 
and often ineffective in eliminating disease and/or preventing recurrence, and, consequently, 
this subtype is associated with a particularly poor prognosis. There is a critical need for the 
development of targeted therapeutic strategies, as well as methods for stratifying TNBC 
patients based on tumor characteristics to predict therapeutic responses.  
One potential therapeutic target in TNBC is AR, a current therapeutic target in castration-
resistant metastatic prostate cancer (CRMPC) [242, 243]. Enzalutamide, a nonsteroidal small 
molecule AR inhibitor, is one of the AR-targeted agents currently FDA-approved to treat 
CRMPC [244–248] and has demonstrated efficacy in preclinical and clinical TNBC studies [89, 
249–251]. Approximately 70% of all primary breast cancers, and 30-40% of TNBCs, are 
positive for AR expression [252]. Although the majority of TNBC tumors are classified as basal-
like [44, 70, 71] and are AR-negative [72–74], approximately 15% of TNBCs are classified as 
the LAR subtype, which defines tumors that are triple-negative, AR-positive, with luminal gene 
expression profiles [70, 71]. LAR TNBCs are driven by AR signaling and are associated with a 
poor prognosis [70, 71], suggesting that patients within this subset may clinically benefit from 
AR-targeted therapies. There is some controversy regarding the role of AR in breast cancer, 
given the discrepancies between studies showing that AR expression is associated with better 
[253, 254] or worse [249, 255] clinical outcomes in breast cancer patients, which may involve 
differences in preclinical models and/or expression of other tumor markers such as ER. 
Regardless of these discrepancies, there is ample evidence to suggest that AR may be a 
suitable target in LAR TNBC, and it is likely that the development of synergistic combination 
regimens containing AR-targeted agents would increase the likelihood of clinical success in 
this subpopulation of TNBC patients.  
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4.2 Experimental approach 
This study sought to investigate AR as a therapeutic target in LAR TNBC and other AR-positive 
PDX models and breast cancer cell lines, and to identify currently FDA-approved drugs that 
are potential candidates for combination with AR inhibitors for this subset of TNBC patients. 
After characterizing the expression of AR in several breast cancer PDXs and cell lines, we 
evaluated the effects of pharmacologic AR inhibition, inducible AR knockdown, and AR 
stimulation on the cell viability of those lines that were found to be AR-positive, and tested the 
efficacy of AR inhibition and knockdown on PDX mammary tumor growth in vivo. We expected 
that AR inhibition/knockdown would have cytotoxic effects in the LAR TNBC models. To identify 
potential therapeutic candidates for combination with AR inhibitors, we utilized the PDX 1,363-
drug screening dataset in conjunction with patient gene expression data to identify drugs and 
drug targets of interest for further exploration in LAR TNBC. 
4.3 Materials and methods 
4.3.1 Breast cancer PDX models and preparation of tumor cell suspensions 
Breast cancer PDX models of varying subtypes were used in these studies: triple-negative, 
basal-like (HCI01, HCI02, HCI04, HCI16, UCD18, UCD52, WHIM2, WHIM30); triple-
negative, LAR type (HCI09); ER-positive, luminal (HCI03, HCI11, HCI13); and HER2-
enriched (HCI08). HCI01, HCI02, HCI03, HCI04, HCI08, HCI09, HCI11, HCI13, and HCI16 
were obtained from the Huntsman Cancer Institute, University of Utah; WHIM2 and 
WHIM30 were obtained from Washington University, St. Louis; UCD18 and UCD52 were 
obtained from the University of Colorado. All experiments were performed in accordance 
with IACUC guidelines and regulations. Tumor fragments were grown in the fourth 
mammary fat pads of female NSG mice. Established tumors were removed from mice, 
finely chopped, and digested for 1h at 37°C in DMEM/F12 containing 5% FBS, 300 U/ml 
collagenase (Sigma), and 100 U/ml hyaluronidase (Sigma). Digested tumor tissue was then 
resuspended in ammonium chloride and trypsinized to generate single cell suspensions. 
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Tumor cells were transduced with a lentivirus (BLIV101PA-1, Systems Biosciences) 
encoding GFP and luciferase, and these tumor cells were suspended 1:1 in Matrigel 
(Corning) and injected into the fourth mammary fat pads of NSG mice (500,000 cells per 
injection). Mammary tumors were removed for experimental use once they reached 
approximately 100mm2 by caliper measurement. Tumors were processed into single cell 
suspensions as described above.  
4.3.2 Breast cancer cell lines 
Seven breast cancer cell lines were employed for these studies: MDA453, MDA468, 
MDA231, MCF7, T47D, ZR751, and BT549. Cell lines were originally obtained from the 
ATCC and were cultured according to ATCC guidelines in the following media: Leibovitz’s 
L15 supplemented with 10% FBS (MDA453, MDA468, MDA231); RPMI-1640 
supplemented with 10% FBS (ZR751) or 10% FBS and bovine insulin (0.2 U/ml T47D, 
0.023 U/ml BT549); and Eagle’s Minimum Essential Medium (EMEM) supplemented with 
10% FBS and 0.01 mg/ml bovine insulin (MCF7); all media were additionally supplemented 
with penicillin/streptomycin. Cell lines were maintained in complete media, and both cell 
lines and PDX cell suspensions were cultured in charcoal-stripped phenol red-free media 
for drug response experiments (cell viability and Western blots). MDA453, MCF7, and 
T47D cells were transduced with a lentivirus (LVP323, GenTarget Inc.) encoding GFP and 
luciferase, followed by selection using blasticidin (Gemini Bio) (15 µg/ml for MDA453, 12.5 
µg/ml for MCF7 and T47D). 
4.3.3 AR knockdown 
Tetracycline-inducible lentiviral shRNAs were generated using TRIPZ Lentiviral shRNA 
Transfection Starter Kit with DharmaFECT kb (Dharmacon, RHS11852-EG367 glycerol 
kit), including one non-silencing control (NSC) shRNA and three shRNAs targeting AR 
(V3THS_367658, V3THS_367662, V3THS_367663; subsequently abbreviated as AR658, 
AR662, AR663, respectively). Lentiviral particles were generated in HEK293T cells using 
85 
 
the Trans-Lentiviral shRNA Packaging Kit with Calcium Phosphate and HEK293T 
(Dharmacon, TLP5917). MDA453, MCF7, and T47D cells were transduced with lentivirus 
(NSC, AR658, AR662, AR663, or all three AR shRNAs combined (ARall3)) according to 
the provided protocols, followed by selection with puromycin (Gemini Bio) (2 µg/ml for 
MDA453, 1 µg/ml for MCF7 and T47D) to generate stable cell lines. HCI09 cell suspension 
cultures were transduced with lentivirus according to the provided protocols, followed by 
fluorescence-activated cell sorting (FACS) for red fluorescent protein (RFP) and 
subsequent injection into the fourth mammary fat pads of NSG mice to generate tumors. 
AR knockdown was induced in vitro using 0.5 µg/ml doxycycline (Sigma, D9891) and in 
vivo using doxycycline chow (625 mg/kg; Envigo Teklad Diets). 
4.3.4 Western blotting 
PDX cell suspensions were prepared from mammary tumors as described above and 
plated in 6-well plates at 1.5 million cells per well in M87 medium. Cell lines were plated in 
6-well plates (500,000 cells per well for MDA453; 250,000 cells per well for MCF7 and 
T47D) in their corresponding ATCC-recommended media and incubated overnight to allow 
for adherence. To assess AR expression levels, protein extracts were collected from frozen 
PDX mammary tumors (WHIM2, WHIM30, HCI03, HCI08, HCI09, HCI11, HCI13) and from 
cell lines (MCF7, ZR751, T47D, MDA453, MDA468, MDA231, BT549) after 24h in culture. 
To assess the effects of TOK-001 treatment on AR expression, HCI09, MDA453, MCF7, 
and T47D cells were treated for 72h with vehicle (DMSO) or TOK-001 (10µM), followed by 
protein extraction. For AR knockdown verification, previously transduced (all shRNAs) and 
selected MDA453, MCF7, and T47D cells, and HCI09 cell suspensions generated from 
control or AR658 shRNA-expressing mammary tumors, were treated for 72h with or without 
doxycycline (0.5 µg/ml), followed by protein extraction. For protein extraction, PDX 
mammary tumors were homogenized, cell suspensions were pelleted and resuspended, 
and adherent cell lines were scraped, in Pierce RIPA buffer (ThermoFisher Scientific, 
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89900) + protease inhibitor (ThermoFisher Scientific, A32963) for cell lysis, and centrifuged 
at max speed at 4°C for 15 min to collect protein lysates. Protein concentrations were 
determined using Pierce BCA Protein Assay Kit (ThermoFisher Scientific, 23225). Proteins 
were resolved by SDS-PAGE and transferred to Immobilon-FL membranes (Millipore), 
which were then blocked in Odyssey Blocking Buffer in TBS (Li-Cor) for 1h at room 
temperature. Primary and secondary antibodies were diluted in Odyssey Blocking Buffer in 
TBS (Li-Cor) + 0.1% Tween-20. Membranes were incubated overnight at 4°C with rabbit 
anti-β-actin (1:1000; Cell Signaling Technology #4970) or rabbit anti-AR (1:1000; Cell 
Signaling Technology #5153). For detection, membranes were incubated with IRDye 
680RD donkey anti-rabbit secondary antibody (1:10,000; Li-Cor 926-68073) for 1h at room 
temperature. All washes were performed using TBS-T. Membranes were imaged using the 
Odyssey Fc Imaging System (Li-Cor). 
4.3.5 Immunohistochemistry 
HCI03, HCI08, HCI09, HCI11, and HCI13 mammary tumor tissues were fixed in 10% 
formalin, paraffin-embedded, and sectioned using a Kedee KD-2258 rotary microtome, at 
10µm per section. IHC was performed by standard procedures, using the following primary 
antibodies: rabbit anti-AR (1:100; Cell Signaling Technology #5153), rabbit anti-ER (1:50; 
One World Lab #59347), rabbit anti-PR (1:1000; Cell Signaling Technology #8757), and 
rabbit anti-HER2 (1:100; Cell Signaling Technology #2242). Heat-induced antigen retrieval 
was conducted using a pressure cooker, in pH 9 Tris-EDTA. Detection was performed 
using the rabbit Dako EnVision system (Agilent K406511-2). Stained tissue sections were 
observed and photographed using a Zeiss AxioLab Upright Microscope and Zeiss AxioCam 
ICc 5 camera. Image analysis was performed using the ZEN2 software, blue edition. 
4.3.6 Cell viability assays 
For PDX cell viability assays, PDX cells were plated in 96-well plates at 25,000 cells per 
well in M87 medium [135] and treated with drugs for 72h, followed by imaging and 
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measurement of luciferase activity (total photon flux per second) two minutes after the 
addition of D-luciferin (15 mg/ml; Gold Biotechnology) to each well (1/10 of total volume 
per well), using the IVIS Spectrum In Vivo Imaging System (Xenogen IVIS-200) and Living 
Image software (PerkinElmer), as described in our previous work [149]. For cell line viability 
assays, cell lines were plated in 96-well plates at 5,000 cells per well (MCF7, T47D) or 
10,000 cells per well (MDA453), cultured overnight to allow for adherence, and 
subsequently treated with drugs for 72h. Viability of cell lines was measured using 
luciferase activity as described above (for luciferase-expressing cells) or the CellTiter-Glo 
Luminescent Viability Assay (Promega), according to the provided protocol. 
4.3.7 1,363-drug screening analyses 
The 1,363-drug screening dataset consisting of drug response data for 10 PDXs 
(Appendix A; described in Chapter 3, Section 3.3.4) [190] was utilized to assess response 
to AR-targeting drugs across multiple breast cancer subtypes. A heatmap was generated 
using GraphPad Prism 8 to show the relative responses (cell viability as percent of vehicle) 
of the 10 PDXs to AR agonists and AR antagonists from the screening dataset. Graphs 
were generated for comparison of enzalutamide and TOK-001 responses across the 
individual PDXs using averaged duplicate data for each PDX. Data were then averaged for 
AR-positive PDXs and AR-negative PDXs to compare overall responses of the two groups 
to enzalutamide and TOK-001, and unpaired two-tailed t-tests were performed to assess 
for significant differences between responses to enzalutamide vs. TOK-001 and between 
responses of AR-positive vs. AR-negative PDXs to each of the two drugs.  
4.3.8 In vitro AR-targeting studies 
For dihydrotestosterone (DHT) and enzalutamide dose response experiments, AR-positive 
PDXs (HCI09, HCI08, HCI13) and cell lines (MDA453, MCF7, T47D) were treated in 
triplicate for 72h with DHT (1, 5, 10, 25, 50 nM) or enzalutamide (1, 10, 50, 75, 100 µM), 
followed by measurement of cell viability as described above (luciferase activity for PDXs, 
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CellTiter-Glo for cell lines). For AR knockdown experiments, MDA453, MCF7, and T47D 
cells expressing both luciferase and lentiviral shRNAs (NSC, AR658, AR662, AR663, or 
ARall3) were treated in triplicate with or without doxycycline (0.5 µg/ml) for 72h, followed 
by measurement of cell viability using luciferase activity. To assess the effects of AR 
knockdown on response to DHT and enzalutamide, the three cell lines expressing all three 
AR-targeted lentiviral shRNAs (ARall3) were treated in triplicate for 72h with DHT (25nM) 
+/- doxycycline (0.5 µg/ml) or enzalutamide (100µM) +/- doxycycline (0.5 µg/ml), followed 
by measurement of cell viability using luciferase activity. To compare the effects of TOK-
001 vs. enzalutamide, HCI08, HCI09, HCI13, MDA453, MCF7, and T47D cells were treated 
in triplicate for 72h with TOK-001 (0.01, 0.1, 1, 10 µM) or enzalutamide (0.01, 0.1, 1, 10 
µM), followed by measurement of cell viability using luciferase activity. To assess the 
effects of AR knockdown on response to TOK-001 vs. enzalutamide, T47D cells expressing 
all three AR-targeted lentiviral shRNAs (ARall3) or NSC shRNA were treated in triplicate 
for 72h with TOK-001 (0.01, 0.1, 1, 10 µM) or enzalutamide (0.01, 0.1, 1, 10 µM) after 
induction of AR knockdown with doxycycline (0.5 µg/ml), followed by measurement of cell 
viability using luciferase activity. For all these studies: DHT, enzalutamide, and TOK-001, 
were obtained from Sigma, Selleck Chemicals, and MedChemExpress, respectively. 
4.3.9 In vivo AR-targeting studies 
HCI09 PDX mammary tumors were processed into single cell suspensions as described 
above, and tumor cells diluted 1:1 with Matrigel (Corning) were injected into the fourth 
mammary fat pads of NSG mice (500,000 cells per tumor). For all experiments, treatments 
were initiated once tumors became palpable and continued until control tumors reached 
protocol-defined burden. For enzalutamide studies, mice were treated with enzalutamide 
(10 mg/kg or 30 mg/kg; Selleck Chemicals) or vehicle (DMSO) every 2 days via IP injection. 
For TOK-001 studies, mice were treated with TOK-001 (90 mg/kg; MedChemExpress) or 
vehicle (0.5% hydroxyethyl cellulose) 5 days per week via oral gavage. For AR knockdown 
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studies, mammary tumors were generated in mice using HCI09 cells expressing inducible 
lentiviral shRNA targeting AR (AR658), and, once tumors became palpable, mice were 
given doxycycline chow (625 mg/kg; Envigo Teklad Diets) or maintained on control chow. 
For all experiments, tumor growth was monitored over time via caliper measurements. 
4.3.10 Analyses using patient clinical and gene expression datasets 
AR expression in breast cancer patients was analyzed using the 855-patient clinical and 
gene expression dataset [18, 53, 195] employed for studies described in Chapter 3, Section 
3.3.10. AR expression was assessed across the intrinsic breast cancer subtypes, and 
Tukey’s multiple comparisons test was used to determine the significance of differences in 
AR expression between each subtype. Also using the 855-patient dataset, ER-negative 
patients (n=256) were ranked by AR expression and divided into two groups: high AR 
expression (top 50%) and low AR expression (bottom 50%); Kaplan-Meier analysis was 
performed to determine the effect of AR expression level on relapse-free survival in this 
group of patients. To identify potential drug targets correlating with AR expression in 
patients with AR-positive TNBC, breast cancer patient gene expression (RNA-sequencing) 
data from The Cancer Genome Atlas (TCGA) were utilized along with the PDX 1,363-drug 
screening dataset [190]. First, all TNBC patients included in the TCGA dataset (n=115) 
were ranked according to AR expression levels. TNBC patients with the highest AR 
expression (n=9) were selected for Pearson correlation analyses between AR expression 
and the expression of all other genes in the TCGA dataset. Subsequently, the HCI09 1,363-
drug screening dataset was used to compare Pearson correlations for particular genes with 
HCI09 cell viability in response to drugs that target the proteins encoded by those genes. 
Genes/drug targets with the strongest correlations with AR expression (Pearson correlation 
>0.50) and corresponding drugs with the highest efficacy (percent of vehicle viability <50%) 
in HCI09 cells were considered to be potential drug targets of interest for future studies in 
AR-positive TNBC. To further explore the seven identified genes of interest, Pearson 
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correlations between these genes and AR expression within the high-AR patient group 
(n=9) were compared with the same analyses performed within all other (low-AR) patients 
(n=106) and within all TNBC patients (n=115). Additionally, heatmaps were generated to 
compare expression levels (TPM values) of AR and the seven genes in the high-AR versus 
low-AR groups, as well as across the nine high-AR patients individually. 
4.3.11 RNA-sequencing analyses 
PDX mammary tumor RNA-sequencing data [141] (GEO Accession: GSE118942) were 
used to assess expression levels of AR and the seven genes of interest identified above 
across 13 PDXs: HCI01, HCI02, HCI03, HCI04, HCI08, HCI09, HCI10, HCI13, HCI16, 
UCD18, UCD52, WHIM2, WHIM30. Log2 (TPM+1) values were averaged across replicates 
for each PDX. Expression of these genes was also assessed in breast cancer cell lines 
using the two RNA-sequencing databases described in Chapter 3, Section 3.3.10: the HMS 
LINCS Breast Cancer Profiling Project (http://lincs.hms.harvard.edu/db/datasets/20348/) 
and the Broad Institute CCLE (https://portals.broadinstitute.org/ccle). For these analyses, 
specific cell lines were selected such that TNBC subtypes, along with ER-positive status 
for comparison,  were each represented by at least one cell line: LAR TNBC (MDA453), 
basal-like TNBC (MDA468, HCC1143, HCC1187, HCC1937, CAL851), mesenchymal 
TNBC (MDA231, CAL51), and luminal ER-positive (T47D, MCF7). It should be noted that 
HCC1187 data were only available in the CCLE database. Gene expression heatmaps 
were generated separately for data from each cell line database as well as the PDX data 
to assess and compare expression levels of the genes of interest across PDXs and cell 
lines of varying subtypes, with a particular focus on comparing AR-positive with AR-
negative models. 
4.3.12 Statistics 
Unpaired two-tailed t-tests were performed to assess significant differences between 
control and drug treated conditions for both in vitro and in vivo experiments, as well as 
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between AR-positive vs. AR-negative PDXs and TOK-001 vs. enzalutamide in the 1,363-
drug screening analyses. Tukey’s multiple comparisons test was used to analyze 
differences in AR expression across intrinsic subtypes using patient data. Log rank test 
was used to assess the effect of AR expression level on relapse-free survival using patient 
data. For all analyses, p<0.05 was considered statistically significant. 
4.4 Results 
4.4.1 AR expression across breast cancer cell lines, PDXs, and patients 
To determine how the expression of AR relates to breast cancer intrinsic subtype, we 
utilized a publicly available 855-patient breast cancer dataset consisting of clinical and 
gene expression data. AR expression was lowest in basal-like and claudin-low tumors and 
highest in HER2-enriched, luminal A, and luminal B tumors (Fig. 4.1a). To determine 
whether AR expression is related to clinical outcome, we analyzed the relationship between 
AR expression level and MFS using the same dataset. Interestingly, when stratified by ER 
status, high AR expression was associated with significantly reduced total relapse-free 




                     
Figure 4.1: AR expression is correlated with breast cancer intrinsic subtype and reduces metastasis-free 
survival in ER-negative patients. (a) Gene expression microarray data from 855 breast cancer patients were 
used to assess expression levels of AR in patients according to intrinsic subtype: basal-like (Basal), claudin-
low (Claudin), luminal A (LumA), luminal B (LumB), HER2-enriched (Her2), normal-like (Normal). Tukey’s 
multiple comparisons test was used to analyze differences in expression levels between each subtype; table 
in right panel depicts p-values. (b) Patients with ER-negative disease (n=256) were ranked by AR expression 
level and divided into high vs. low AR expression (top and bottom 50% of patients, respectively). Graph 
shows Kaplan-Meier analysis for effect of high vs. low AR expression on metastasis-free survival (MFS) in 
ER-negative patients.  
 
 
To identify breast cancer cell lines and PDX lines that express AR, we performed Western 
blot analyses which revealed AR protein expression in four cell lines (ER-positive: MCF7, 
ZR751, T47D; ER-negative: MDA453) and five PDX lines (ER-positive: HCI03, HCI11, 
HCI13; ER-negative: HCI08, HCI09) (Fig. 4.2a). AR expression and ER/PR/HER2 status 
in PDX mammary tumor tissues were confirmed by IHC (Fig. 4.2b); note that HCI09 is 
triple-negative whereas HCI08 is ER/PR-negative but HER2-positive. Collectively, these 
studies identified two AR-positive TNBC models (HCI09 and MDA453), several AR-positive 
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ER-positive models (HCI03, HCI11, HCI13, MCF7, ZR751, T47D), and one AR-positive 
HER2-positive model (HCI08). HCI09 and MDA453 can both be classified as LAR TNBC 
models. HCI09 liver metastasis tissue was also positive for AR by IHC (Fig. 4.2c), 
indicating that the AR status of primary tumors is maintained in the metastatic setting in 
this LAR TNBC model. Consistent with AR protein analyses, analysis of previous PDX 
RNA-sequencing data revealed that AR mRNA expression in mammary tumors was 
highest by far in HCI03, HCI08, HCI09, and HCI13, with zero to minimal expression of the 
AR transcript in the other nine PDXs included in the dataset, which are all basal-like TNBC 





Figure 4.2: Identification of AR-positive breast cancer PDXs and cell lines. (a) Western blots depicting AR 
expression across breast cancer PDXs (WHIM2, WHIM30, HCI03, HCI08, HCI09, HCI11, HCI13) and cell 
lines (MCF7, ZR751, T47D, MDA453, MDA468, MDA231, BT549). (b) IHC for AR, ER, PR, and HER2 in 





                                 
Figure 4.3: AR gene expression in breast cancer PDX tumors. RNA-sequencing data were used to assess 
AR expression across 13 PDXs of varying breast cancer histologic and intrinsic subtypes, as labeled beneath 
the graph. Log2 (TPM+1) values for each PDX were averaged when applicable across mammary tumor 
samples (UCD18 n=1, UCD52 n=6, WHIM2 n=3, WHIM30 n=5, HCI01 n=3, HCI02 n=3, HCI04 n=1, HCI10 
n=2, HCI16 n=1, HCI09 n=4, HCI03 n=1, HCI13 n=1, HCI08 n=1). Error bars represent standard deviation 
between replicate samples, where applicable. 
 
 
4.4.2 DHT and enzalutamide variably affect viability of AR-positive breast cancer cells 
AR-positive breast cancer PDXs (HCI09, HCI08, HCI13) and cell lines (MDA453, MCF7, 
T47D) were treated in vitro with DHT to determine the effect of AR stimulation on cell 
viability, and with enzalutamide to determine the effect of AR inhibition on cell viability. DHT 
caused an increase in viability of HCI08 cells, which tapered off with increasing doses, 
whereas it caused a dose-dependent reduction in viability of HCI09 cells and did not 
considerably affect HCI13 cells (Fig. 4.4a). DHT also increased the viability of T47D cells 
and slightly but insignificantly increased the viability of MDA453 cells, whereas it did not 
affect the viability of MCF7 cells (Fig. 4.4b). In contrast, the AR inhibitor enzalutamide 
dose-dependently reduced cell viability in all three PDX lines (Fig. 4.4c) and all three cell 
lines (Fig. 4.4d), although these cytotoxic effects of enzalutamide reached significance only 
for HCI09, MDA453, and T47D cells. All p-values are listed in Table 4.1. 
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Figure 4.4: DHT and enzalutamide variably affect viability of AR-positive breast cancer cells. Upper panel 
graphs depict cell viability (% of vehicle) in response to dihydrotestosterone (DHT) in breast cancer PDXs 
(HCI09, HCI08, HCI13) (a) and cell lines (MDA453, MCF7, T47D) (b). Lower panel graphs depict cell viability 
(% of vehicle) in response to enzalutamide in breast cancer PDXs (HCI09, HCI08, HCI13) (c) and cell lines 
(MDA453, MCF7, T47D) (d). For cell viability assays, cells were treated in triplicate for 72h with either DHT 
or enzalutamide, followed by IVIS imaging (PDXs) or CellTiter-Glo assay (cell lines). Error bars represent 
standard deviation. For DHT experiments: HCI09 N=9, HCI08 N=5, HCI13 N=2, MDA453 N=2, MCF7 N=2, 
T47D N=2. For enzalutamide experiments: HCI09 N=3, HCI08 N=2, HCI13 N=1, MDA453 N=2, MCF7 N=2, 


















Table 4.1: P-values for in vitro dose response experiments shown in Figure 4.4. t-tests were performed to 
compare each drug treatment condition with vehicle controls for each PDX/cell line. Significant values 
(p<0.05) are bolded and italicized. 
DHT (nM) 1 5 10 25 50 
HCI09 4.6E-05 2.3E-05 5E-06 <0.000001 <0.000001 
HCI08 0.00027 0.02092 0.00807 0.244171 0.909225 
HCI13 0.11027 0.0219 0.10809 0.222232 N/A 
MDA453 0.24435 0.19399 0.32604 0.310154 0.799312 
MCF7 0.05721 0.44613 0.06034 0.039903 0.464411 
T47D 0.10724 0.0468 0.00135 0.010914 0.027876 
Enzalutamide (µM) 1 10 50 75 100 
HCI09 0.12828 0.00178 1.6E-05 0.000023 0.015842 
HCI08 0.19913 0.74295 0.52782 0.408143 0.190043 
HCI13 N/A N/A N/A N/A N/A 
MDA453 0.32959 0.84274 5.9E-05 0.001341 0.01215 
MCF7 0.24955 0.13743 0.20944 0.092788 0.014661 
T47D 0.4449 0.00047 0.06659 0.012222 0.052188 
 
 
4.4.3 AR knockdown does not reduce viability of AR-positive breast cancer cells or abrogate the 
effects of enzalutamide 
To determine the effect of reduced AR expression on cell viability, we used a doxycycline-
inducible system to knockdown AR in MDA453, MCF7, and T47D cells using three different 
AR-targeted shRNAs (AR658, AR662, AR663), separately and in combination, and one 
NSC shRNA; the combination of all three AR-targeted shRNAs (ARall3) produced the most 
efficient knockdown in all three cell lines (Fig. 4.5a). In contrast to pharmacological 
inhibition with enzalutamide, doxycycline-induced AR knockdown did not reduce the 
viability of MDA453 cells (Fig. 4.5b), MCF7 cells (Fig. 4.5c), or T47D cells (Fig. 4.5d) 
compared to NSC conditions, although doxycycline itself had cytotoxic effects on the three 
cell lines. We next sought to determine the effect of AR knockdown on responses to DHT 
and enzalutamide in the three cell lines. Doxycycline-induced AR knockdown inhibited the 
DHT-induced increase in viability of MDA453 cells but did not abrogate the cytotoxic effects 
of enzalutamide (Fig. 4.5e). However, AR knockdown did not alter the effects of DHT or 




Figure 4.5: AR knockdown does not reduce viability of AR-positive breast cancer cells or abrogate the 
effects of enzalutamide. AR knockdown was performed using an inducible knockdown system with three 
lentiviral shRNAs targeting AR (AR658, AR662, AR663), separately and in combination (ARall3), as well as 
one non-silencing control (NSC) shRNA. (a) Western blots showing AR knockdown efficiency in breast 
cancer cell lines (MDA453, MCF7, T47D) after 72h of induction with doxycycline (0.5 µg/ml). Middle panel 
graphs show effect of doxycycline-induced AR knockdown on viability of luciferase-expressing MDA453 cells 
(b), MCF7 cells (c), and T47D cells (d); cell viability was measured as total flux (p/s) using IVIS imaging. 
Graphs in lower panel show the effect of doxycycline-induced AR knockdown (ARall3) on response to DHT 
(25nM) and enzalutamide (100µM) in luciferase-expressing MDA453 cells (e), MCF7 cells (f), and T47D 




















4.4.4 Drug screening reveals TOK-001 as a promising antiandrogen for AR-positive breast 
cancer 
To identify drugs other than enzalutamide with efficacy in AR-positive breast cancer, we 
utilized the 1,363-drug screening dataset (10µM) consisting of drug response data for ten 
PDX lines (Appendix A; described in Chapter 3, Section 3.3.4) [190]: AR-positive (HCI08, 
HCI09, HCI03, HCI11, HCI13) and AR-negative (HCI01, HCI16, UCD52, WHIM2, 
WHIM30). Interestingly, of the eight AR antagonists included in the screening library, TOK-
001 was the most effective AR inhibitor in AR-positive PDXs, with the most consistent 
differential responses between AR-positive vs. AR-negative disease and the highest 
efficacy in the LAR TNBC PDX HCI09 (Fig. 4.6a). Notably, TOK-001 had efficacy superior 
to that of enzalutamide in four out of the five AR-positive PDXs, including HCI09 (Fig. 4.6b). 
When data were averaged for AR-positive vs. AR-negative PDXs, TOK-001 was 
significantly more effective than enzalutamide in AR-positive PDXs (p=0.0106) but not in 
AR-negative PDXs (p=0.2109), and TOK-001 was significantly more effective in AR-
positive PDXs than in AR-negative PDXs (p=0.0229) whereas enzalutamide showed no 
difference in response between AR-positive vs. AR-negative disease (p=0.5086) (Fig. 
4.6c). These data suggest that the dual AR/CYP17A1 (cytochrome P450 family 17 
subfamily A member 1) inhibitor TOK-001 is a promising candidate for treatment of AR-





                            
Figure 4.6: Drug screening reveals TOK-001 as a promising antiandrogen for AR-positive breast cancer. 
PDX cells were treated for 72h with 1,363 drugs (10µM) as well as the indicated concentrations of DHT, 
followed by measurement of cell viability using IVIS imaging (luciferase activity); all screening data are 
provided in Appendix A. (a) Heatmap depicting cell viability of ten PDXs (AR-negative: HCI01, WHIM2, 
HCI16, WHIM30, UCD52; AR-positive: HCI13, HCI11, HCI03, HCI08, HCI09) in response to drugs targeting 
AR (agonists and antagonists). Color scale represents cell viability as percent of vehicle controls.  (b) 
Comparison of responses of the ten PDXs to enzalutamide vs. TOK-001 in the drug screen. (c) Comparison 
of averaged responses of AR-negative vs. AR-positive PDXs to enzalutamide vs. TOK-001 in the drug 
screen; *p<0.05. 
 
Given the promising results with TOK-001 in the 1,363-drug screen, we performed follow-
up dose response testing to further compare the efficacies of TOK-001 and enzalutamide 
in AR-positive PDXs (Fig. 4.7a-d) and cell lines (Fig. 4.7e-g). In this set of studies, TOK-
001 and enzalutamide did not show considerable cytotoxicity or differential efficacy, except 
slightly in HCI09 and HCI13. Notably, however, AR knockdown abrogated the dose-
dependent effects of TOK-001 in T47D cells, whereas it did not completely abrogate the 
dose-dependent effects of enzalutamide in these cells (Fig. 4.7h), indicating that TOK-001 
may target AR more specifically than enzalutamide. P-values are listed in Table 4.2. 
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Figure 4.7: Comparison of the effects of TOK-001 vs. enzalutamide on the viability of AR-positive breast 
cancer cells. Luciferase-expressing PDXs and cell lines were treated for 72h with increasing concentrations 
of TOK-001 or enzalutamide, followed by measurement of cell viability using IVIS imaging (luciferase 
activity); cell viability is shown as percent of vehicle controls. Graphs depict TOK-001 and enzalutamide 
dose responses for HCI08 (N=3) (a), HCI09 (N=6) (b), HCI11 (N=2) (c), HCI13 (N=1) (d), MDA453 (N=3) 
(e), MCF7 (N=2) (f), and T47D (N=1) (g). P-values are provided in Table 4.2. (h) Graph depicts enzalutamide 
vs. TOK-001 responses of T47D cells expressing inducible lentiviral shRNAs (non-silencing control, NSC; 
AR knockdown, ARKD, using ARall3), after 72h induction with doxycycline (0.5 µg/ml); N=1. 
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Table 4.2: P-values for in vitro dose response experiments shown in Figure 4.7. t-tests were performed to 
compare each drug treatment condition with vehicle controls, and enzalutamide with TOK-001, for each 








0.01 µM 0.556252 0.904131 0.579418 
0.10 µM 0.595403 0.728114 0.530294 
1 µM 0.456948 0.472687 0.933487 





 vs. Vehicle 
Enzalutamide  
vs. TOK-001 
0.01 µM 0.001011 0.146192 0.220968 
0.10 µM 0.000903 0.125972 0.334094 
1 µM 0.001238 0.201266 0.564059 








0.01 µM 0.079189 0.828885 0.603979 
0.10 µM 0.045337 0.040966 0.848208 
1 µM 0.005748 0.273786 0.896136 
10 µM 0.065693 0.696617 0.386816 
MDA453 
Enzalutamide 
 vs. Vehicle 
TOK-001 
 vs. Vehicle 
Enzalutamide 
 vs. TOK-001 
0.01 µM 0.004067 0.008552 0.025064 
0.10 µM 0.003472 0.025758 0.956975 
1 µM 0.001261 0.047788 0.840493 








0.01 µM 0.056139 0.080027 0.668425 
0.10 µM 0.248165 0.220171 0.868294 
1 µM 0.16994 0.491889 0.897054 
10 µM 0.28278 0.219452 0.713895 
 
As TOK-001 is a dual inhibitor of both AR and CYP17A1 that has been reported to reduce 
AR expression levels in prostate cancer [256], we were interested in determining the effect 
of TOK-001 on AR expression in AR-positive breast cancer cells. Interestingly, TOK-001 
reduced AR expression in MDA453 cells, but did not affect AR expression in MCF7, T47D, 




                            
Figure 4.8: TOK-001 reduces AR expression in a luminal AR TNBC cell line. MDA453, MCF7, T47D, and 
HCI09 cells were treated for 72h with vehicle (DMSO) or TOK-001 (10µM), followed by Western blotting for 
AR, with actin as a loading control. 
 
 
4.4.5 AR inhibition/knockdown does not reduce AR-positive mammary tumor growth in vivo 
To determine the effects of targeting AR in vivo, we tested the efficacy of enzalutamide, 
TOK-001, and AR knockdown in mice bearing HCI09 mammary tumors. Tumor growth was 
only very slightly reduced by enzalutamide (Fig. 4.9a) and not at all reduced by TOK-001 
(Fig. 4.9b). Although a successful knockdown of AR expression was achieved in HCI09 
mammary tumor cells (Fig. 4.9c), doxycycline-induced AR knockdown did not reduce 
mammary tumor growth (Fig. 4.9d). All p-values are listed in Table 4.3. Thus, the efficacy 
of targeting AR in this LAR TNBC model was not validated in vivo.  
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Figure 4.9: Targeting AR does not reduce PDX mammary tumor growth in vivo. (a) Mice bearing HCI09 
mammary tumors were treated with enzalutamide (n=5) or vehicle (n=5) at the indicated doses. Graph 
depicts tumor area over time. (b) Mice bearing HCI09 mammary tumors were treated with TOK-001 (n=3) 
or vehicle (n=3) at the indicated doses. Graph depicts tumor area over time. (c) Western blot showing 
efficiency of doxycycline-induced AR knockdown in HCI09 cells expressing lentiviral shRNA (AR knockdown, 
ARKD, using AR658) vs control cells. (d) Mice bearing HCI09 mammary tumors expressing AR658 shRNA 
were fed control chow (n=2) or doxycycline chow (n=3) to induce AR knockdown. Graph depicts effect of AR 
knockdown on tumor growth (tumor area) over time. All p-values are listed in Table 4.3. 
 
 
Table 4.3: P-values for in vivo experiments shown in Figure 4.9. t-tests were performed to compare each 
treatment condition (enzalutamide, TOK-001, or doxycycline-induced AR knockdown (ARKD)) with controls, 
at each indicated timepoint. Significant values (p<0.05) are bolded and italicized. 










Day 28/Day 18/Week 3 0.481618 0.823621 0.507158 0.581718 
Day 35/Day 25/Week 4 0.05351 0.106762 0.885221 0.206605 
Day 42/Day 32/Week 5 0.046194 0.007275 0.411243 0.86834 







4.4.6 AR expression correlates with expression of other potential drug targets in patients with 
AR-positive TNBC 
Given the prior findings, it is likely that AR inhibitors need to be combined with other drugs 
in order to achieve efficacy that is likely to translate into clinical success for patients with 
AR-positive disease. To search for potential candidates for combination with AR inhibitors, 
focusing particularly on AR-positive TNBC, we utilized the 1,363-drug screening dataset 
[190] along with the breast cancer TCGA dataset to identify drug targets whose genes 
correlate with AR expression and whose inhibitors are cytotoxic to LAR TNBC cells. Of the 
115 TNBC patients in the TCGA dataset, we selected the patients with high AR expression 
(n=9) (Fig. 4.10a). Within this subset of patients, we performed Pearson correlation 
analyses between the expression of AR and the expression of all other genes in the 
dataset. We subsequently plotted these values against HCI09 cell viability data from the 
1,363-drug screen, where a Pearson correlation value for a particular gene corresponded 
to the HCI09 cell viability in response to a drug targeting the protein encoded by that gene 
(Fig. 4.10b). Drug targets of interest, with the highest correlation with AR expression and 
the lowest cell viability (highest efficacy), were selected using a cutoff Pearson correlation 
value of 0.5 or higher and a cutoff cell viability value of 50% or lower (Fig. 4.10c). This 
analysis identified seven drug targets of interest, listed in order of decreasing correlation 
with AR expression: VDR, catechol-O-methyltransferase (COMT), potassium inwardly 
rectifying channel subfamily J member 5 (KCNJ5), FK506 binding protein 1A (FKBP1A), 
gamma-glutamyl carboxylase (GGCX), adenosine A3 receptor (ADORA3), and potassium 
voltage-gated channel subfamily A member 7 (KCNA7). These drug targets corresponded 
to 11 drugs of interest, which were cytotoxic to HCI09 cells: 
doxercalciferol/calcitriol/alfacalcidol, tolcapone/entacapone, fingolimod, rapamycin 
(sirolimus)/pimecrolimus, menadione, nicardipine, and amiodarone, respectively. Notably, 
most of these drugs were more effective in HCI09 than in PDX models of other breast 
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cancer subtypes (Appendix A). Pearson correlations for each gene of interest are shown 
in Fig. 4.11a, and expression levels for each gene across the nine patients are shown in 
Fig. 4.11b. Expression of all seven genes increased with increasing AR expression, 
although this was most robust for VDR, COMT, FKBP1A, and GGCX, which were 
consistently more highly expressed across the patients compared to KCNJ5, ADORA3, 






              
Figure 4.10: Identification of potential drug targets correlating with AR expression in patients with AR-
positive TNBC. (a) AR expression levels (TPM values) in TNBC patients using the breast cancer TCGA 
RNA-sequencing dataset. Each point on the graph represents an individual TNBC patient’s AR expression 
level (n=115). The red box indicates the 9 patients considered to have high AR expression compared to the 
rest of the TNBC patients. (b) Pearson correlations were performed between expression of AR and 
expression of all other genes in TNBC patients with high AR expression (n=9). HCI09 1,363-drug screening 
data were used to compare Pearson correlations for particular genes with LAR TNBC cell viability in 
response to drugs that target those genes. Graph depicts Pearson correlation values vs. HCI09 cell viability, 
with each point representing a particular drug. The region of interest highlighted with a yellow box is shown 
zoomed in (c); this region depicts high Pearson correlation values and low cell viability values. The gray box 
represents drugs that target AR (for which Pearson correlation between drug target expression and AR 
expression is 1.0). The green boxes represent effective drugs whose target genes correlate strongly with 
AR expression (Pearson correlation > 0.5); labels indicate the genes encoding the proteins that the drugs in 
each green box target. Vitamin D receptor (VDR): doxercalciferol, calcitriol, alfacalcidol. Catechol-O-
methyltransferase (COMT): tolcapone, entacapone. Potassium inwardly rectifying channel subfamily J 
member 5 (KCNJ5): fingolimod. FK506 binding protein 1A (FKBP1A): rapamycin (sirolimus), pimecrolimus. 
Gamma-glutamyl carboxylase (GGCX): menadione. Adenosine A3 receptor (ADORA3): nicardipine. 




Figure 4.11: Relative expression of select genes of interest in patients with AR-positive TNBC. (a) Heatmap 
showing Pearson correlations between expression of AR and the indicated genes in AR-positive TNBC 
patients using TCGA data (n=9). Correlation values for each gene are indicated on the heatmap and the 
range is indicated in the color scale legend. (b) Heatmap showing TCGA expression data for the indicated 
genes in the nine individual patients. Patients are ranked by AR expression, and genes are ranked by 
correlation with AR expression. Expression values for each gene are indicated on the heatmap and the 
range is indicated in the color scale legend. 
 
 
Notably, all seven genes (VDR, COMT, KCNJ5, FKBP1A, GGCX, ADORA3, and KCNA7) 
were weakly or negatively correlated with AR expression within the low-AR expression 
subset of TNBC patients and within all TNBC patients in the TCGA dataset (Fig. 4.12a). 
Although AR was expressed to some extent in the low-AR subset, and there were no 
considerable differences in expression of the seven genes between high-AR and low-AR 
TNBC groups (Fig. 4.12b), these findings indicate that the association of the genes with 




Figure 4.12: Relative expression of select genes of interest based on AR expression across TNBC patients. 
(a) Heatmap showing Pearson correlations between expression of AR and the indicated genes in different 
populations of TNBC patients from the TCGA dataset: patients grouped based on AR expression (High AR 
or Low AR) and all TNBC patients (All). (b) Heatmap showing relative expression of the indicated genes in 
High AR vs. Low AR TNBC patients. Fractions of total number of TNBC patients for each group are labeled 
on each heatmap. Correlation/expression values for each gene are indicated on the heatmaps and the 
ranges are indicated in the color scale legends. 
 
 
To gain further insight into the importance of the identified genes, and thus their encoded 
drug targets, of interest in LAR TNBC, we utilized the PDX RNA-sequencing dataset along 
with two breast cancer cell line RNA-sequencing databases (CCLE and LINCS) to assess 
relative expression levels of the genes across breast cancer subtypes (Fig. 4.13). 
Correlation analyses of AR expression with other genes within the LAR TNBC subtype 
could not be performed using these datasets as each only contains one LAR TNBC model 
(HCI09 or MDA453), however patterns in gene expression could still be observed and 
compared between subtypes. As previously shown, AR expression was highest in the 
HCI03, HCI13, HCI08, and HCI09 PDXs (Fig. 4.13a) and MDA453 cell line (Fig. 4.13b,c) 
compared to other PDXs/cell lines, with the lowest expression in basal-like models. The 
seven genes of interest (VDR, COMT, ADORA3, KCNA7, KCNJ5, FKBP1A, GGCX) had 
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fairly consistent expression levels across PDXs and cell lines of different subtypes, with 
relatively higher overall expression of VDR, COMT, FKBP1A, and GGCX than ADORA3, 
KCNA7, and KCNJ5 (Fig. 4.13a-c), consistent with the TCGA data. Note that ADORA3 
expression data were not available in the LINCS database, therefore analysis of this gene 
in cell lines was only performed using the CCLE database. Although, as with the TCGA 
data, no drastic differences in expression of the seven genes were observed between AR-
positive and AR-negative models, COMT expression was moderately higher in the 
MDA453 model compared to other cell lines (Fig. 4.13b,c), and GGCX expression was 
slightly higher in AR-positive PDXs compared to AR-negative PDXs (Fig. 4.13a) and in 
LAR and mesenchymal TNBC cell lines compared to basal-like TNBC cell lines (Fig. 
4.13b,c). Thus, although correlated with AR expression exclusively within AR-positive 
TNBC patients, these genes do not appear to be expressed or upregulated exclusively in 
LAR TNBC, i.e. the expression of the genes is not dependent on AR expression. These 
collective findings suggest that these genes may play roles in LAR TNBC that are distinct 
from their roles in other breast cancer subtypes, and that these distinctions cannot be solely 





Figure 4.13: Relative expression of select genes of interest across breast cancer PDXs and cell lines. 
Heatmaps depict expression data for the indicated genes using (a) PDX RNA-sequencing data (averaged 
replicates where applicable), (b) cell line RNA-sequencing data from the CCLE database, and (c) cell line 
RNA-sequencing data from the LINCS database. PDXs and cell lines are shown ranked by AR expression 
levels. Expression values for each gene are indicated on each heatmap and ranges are indicated in each 
color scale legend. Breast cancer subtypes of PDXs and cell lines are indicated by colored bars underneath 
each heatmap.  
 
 
4.5 Discussion and conclusions 
Previous studies have implicated AR as a potentially important therapeutic target in breast 
cancer, particularly in the luminal subtypes and the LAR subtype of TNBC, given the high levels 
of AR expression in these subsets of patients [70, 71, 74, 252]. Our analyses using patient 
data indicated that AR expression is highest in luminal tumors, which are typically ER-positive 
and associated with relatively favorable outcomes, and lowest in basal-like tumors, which are 
typically triple-negative and associated with relatively poor outcomes. However, when stratified 
112 
 
by ER status, AR expression was correlated with reduced relapse-free survival in patients with 
ER-negative tumors, suggesting that patients with AR-positive/ER-negative disease, many of 
which would fall into the LAR TNBC category, may be ideal candidates for AR-targeted therapy. 
These findings highlight the importance of further stratifying patients based on molecular tumor 
characteristics to predict clinical outcomes and to determine optimal therapeutic strategies. 
Of the seven breast cancer PDXs and seven breast cancer cell lines tested, AR was 
expressed in five PDXs and four cell lines, of varying histologic and intrinsic subtypes. Of these, 
one PDX line (HCI09) and one cell line (MDA453) could be categorized as suitable models of 
LAR TNBC, consistent with previous data establishing MDA453 as a LAR TNBC model [70]. 
Of those remaining, three PDX lines (HCI03, HCI11, HCI13) and three cell lines (MCF7, T47D, 
ZR751) were classified as AR-positive/ER-positive, and one PDX line (HCI08)  was classified 
as AR-positive/HER2-positive, making the latter an additional model that could be used to 
study AR in ER-negative disease. To determine the effect of targeting AR in these models, 
PDXs (HCI08, HCI09, HCI13) and cell lines (MDA453, MCF7, T47D) were treated with DHT 
(AR agonist) or enzalutamide (AR antagonist). Although DHT had stimulatory effects on the 
viability of HCI08 and T47D cells, and little to no effect on MDA453 and MCF7 cells, DHT was 
cytotoxic to HCI09 cells and did not considerably affect HCI13 cells. This was likely due to the 
intrinsic lack of cell proliferation in PDX suspension cultures, which we have observed 
previously with several PDX models [149]. In contrast, enzalutamide reduced cell viability 
across the PDXs and cell lines tested, with the greatest efficacy in the LAR TNBC models, 
validating the current interest in its use as a targeted therapeutic for AR-positive breast cancer. 
Given this efficacy of enzalutamide and its approved use as an AR inhibitor, it was therefore 
surprising that AR knockdown did not affect cell viability or abrogate the effects of enzalutamide 
in any of the three AR-positive cell lines tested. These findings suggest that enzalutamide may 
have off-target effects that are responsible for its efficacy in breast cancer cells. Indeed, 
another study found that enzalutamide and bicalutamide reduced proliferation of breast cancer 
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cells regardless of AR status [257], which is consistent with this class of drugs possibly having 
an AR-independent mechanism of action in breast cancer. Many drugs that are currently FDA-
approved or undergoing clinical trials are known to have off-target effects [258, 259], and AR 
antagonists in particular have been shown to additionally inhibit other nuclear hormone 
receptors [260], gamma aminobutyric acid (GABA) receptors [261], and CYP27A1 (cytochrome 
P450 family 27 subfamily A member 1) [262]. At least some of these known off-target effects, 
or perhaps others that have yet to be identified, may be responsible for the AR-independent 
efficacy of enzalutamide and similar drugs in breast cancer, in contrast to the AR-dependent 
efficacy of these drugs in prostate cancer. Despite its in vitro efficacy, however, enzalutamide 
did not reduce HCI09 mammary tumor growth in vivo. Not surprisingly, AR knockdown also 
failed to produce anti-tumor effects in vivo. These findings suggest that monotherapeutic 
targeting of AR is not sufficient to treat LAR TNBC. 
Using the PDX 1,363-drug screening dataset, we identified TOK-001 as a more effective 
and more potent AR-targeting agent compared to enzalutamide and other AR inhibitors. The 
drugs in this screen were tested at 10µM, a dose at which enzalutamide was not cytotoxic to 
any of the models previously tested in vitro. The efficacy of TOK-001 was also more specific 
to AR-positive PDXs, with the greatest efficacy in the LAR TNBC PDX model, HCI09. TOK-
001 is a dual inhibitor of AR and CYP17A1 [263, 264], therefore it inhibits both the synthesis 
of androgens and the activity of AR, making it a drug of keen interest for prostate cancer studies 
[265]  [NCT00959959, NCT01709734, NCT02438007]. Interestingly, this investigational drug 
has not yet been examined in the context of breast cancer. Although the efficacy of TOK-001 
could not be validated through further in vitro and in vivo studies, the effects of TOK-001 were 
abrogated by AR knockdown, in contrast to enzalutamide. This finding, along with the 
differential efficacy of TOK-001 between AR-positive and AR-negative PDXs, suggest that this 
drug may target AR more specifically than enzalutamide and that its effects in breast cancer 
are likely AR-dependent. TOK-001 is therefore of great interest for further studies that seek to 
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identify synergistic combinations with other targeted agents in AR-positive breast cancer. This 
drug may also be of interest for testing in ER-positive disease, given that CYP17A1 is upstream 
of the precursor for estrogens, and thus CYP17A1 inhibition would affect the synthesis of 
estrogens in addition to androgens. 
To preliminarily search for potentially promising drug targets and candidates for 
combination with AR inhibitors in LAR TNBC, we utilized the breast cancer TCGA gene 
expression dataset to determine genes that correlate strongly with AR expression in patients 
with AR-positive TNBC, along with the HCI09 drug response data from the 1,363-drug 
screening dataset to determine which of the drugs that target the proteins encoded by those 
genes were cytotoxic to LAR TNBC cells. Using this approach, we identified several drugs and 
drug targets of interest for future combination studies. Interestingly, none of these drugs or 
their target pathways are currently approved for any type of cancer treatment: vitamin D 
analogs (doxercalciferol, calcitriol, alfacalcidol), COMT inhibitors used for Parkinson’s disease 
(tolcapone, entacapone), immunosuppressive agents (sirolimus, pimecrolimus), an 
antiarrhythmic agent (amiodarone), an antihypertensive agent (nicardipine), an 
immunomodulator used for multiple sclerosis (fingolimod), and a vitamin K precursor 
(menadione). Although the genes encoding the targets of these drugs (VDR, COMT, FKBP1A, 
KCNA7, ADORA3, KCNJ5, and GGCX, respectively) were not differentially expressed 
between AR-positive and AR-negative PDXs, cell lines, and patients, the positive correlation 
of their expression with AR expression was exclusive to strongly AR-positive TNBC patients. 
Thus, although the expression of these genes appears to be independent of AR expression 
levels, the findings suggest potential distinct roles of these genes in AR-positive versus AR-
negative TNBC that are not solely due to the extent of expression of AR. 
Although the drugs listed above are not currently used clinically to treat cancer, some of 
their target pathways have been implicated in cancers of the breast and other organs. VDR 
expression was the most highly correlated with AR expression in AR-positive TNBC patients, 
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and co-targeting of AR and VDR has been shown to be effective in TNBC cell lines expressing 
both genes [257]. VDR is expressed in over 25% of TNBCs and has been shown to negatively 
correlate with proliferation index and tumor grade and positively correlate with overall survival 
[266], suggesting that VDR agonists, such as calcitriol, may have therapeutic benefit in TNBC 
patients. Indeed, several studies have demonstrated promising anti-tumor activity of calcitriol 
and other vitamin D analogs in preclinical TNBC models [267–272]. Interestingly, one of these 
studies combined calcitriol with menadione [272], another drug of interest identified in the 
analyses performed herein. Menadione, a vitamin K3 analog, and other vitamin K compounds 
are known to have anticancer activity in many tumor types, including TNBC, by inhibiting 
proliferation and migration and promoting apoptosis by inducing oxidative stress [273–277]. 
The role of vitamin K specifically in AR-positive TNBC is currently unknown. However, one of 
the major pathways characterizing LAR TNBC tumors is glutathione metabolism [70], and 
glutathione functions to reduce vitamin K so that it can act as a cofactor for the GGCX enzyme, 
which catalyzes the gamma-carboxylation and consequent activation of coagulation factors. 
Interestingly, AR is also gamma-carboxylated by GGCX, which stabilizes the protein [278, 279]; 
this may explain mechanistically why GGCX expression is correlated with AR expression in 
AR-positive tumor cells, as the studies herein have revealed to be the case in AR-positive 
TNBC patients. These findings further suggest that GGCX and vitamin K may play a role in 
this subtype. Furthermore, studies have shown that inhibition of vitamin K epoxide reductase 
(VKOR) using the anticoagulant warfarin reduces AR signaling and activity [279], and that 
vitamin K reduces AR expression and exerts antitumor activity in androgen-dependent prostate 
cancer [280]. Similarly, the VKOR antagonist phenprocoumon, another anticoagulant, 
synergizes with the AR inhibitor flutamide in prostate cancer by preventing its gamma-
carboxylation, thus leading to AR degradation and sensitizing the cancer cells to AR inhibitor 
treatment [278]. The same group recently filed a patent application focused on combining AR 
inhibitors with vitamin K antagonists in prostate cancer and other AR-positive cancers, 
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including breast cancer [281]. Given the parallels between LAR TNBC and androgen-
dependent prostate cancer, these findings collectively suggest that vitamin K pathways may 
indeed play a role in both diseases. 
COMT, whose expression was the second most highly correlated with AR expression, 
encodes an enzyme which degrades not only catecholamines such as dopamine, but also 
catechol-estrogens, which are metabolites of estradiol and estrone [282] that have been 
implicated in carcinogenesis in various hormone-sensitive tissues [283–286]. Although past 
studies have shown that polymorphisms in the COMT gene are not associated with breast 
cancer risk [287, 288], the COMT protein has recently been associated with lymph node 
metastasis and tumor grade in TNBC [289]. Furthermore, COMT inhibition has been shown to 
enhance the proteasome inhibitor activity of epigallocatechin gallate (EGCG), a component of 
green tea, in MDA231 cells [290]. These findings collectively suggest that COMT may play 
different roles in hormone receptor-positive versus triple-negative disease. However, the role 
of COMT in AR-positive TNBC has not yet been explored.  
Amiodarone, a potassium-channel blocker, was identified as a drug of interest for LAR 
TNBC given the correlation of its drug target (KCNA7) with AR expression and its cytotoxicity 
in HCI09 cells. Potassium channels have been shown to promote cancer cell proliferation and 
migration, as well as angiogenesis [291, 292]. Likewise, potassium channel blockers, such as 
amiodarone, have demonstrated efficacy in several solid tumor types [293, 294], including 
breast cancer [295, 296], consistent with the PDX drug screening data presented herein. One 
study found that amiodarone potentiates the cytotoxic effects of tamoxifen in both MCF7 (ER-
positive) and MDA231 (TNBC) cells [295]. A more recent study showed that dronedarone was 
cytotoxic to breast cancer cell lines of varying subtypes in vitro, with similar IC50s in both basal-
like (MDA468 and others) and LAR (MDA453) TNBC, however in vivo validation studies were 
performed using a HER2-positive cell line model [296]. Follow-up studies focusing on 
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potassium channel inhibition in TNBC in general or LAR TNBC specifically have not yet been 
performed.  
Fingolimod is currently approved for multiple sclerosis based on its activity as a sphingosine 
1-phosphate (S1P) receptor antagonist, however, through initial transient activation of S1P 
receptors, the drug also activates G-protein-coupled inwardly-rectifying potassium (GIRK) 
channels, leading to its cardiovascular side effects [297]. In the analyses performed herein, 
fingolimod was identified as a drug of interest for LAR TNBC due to its efficacy in HCI09 cells 
as well as the correlation of the expression of KCNJ5 (which encodes GIRK4) with AR 
expression in AR-positive TNBC patients. Fingolimod has demonstrated promising anticancer 
activity in TNBC due to its inhibition of S1P receptor signaling [298], which is associated with 
increased metastasis and reduced patient survival [299, 300]. However, it is possible that its 
efficacy in breast cancer may additionally be due to its targeting of GIRK channels. GIRK 
channels are known to be expressed in breast cancer, with GIRK4 being the most common 
across cell lines of varying breast cancer subtypes, including the LAR TNBC cell line MDA453 
[301, 302]. GIRK1 is associated with lymph node metastasis in breast cancer patients, 
irrespective of subtype [303], and knockdown of GIRK1 in MDA453 cells was shown to inhibit 
MAPK and PI3K signaling [304], suggesting that inhibition of GIRK1 may have anticancer 
effects. However, the role of GIRK4 in breast cancer is currently unknown. Further studies are 
warranted to explain why activation of GIRK4 by fingolimod may be cytotoxic to TNBC cells, 
and to determine how this mechanism may be related to AR status, given that KCNJ5 (GIRK4) 
expression was found to be correlated with AR expression in patients.  
Sirolimus and pimecrolimus were identified as drugs of interest in LAR TNBC due to their 
efficacy in HCI09 cells as well as the correlation of FKBP1A expression with AR expression in 
patients. By forming a complex with FKBP12 (encoded by FKBP1A), these drugs inhibit mTOR, 
thereby blocking the G1-S transition of the cell cycle and, consequently, proliferation [305, 306]. 
This makes mTOR inhibitors useful not only for preventing rejection in organ transplant 
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recipients by suppressing immune cell responses, which is their currently approved indication, 
but also for hindering cancer progression by blocking cancer cell proliferation and other 
malignant processes. In breast cancer, mTOR is commonly activated and plays a prominent 
role in tumor progression, therefore it has been widely studied as a potential therapeutic target 
in this disease [307–309]. Clinical trials testing the mTOR inhibitor everolimus in TNBC have 
thus far been unsuccessful [310, 311], however it is possible that stratifying patients based on 
TNBC subtype, particularly AR status, could increase the likelihood of clinical success. 
Activating mutations in PI3K, upstream of mTOR, are particularly prevalent in LAR TNBC cells 
[70], including the HCI09 PDX model used in the studies herein, and co-targeting of AR and 
PI3K has shown promising efficacy in PIK3CA-mutated LAR TNBC xenograft models [75], thus 
it stands to reason that mTOR inhibitors may be similarly effective in this subtype. One study 
using several PDX models found that response to the mTOR inhibitor everolimus was not 
associated with particular TNBC subtypes or PIK3CA mutation status [312], whereas another 
study demonstrated that the mTOR inhibitor deguelin had selective activity in LAR TNBC cells 
(MDA453) compared to all other TNBC subtypes, in addition to showing promising efficacy of 
combination therapy with sirolimus and enzalutamide in MDA453 xenografts [313]. It is 
possible that the LAR-selectivity of deguelin in the latter study was due to its dual inhibition of 
mTOR and AR [313], however further investigation is warranted to validate the findings of both 
these studies in additional models. 
Finally, the dihydropyridine (DHP) calcium channel blocker nicardipine, which is currently 
approved to treat hypertension, was also identified as a drug of interest for LAR TNBC. Studies 
on calcium channel blockers in cancer are limited and somewhat conflicting. Efficacy of 
nicardipine and amlodipine has been demonstrated in GBM [314] and neuroblastoma [315], 
respectively. In contrast, a study found that nifedipine exerted pro-tumorigenic effects in breast 
cancer cell lines [316], whereas nicardipine and other DHPs were found to sensitize TNBC 
cells to proteasome inhibitors [317] through their inhibition of the multidrug efflux transporter 
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BCRP (ABCG2) [318]. In addition to its targeting of DHP calcium channels (intended target) 
and BCRP, nicardipine also targets the G protein-coupled A3 adenosine receptor (ADORA3) 
[319], and DHP calcium channel blockers in general have been shown to interact with 
adenosine receptors [320]. DHP derivatives such as nicardipine are antagonists of the A3 
adenosine receptor specifically [321, 322], and our analyses indicated that ADORA3 
expression was positively correlated with AR expression in AR-positive TNBC patients. 
Adenosine receptors are known to play a role in cancer progression and have been implicated 
as potential targets in various cancers, with the effects of agonism versus antagonism 
depending on the target receptor subtype [323–329]. In breast cancer, ADORA3 agonism has 
been shown to promote apoptosis of breast cancer stem cells [329]. Interestingly, A3 
adenosine receptors are also highly expressed in androgen-dependent prostate cancer [330], 
and the endogenous A3 agonist adenosine is cytotoxic to prostate cancer cells [331]. These 
findings are paradoxical considering the efficacy of the A3 receptor antagonist nicardipine in 
the present study. Further studies are needed to determine whether the efficacy of nicardipine 
in LAR TNBC cells is mediated by ADORA3 and/or DHP calcium channels, and how these 
pathways may relate to AR signaling.  
In conclusion, the studies reported herein suggest that AR inhibition alone is not sufficient 
to successfully treat LAR TNBC, and it is therefore imperative to identify additional pathways 
that may be targeted along with AR inhibitors to achieve optimal efficacy. Collectively, our 
studies provide multiple drug candidates and targets that warrant further investigation in AR-
positive TNBC, both alone and in combination with AR-targeted agents. Although other studies 
have provided evidence that many of these drugs exhibit activity in breast cancer and other 
cancers, much remains to be explored regarding their efficacy and mechanisms in AR-positive 
disease. Furthermore, given that all these drugs are currently FDA-approved, albeit for other 
indications, successful preclinical studies may be more expeditiously translated to the clinic 
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relative to investigational compounds. Repurposing of such drugs has the potential to provide 
rapid clinical benefit for this unique subset of TNBC patients.  
4.6 Future directions 
Future studies will focus on performing further testing of the eleven drugs identified as both 
cytotoxic in the HCI09 PDX model and related to AR expression in patients, as well as exploring 
the role of their drug targets and associated pathways in AR-positive TNBC. These studies will 
employ both the HCI09 PDX model and the MDA453 cell line. The drugs will be tested in dose 
escalation studies as single agents, followed by combination studies with the AR inhibitor TOK-
001, using Chou-Talalay analysis to assess for synergistic effects. It would also be of interest 
to test TOK-001 analogs that have been shown to have greater efficacy and pharmacokinetic 
profiles in prostate cancer [332]. Promising combinations will then be validated in vivo in both 
the primary and metastatic setting. Given that AR expression was shown to be maintained in 
HCI09 liver metastases, we expect that treatments effective in reducing mammary tumor 
growth will maintain their efficacy in the metastatic setting, consistent with our previous findings 
regarding chemotherapeutic efficacy in basal-like PDX models [149]. Mechanistic analyses will 
involve inhibition or ablation of drug targets and key molecules in their associated pathways, 
especially for the drugs that have been shown to target multiple proteins that may play a role 
in tumor progression and/or be related to AR activity. Additionally, it would be interesting to 
perform RNA-sequencing on tumors before and after drug treatment to reveal consequent 
changes in gene expression. This would not only provide additional mechanistic insights, but 
also shed light on potential alternative therapeutic targets. Lastly, it would be important to test 
promising drugs and combinations in AR-positive and AR-negative models of other breast 
cancer subtypes, which would provide insight into the specificity of these agents for LAR TNBC 
as well as identify potentially effective agents in other subtypes of the disease, including ER-




CHAPTER 5: Overall impact and implications of this work 
The studies presented herein collectively provide valuable tools and insights to the field of 
translational breast cancer research. Namely, this work highlights the utility of clinically relevant 
PDX models for both in vitro and in vivo drug response studies in the primary and metastatic 
setting, identifies promising pharmacologic candidates for two distinct subtypes of TNBC, and 
provides data and examples of analytic approaches that can be used to inform many future drug 
development studies to advance therapeutic strategies for all breast cancer subtypes.  
We have demonstrated that breast cancer PDX cells in suspension culture maintain the 
molecular profiles of parental mammary tumors, validating the use of these models for in vitro drug 
screening studies to rapidly identify drug candidates of interest for further testing. Indeed, using 
this in vitro approach, we generated a dataset compiling the responses of ten breast cancer PDXs, 
representing each subtype, to 1,363 drugs with a wide variety of mechanisms of action and clinical 
indications. This led to the identification of a promising drug combination for basal-like TNBC, as 
well as the identification of several potential therapeutic candidates for combination with AR-
targeted therapies in LAR TNBC, each of which shed light on major potential areas of future 
investigation for translational research in the most clinically challenging subtype of breast cancer. 
These are merely two examples of the utility of these data. The 1,363-drug screening dataset 
provides countless opportunities for breast cancer drug development research, as it can inspire 
and inform research focusing on drug development in particular breast cancer subtypes, 
repurposing of drugs not currently indicated for cancer, and/or uncovering potentially important 
pathways in breast cancer, all of which the studies reported herein have exemplified in basal-like 
and LAR TNBC. The data may also provide insight into drugs or pathways of interest for testing in 
other cancer types. Furthermore, given that most of the drugs in the screening library are FDA-
approved, it is likely that promising preclinical research could be expeditiously translated to the 
clinical setting to provide immediate benefit to patients.  
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In addition to highlighting the value of in vitro drug screening using PDXs, we have shown that 
the molecular profiles of mammary tumors are maintained in the metastatic setting, and that PDX 
metastases have drug response profiles similar to those of primary tumors despite the cells 
growing in a foreign microenvironment, indicating that the results of drug studies performed using 
PDX mammary tumor models can be applicable in the setting of advanced disease. Our studies 
further demonstrated that multiple PDX models of the same histologic and intrinsic subtype 
respond differently to standard-of-care chemotherapies, mirroring one of the major limitations 
currently faced in the clinic and emphasizing the critical need for discovery of novel biomarkers 
with better precision and predictive power. Indeed, these studies shed light on the existence of 
different subpopulations of tumor cells that preferentially seed and form metastases in distinct 
sites, and the differential existence of these subpopulations between PDXs of the same breast 
cancer subtype paralleled the differential responses of these PDXs to chemotherapy. The efficacy 
of afatinib and YM155 in both of these PDXs as well as others within the basal-like TNBC subtype, 
along with the impact of co-expression of their drug targets on patient outcomes, provide a good 
example of how novel therapeutic strategies and potential biomarkers may be discovered by 
integrating drug screening data with gene expression data. This approach led to the identification 
of a drug combination that was effective across multiple basal-like TNBC models that respond 
differently to the therapies that patients with this subtype of breast cancer are currently receiving 
in the clinic. Furthermore, it led to the identification of several drug candidates whose target 
pathways may play important roles in LAR TNBC. Given the heterogeneity of TNBC and the failure 
of many targeted therapies in clinical trials, even when combined with standard-of-care 
therapeutics, the identification of novel therapeutic combination strategies for distinct TNBC 
subtypes is critical for improving the likelihood of clinical success. These studies have the potential 
to provide not only clinical benefit for these subsets of breast cancer patients, but also insights for 
many future studies that seek to build on these findings or to identify additional therapeutic 
candidates and strategies for TNBC and other breast cancer subtypes. 
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We hope that the data presented herein will be useful for many future translational research 
endeavors both within and outside of our lab, and that the findings resulting from these data will 
eventually lead to the implementation of therapeutic advancements that will improve clinical 
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